 
 
Protocol  
A Two -Part, Double -Blind, Placebo -Controlled, Si ngle- and Mu ltiple-Dose (Part A) or 
Twice Daily Dose (Part B) S tudy of AGN -241751 in Adult Participants with Major 
Depressive Diso rder 
 
NCT Number 03726658  
 
Document Date May 3, 2019  
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
1
Title Page
Protocol Title: A Two -Part, Double -Blind, Placebo -Controlled, Single -and Multiple -Dose 
(Part A) or Twice Daily  Dose (Part B) Study  of AGN -241751 in Adult Participants with Major 
Depressive Disorder
Brief Protocol Title: AGN- 241751 in the treatment of major depressive disorder 
Protocol Number: 3125 -104-002
Amendment Number: 2
Study Phase: 1b/2a
Product: AGN -241751
Sponsor Name and Legal Registered Address: Naurex, Inc., an indirect subsidiary  of Allergan 
plc, 5 Giralda Farms ,Madison, NJ 07940 USA
Regulatory Agency Identifying Number: IND 129,495
Emergency Telephone Number: Refer to the study  contact spage
SAE Reporting Fax Number/Email: 
Business Unit Email Fax
Allergan IR-Clinical -SAE@allergan.com +1-714-796-9504 
Backup fax: 
+1-714-246-5295
Approval Date: 03May 2019
Sponsor Signatory:
Armin Szegedi, MD , PhD
Vice President, Clinical Development
CNS Therapeutic Area Head
The signature of the sponsor signatory  is collected on the protocol approval page.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
2
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment 2 May 2019
Amendment 1 March 2019
Original Protocol August 2018
Amendment 2 ( May 2019)
Overall Rationale for the Amendment:
The primary  reason for this amendment was to add a 2nd cohort (Part B) to this study ,which will 
evaluate twice dail y [BID] dosing for 14 day s. This BID dosing cohort was added because the 
effective dose and regimen of AGN -241751 within MDD participants may  require weekl y, once 
daily , and BID administration. The once weekl y and once dail y dosing information is included as 
Part A and the BID dosing is now added as Part B. Revisions were made throughout the protocol 
to clarify  sections that are included in Part A and to add new information that pertains to Part B 
of the study . In addition, minor administrative , editorial, and formatting changes have been made 
throughout the protocol.
Revisions to Part A included additions and cl arifications to current efficacy  and safet y 
assessments, updates and clarifications to the objectives and endpoints for consistency  with 
presentation for Part B, and other minor revisions (eg, in -clinic to inpatient) for consistency with 
PartB
.The title of the protocol was revised to reflect the newl y added cohort.
The new Part B includes, but is not limited to, the following modifications: 
New schedule of activities
Updated objectives and endpoints
Study  design, study  information, sample size, study  treatment, and treatment compliance 
New ef ficacy , pharmacokinetic, and pharmacod ynamic  assessments
oLikert Patient Depressive Sy mptom Scales
oHopkins Verbal Learning Test –Revised
oQuantitative electroencephalograph y/event related potential assessments and outputs
oCerebrospinal fluid analysis (optional)
Updated statistical anal yses
Additional appendices
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
3
Table of Contents
Title Page ........................................................................................................................................ 1
Protocol Amendment Summary  of Changes Table ......................................................................... 2
Table of Contents ................................................................................................
........................... 3
List of Figures ................................................................................................................................ .7
1. Synopsis ............................................................................................................................ 8
2. Schedule of Activities (SoA) ......................................................................................... 19
2.1. Part A .............................................................................................................................. 19
2.2. Part B .............................................................................................................................. 21
3. Introduction ................................................................................................................... 24
3.1. Study  Rationale ............................................................................................................... 27
3.2. Background ..................................................................................................................... 27
3.3. Benefit/Risk Assessment ................................................................................................ 28
4. Objectives and Endpoints ............................................................................................ 29
4.1. Part A.............................................................................................................................. 29
4.2. Part B .............................................................................................................................. 30
5. Study Design .................................................................................................................. 32
5.1. Overall Design ................................................................................................................ 32
5.1.1. Part A .............................................................................................................................. 32
5.1.2. Part B .............................................................................................................................. 34
5.2. Participant and Study  Completion .................................................................................. 37
5.2.1. Part A .............................................................................................................................. 37
5.2.2. Part B .............................................................................................................................. 37
5.3. End of Study  Definition .................................................................................................. 37
5.4. Scien tific Rationale for Study  Design ............................................................................ 38
5.5. Justification for Dose ................................................................
...................................... 38
6. Study Population ........................................................................................................... 39
6.1. Inclusion Criteria ............................................................................................................ 39
6.2. Exclusion Criteria ................................................................
........................................... 40
6.3. Lifesty le Restrictions ...................................................................................................... 44
6.3.1. Meals and Dietary Restrictions ................................
....................................................... 44
6.3.2. Caffeine, Alcohol, and Tobacco ..................................................................................... 44
6.3.3. Activity ........................................................................................................................... 44
6.4. Screen Failures ................................................................................................................ 44
7. Treatments ..................................................................................................................... 45
7.1. Treatments Administered ................................................................................................ 45
7.1.1. Part A .............................................................................................................................. 45
7.1.2. Part B .............................................................................................................................. 46
7.2. Dose Modification .......................................................................................................... 48
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
4
7.3. Method of T reatment Assignment .................................................................................. 48
7.4. Blinding/Masking ........................................................................................................... 48
7.5. Preparation/Handling/Storage/Accountability ................................................................ 49
7.6. Treatment Compliance.................................................................................................... 49
7.6.1. Part A .............................................................................................................................. 49
7.6.2. Part B .............................................................................................................................. 50
7.7. Concomitant Therap y..................................................................................................... 50
7.7.1. Prohibited Treatments ..................................................................................................... 51
7.7.2. Permitted Treatments ...................................................................................................... 51
7.8. Treat ment after the End of the Study .............................................................................. 52
8. Discontinuation/Withdrawal Criteria ......................................................................... 53
8.1. Discontinuation of Study Treatment ............................................................................... 53
8.2. Withdrawal from the Study ............................................................................................. 54
8.3. Lost to Follow Up ........................................................................................................... 54
9. Study Assessments and Procedures............................................................................. 56
9.1. Efficacy  Assessments ..................................................................................................... 56
9.1.1. Diagn ostic Assessments ................................................................
.................................. 57
9.1.2. The Montgomery -Åsberg Depression Rating Scale ....................................................... 57
9.1.3. The Clinical Global I mpressions -Severity ...................................................................... 57
9.1.4. The Hamilton Anxiety  Rating Scale (Part A Onl y)................................
........................ 57
9.1.5. Likert Patient Depressive Sy mptom Scales (Part B Only )............................................. 58
9.1.6. Hopkins Verbal Learning Test -Revised (Part B On ly)................................................... 58
9.2. Adverse Events ................................................................................................
............... 58
9.2.1. Time Period and Frequency  for Collecting AE and SAE 
Information ..................................................................................................................... 59
9.2.2. Method of Detecting AEs a nd SAEs ................................................................
.............. 59
9.2.3. Follow -up of AEs and SAEs ........................................................................................... 59
9.2.4. Regulatory  Reporting Requirements for SAEs ............................................................... 60
9.2.5. Pregnancy ........................................................................................................................ 60
9.2.6. Potential Hy ’s Law ......................................................................................................... 61
9.2.7. Medic ation Errors ........................................................................................................... 61
9.3. Treatment of Overdose ................................................................................................... 61
9.4. Safety  Assessments ......................................................................................................... 62
9.4.1. Physical Examinations .................................................................................................... 62
9.4.2. Vital Signs................................
....................................................................................... 62
9.4.3. Electrocardio grams ......................................................................................................... 63
9.4.4. Clinical Safety  Laboratory  Assessments ........................................................................ 63
9.4.5. Columbia -Suicide Severity  Rating Scale ........................................................................ 64
9.4.6. Brief Ps ychiatric Rating Scale —Positive Sy mptoms Subscale ...................................... 64
9.4.7. Clinician Administered Dissociative States Scale .......................................................... 64
9.5. Pharmacokinetics (Part B Only )..................................................................................... 65
9.6. Pharmacod ynamics (Part B Onl y)................................
.................................................. 65
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
5
9.6.1. Quantitative Electroencephalograph y and Event Related 
Potential Assessments and Outputs ................................................................................ 65
9.7. Genetics ................................................................................................
.......................... 68
9.8. Biomarkers ...................................................................................................................... 68
9.9. Medical Resource Utilization and Health Economics .................................................... 68
10. Statistical Considerations ............................................................................................ 68
10.1. Sample Size Determination ............................................................................................ 68
10.1.1 .Part A .............................................................................................................................. 68
10.1.2. Part B .............................................................................................................................. 68
10.2. Populations for Analy ses................................................................................................ 69
10.2.1. Part A .............................................................................................................................. 69
10.2.2. Part B .............................................................................................................................. 69
10.3. Statistical Analy ses......................................................................................................... 69
10.3.1. Efficacy  Anal yses (Part A and Part B) ................................................................
........... 70
10.3.2. Exploratory  Anal yses................................................................................................
......73
10.3.3. Pharmacokinetic Analysis (Part B Onl y)........................................................................ 74
10.3.4. Pharmacod ynamic Anal ysis (Part B Onl y)..................................................................... 74
10.3.5. Safety
 Anal yses (Part A and Part B) ............................................................................... 74
10.3.6. Interim Anal yses............................................................................................................. 77
11. References ................................................................
...................................................... 78
12. Appendices ..................................................................................................................... 81
12.1. Appendix 1: Abbreviations and Trademarks .................................................................. 81
12.2. Appendix 2: Clinical L aboratory  Tests .......................................................................... 84
12.3. Appendix 3: Study  Governance Considerations ............................................................. 87
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ......................................................... 90
12.5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information ................................................................................................
...96
12.6. Appendix 6: Concomitant Medications .......................................................................... 99
12.7. Appendix 7: Standard Discontinuation Criteria ............................................................ 104
12.8. Appendix 8: Montgomery -Åsberg Depression Rating Scale ....................................... 105
12.9. Appendix 9: Clinical Global I mpressions –Severity ..................................................... 109
12.10. Appendix 10: Brief Psychiatric Rating Scale –Positive 
Symptoms Subscale ...................................................................................................... 110
12.11. Appendix 11: Clinician Administered Dissociative States Scale ................................ .111
12.12. Appendix 12: Columbia -Suicide Severity  Rating Scale –
Baseline/Screening ................................................................
........................................ 116
12.13. Appendix 13: Columbia –Suicide Severity  Rating Scale -Since 
Last Visit ................................................................
....................................................... 119
12.14. Appendix 14: Hamilton Anxiety  Rating Scale (Part A Only )...................................... 123
12.15. Appendix 15: L ikert Patient Depressive Sy mptom Scales (Part B 
Only )............................................................................................................................. 124
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
6
12.16. Appendix 16: Hopkins Verbal Learning Test -Revised (Part B 
Only )............................................................................................................................. 136
12.17. Appendix 17: Karolinska Sleepiness Scale (Part B Only )............................................ 137
12.18. Appendix 18: CSF Sample Collection, Handling, and Stora ge 
Instructions (Part B Only) ............................................................................................. 138
12.19. Appendix 19: Sample Shipment Guide (Part B Only ).................................................. 139
12.20. Appendix 20: qEEG and ERP Assessments and Outputs (Part B 
Only )............................................................................................................................. 141
12.21. Appendix 21: Protocol Amendment History ................................................................ 144
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
7
List of Figur es
Figure 5–1 Study  Design Diagram –Part A ........................................................................ 33
Figure 5–2 Study  Design Diagram –Part B ................................
........................................ 37
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
8
1. Synopsis
Protocol Title: A Two -Part, Double -Blind, Placebo -Controlled, Single -and Multiple -Dose 
(Part A) or Twice Daily  Dose (Part B) Study  of AGN -241751 in Adult Participants with Major 
Depressive Disorder
Protocol Number: 3125 -104-002 Amendment 2
Brief Title: AGN -241751 in the treatment of major depressive disorder 
Study Phase: 1b/2a
Study Rationale:
AGN -241751 is a functional modulator of the N-methy l D-aspartate receptor ( NMDAR) with 
partial agonist properties. I n rodent models of depression, AGN -241751 elicited potent, rapid, 
and long -lasting antidepressant activity  without adverse central nervous s ystem ( CNS )effects. 
AGN -241751 is an orally bioavailable small molecule with NMDAR partial co -agonist 
pharmacology . Thus, it represents a novel pharmacology  that may address a significant 
unmet need with minimal side effects and the feasibility  of an oral dosage for m. This is a 2-part 
(Part A and Part B) proof -of-concept study  of AGN -241751 monotherap yfor the treatment of 
patients with major depressive disorder (MDD) . Part A includes weekl y and once daily
administration sof AGN -241751 , and PartB includes twice dail y (BID) administration .PartB 
participants should not have participated in Part A at an y time, and Part A participants should not 
have participated at an y timein Part B (ie, Part A is not a contingent step to participate in 
PartB).
Objectives and En dpoints:
Part A:
The primary  objective of Part A is to evaluate the efficacy , as measured b y improvement in 
Montgomery -Asberg Depression Rating Scale ( MADRS )total score, at 1 day  after the initial 
single oral dose of AGN -241751 compared with placebo in pa rticipants with MDD (Day 1 
[predose, defined as baseline] vs Day  2). The key  secondary  objectives are to evaluate the 
efficacy  at Day  8, at Day 9after a single oral dose , atDay 15 after repeated dose sof 
AGN -241751 ,and at Day 22 (7days after completion of AGN -241751 dosing) compared with 
placebo in participants with MDD.
Objectives Endpoints
Primary
To evaluate the efficacy  at 1 day  post 
the initial single oral dose of 
AGN -241751 compared with placebo Change from baseline (Day  1,predose ) in 
MADRS total score at 1 day after the first 
dose of treatment (Day  2)
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
9
Objectives Endpoints
inparticipants with MDD
Key Secondary
To evaluate the efficacy  at Day  8, at
Day 9 (single dose) , atDay 15 (repeated 
dose) of AGN -241751 administered 
orally  once dail y,and at Day  22 (7 days 
after completion of AGN -241751 
dosing) compared with placebo in 
participants with MDDChange from baseline (Day 1,predose ) in 
MADRS total score at Day  8, Day 9, Day 15, 
and Day  22
Additional
Additional endpoint to be explored to 
determine differences between 
AGN -241751 and placebo in 
participants with MDDChange from baseline in CGI -S total score at 
Day 2, Day  8, Day  9, and Day  15 
Rate of responders on MADRS or CGI  S at 
Day 2, Day  8, Day  9, Day  15, and Day  22
Rate of remitters on MADRS at Day 2, 
Day 8, Day  9, Day  15, and Day  22
Time to first response on MADRS
Time to first remission on MADRS
Change from baseline (Day 1,predose) in 
HAM -Aat Day  2, Day  8, and Day  15
Safety  Measures AE recording, clinical laboratory  measures, 
vital sign para meters, ECGs, and ph ysical 
examinations
Measure of ps ychotomimetic effects: BPRS+ 
Measure of dissociative effects: CADSS
Measure of suicidality : C-SSRS
Part B:
The primary  objective of Part B is to evaluate the efficacy of the change from baseline in 
Montgomery -Asberg Depression Rating Scale ( MADRS ) total score at 7 day s after the 1stdose 
of AGN -241751 (3 mg and 25 mg) compared with placebo in participants with MDD . The key  
secondary  objectives are to evaluate the efficacy  at Day 2, Day  11, Day  14, Day 18, and Day 21
after the 1stdose of AGN -241751 (3 mg and 25 mg) compared with placebo in participants with 
MDD. In addition, optional CSF samples will be collected in a subset of participants for 
pharmacokinetic anal ysis, and qEEG and ERP assessments will be collected in a subset of 
participants forpharmacody namic analysis.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
10
Objectives Endpoints
Primary
To evaluate the efficacy  at Day 7of 
AGN -241751 compared with placebo in 
participants with MDD dosed twice dail y 
(BID)Change from baseline in MADRS at 
7days after the first dose of treatment
Key Secondary
To evaluate the efficacy  on Day 2,
Day 11,Day 14, Day 18, and Day  21
(7days after completion of dosing) after 
BID administration of AGN -241751 
compared with placebo in participants 
with MDD dosed BIDChange from baseline in MADRS total 
score at Day  2,Day 11,Day 14, Day 18, 
and Day  21 
Additional
Additional endpoints to be explored to 
determine differences between 
AGN -241751 and placebo in participants 
with MDD dosed BIDChange from baseline in CGI -S total score 
by visit
Rate of responders on MADRS at Day 2, 
Day 7, Day 11, Day 14, Day  18,and 
Day 21
Rate of remitters on MADRS at Day 2, 
Day 7, Day 11, Day 14, Day  18,and 
Day 21
Rate of responders on CGI -S by visit 
Time to first response on MADRS
Time to first remission on MADRS
Symptoms over time based on Likert 
Patient Depressive S ymptom S cales
Total recall scores at specified timepoints 
in HVL T-R
Evaluation of pharmacodynamic 
endpoints (qEEG/ERP) and CSF between 
AGN -241751 and placebo in participants 
with MDD dosed BIDChange from baseline in qEEG 
parameters collected during Day  1, Day 7, 
Day 14, and Day 21
Change from baseline in ERP parameters 
collected during Day  1, Day 7, Day 14, 
and Day 21
Descriptive anal ysis of CSF 
concentrations of AGN -241751
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
11
Objectives Endpoints
Safety  Measures AE recording, clinical laboratory  
measures, vital sign parameters, ECGs, 
and phy sical examinations
Measure of ps ychotomimetic effects: 
BPRS+ 
Measure of dissociative effects: CADSS
Measure of suicidality : C-SSRS
Overall Study Design:
Part A of th isstudy  is a multicenter, randomized, double -blind, placebo -controlled, 
parallel -group (4 arms), weekl y and once daily dose, 2 -week double -blind treatment in 
participants with MDD. Part B of this study  is a multi center, randomized, double -blind, 
placebo -controlled, parallel -group (3 arms ), BID dose, 2 -week double -blind treatment in 
participants with MDD.  
Part A:
Part A of the stud y will include a total of 7 visits and will be approximately  5 weeks in duration:
Up to 2 -week screening period 
2-week double -blind treatment period 
1-week safet y follow -up period 
After providing written consent, participants will enter a screening period of up to 14 day s. 
Screening procedures may be conducted on up to 2 separate date s where necessary  to 
accommodate participant and site schedule; however, every  effort should be made to conduct all 
procedures as earl y as possible in the screen ing period . Participants meeting the eligibili ty 
criteria at the end of Visit 2 (Day 1 of the randomized inpatient treatment ) will be assigned a 
treatment and enter the double -blind treatment period.
Approximately  100 participants are planned for enrollment in the double -blind treatment period 
(25 participants each in 3 different AGN-2 41751 dose groups and a placebo group). Participants 
will be randomized in a ratio of 1:1:1:1 to 1 of 4 treatment groups: 3 mg, 10 mg, and 25 mg dose 
AGN -241751 and placebo.  All participants will be randomized to receive active treatment or
placebo (Day 1and Day s 8to 15) andplacebo alone (Day s 2 through 7). 
AGN -241751 is being developed for once -weekl ydosing; however, the impact of repeated
administration of AGN -241751 requires testing. In order to minimize participant’s expectations 
and control for p lacebo response while changing dosing regimens, all treatment swill be 
presented to participants as oral dail y dosing throughout the study. On Day 1, all participants will 
be randomized to receive the first treatment (ie ,4 treatment groups: 3 mg, 10 mg, and 25 mg 
dose AGN -241751 or placebo), followed by  blinded placebo on Day s 2 through 7. Starting on 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
12
Day 8, participants will then start 7 consecutive day s of randomized treatment, administered 
once dail y through Day 15.  
On Day  1, site staff will give the participant the single dose of double -blind study  treatment from 
Bottle 1 (for applicable visit) to take by  oral ingestion in the clinic (ie, the first dose of study  
treatment for that week). Site staff will then give Bottle 2 (for applicable visits) , whic h contains 
the single- blind placebo tablets, to the participant with the instruction to take 1 tablet dail y by 
oral ingestion for the remainder of that week (Days 2 through 7). On Day 8, site staff will give 
the participant the single dose of double -blind study  treatment from Bottle 1(for applicable visit) 
to take by  oral ingestion in the clinic (ie, the first dose of study  treatment for that week). Site 
staff will then give Bottle 2(for applicable visits) , which contains double -blind study  treatment, 
to the participant with the instruction to take 1 tablet daily b y oral ingestion for the remainder of 
that week (Day s 9 through 15).
Participants will have 7study  visits during the study . The first 6 visits will occur in the following 
pattern: the Screening Visit (Visit 1; up to Day  –14);at Visit 2(Day  1 of the random ized 
inpatient treatment) ;at Visit 3(1 day  following the inpatient treatment day) ;at Visit 4(7days 
following the first inpatient treatment day , which is the 2ndinpatient treatment day );at Visit 5
(1day following the 2ndinpatient treatment day );and at Visit 6(7days following the 
2ndinpatient treatment day ). If necessary , study  visits may  be conducted up to 2 day s before or 
after the scheduled visits with the exception of visits tha t are 1 day apart (ie, Visits 2and 3must 
be conducted 1 day  apart; and Visits 4and 5must be conducted 1 day  apart). Participants will 
enter a 1 -week safety  follow -up period and return for Visit 7. Participants who prematurely 
discontinue from the study before completing the double -blind treatment should enter the 1 -week 
safet y follow -up period. Additional follow -up visits may  be scheduled within 30 day s, if 
necessary  for safet y reasons.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
13
Study Design Diagram –Part A
FU = follow -up; IP = investigational product.
All treatment swill be presented to participants as oral once daily  dosing throughout the study . 
Daily  dosing of AGN -241751 should occur at a similar time throughout the entire stud y. 
At Visit 2 (Day 1 of the randomized inpatient treatment ), all participants will be randomized to 
receive the first treatment, followed by  blinded placebo on Day s 2 through 7.
Starting at Visit 4(Day  8), participants will then start 7 consecutive days of randomi zed 
treatment, administered once dail y through Day 15 .
Part B:
Part B of this study  will include a total of 14 visits and will be approximately 5 weeks in duration 
as described below.
Up to a 2 -week screening period 
2-week double -blind treatment period ( Week 1 inpatient , Week 2 outpatient)
1-week outpatient safet y follow -up period 
IP Administered
 IP Administered
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
14
Approximately  120 participants are planned for randomization in the double -blind treatment 
period (40 placebo participants, 40 AGN -241751 3 mg participants, 40 AGN -241751 25 mg
participants ). Eligible participants will be randomized in a ratio of 1:1:1 to one of 3 double -blind 
oral administration treatment groups: 3 mg dose of AGN -241751, 25 mg dose of AGN -241751, 
or placebo , administered BID. Participants who enrolled ( were randomized) in Part A will not be 
permitted to screen into Part B (and vice versa).
Screening Period
After providing written consent, participants will enter a screening period of up to 14 days. 
Screening procedures may be conducted on up to 2 separate dates where necessary to 
accommodate participant and site schedule; however, every effort should be made to conduct all 
procedures as earl y as possible in the screening period. Participants will wash out of any ADT 
and prohibited medications under the supervision of the study investigator staff during the 
screening period. At Visit 2 (Day –1), stud y procedur es required to determine eligibility  will be 
completed prior to admission to the clinic. Participants meeting the eligibility  criteria at Visit 2 
(Day –1, Baseline) will be admitted to the inpatient facility , and the remainder of the Visit 2 
study  procedur es will be completed. A urine pregnancy  test should be done on Day –1 (at 
baseline), if more than a week has passed since the serum pregnancy test was done at Screening.
Participants are required to not use any nicotine substances 1 hour prior to administr ation of the 
HVLT -R.
Double -Blind Treatment Period
Participants will be randomized in a ratio of 1:1:1 to 1of 3 treatment groups (AGN -241751 3 mg 
BID, AGN- 241751 25 mg BID, or placebo BID )for the 2-week double -blind treatment . 
Participants will be administered 1tablet in the morning and 1tablet in the afternoon. At Visit 3 
(Day  1), the participant will be randomized and assigned a treatment by the interactive web 
response s ystem (IWRS) ,and t he 1stdose of stud y medicat ion will be administered in the 
morning after all predose asessments have been completed.
Week 1 Inpatient Double -Blind Treatment Period 
It is expected that participants in the double -blind treatment period will remain inpatient
during the 1stweek (Visit 2 to Visit 10/Discharge) .
During the inpatient treatment period , participants will have 7 visits (Visits 3 to 9); each 
visit will occur daily  with no visit windows .
At Visit 3 (Day  1) during the predose evaluation period ,if there is a significant change 
(worsening or improvement in depressive s ymptoms) from the baseline Visit 2 ( Day –1) 
MADRS based on the judgment of the PI, a MADRS assessment should be performed prior 
to the 1stdose of study  medication.
Participants will be discharged at Visit 10 (Day  8) after all predose assessments , morning 
dosing ,and 4 -hour post dose assessments are completed .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
15
During the inpatient treatment period ,predose assessments will be performed prior to 
morning dosing at all inpatient visits ( Visit 3 through Visit 10). Postdose assessments will be 
performed ,as follows:
oVisit 3to Visit 6: 1, 2, 4, 8 ,and 12 hours after the morning dose ( ±20 min utes) 
oVisit 7to Visit 9: 4, 8 ,and 12 hours after the morning dose (±20 minutes )
oVisit 10: 4 hour s after the morning dose (±20 minutes ) 
Within each timepoint ,multiple assessments will be performed ,as follows:
oAssessment sshould be performed within  ± 20minutes of each other
oAll psy chiatric assessments ( Likert Patient Depressive Sy mptom Scales , CSSR-S, 
MADRS, and CGI -S) are to be completed first prior to any  other assessments (ie ,qEEG, 
ERP) within the timepoint.
oParticipants are required to not use any nicotine substances 1 hour prior to administration 
of the HVLT -R.
The afternoon dose of study  medication is to be administered 8 hours ( ± 1hour) after the 
morning dose .
Week 2 Outpatient Double -Blind Treatment P eriod
During the outpatient treatment period ,there will be 2 visits conducted every  3 day s
(Visit 11 [Day 11] and Visit 12 [Day  14/ET]). Ifnecessary ,these stud y visits may be 
conducted up to 1 day before or after the scheduled visit day.
All participants who receive study  medication should complete Visit 12 (Day  14/ET)
At Visit 10 (Day  8) prior to discharge, the participant will be dispensed Bottle 2 of study  
medication (refer to Section 7.1.2 for dosing instruction). Participants will be instructed to 
bring the stud y medication bottle to Visit 11 for the site staff to confirm dosing compliance
The s tudy medication bottle will be returned at Visit 12; site staff will confirm dosing 
compliance.
A Patient Diary  will be provided at Visit 10 and Visit 11 for completion by  the participant at 
home. At Visits 11 and 12, the participant will return the diary which was provided at the 
prior visit. Site staff will review the diary  to confirm compliance and proper completion of 
thediary . At Visit 11 and Visit 12, prior to leaving the clinic, the participant will be given a 
new diary . 
The Patient Diary will include a Study  Medication Dosing Log and L ikert scales .
oStudy  Medication Dosing Log: Participants will be instructed b y site staff to record the 
date and time of the Visit 10 (Day  8) afternoon dose and each subsequent dose the 
participant has taken (morning and afternoon) at home, inclusive of doses on days when 
the participant has a clinic visit (Visit 11 [Day 11] and Visit 12 /ET[Day 14/ET] ). 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
16
oLikert Patient Depressive Sy mptom Scales : Participants will be instructed by site staff to 
complete the Likert assessments at home on Day  9 and Day 10 (between Visit 10 and 
Visit 11) and on Day  12 an d Day 13 (between Visit 11 and Visit 12/ET). The date and 
time each Likert assessment was completed arealso to be recorded. The Likert 
assessments on day s when the participant has a clinic visit (Visit 11 [Day 11]and 
Visit 12 [Day 14/ET ]) will be complet ed by the participant in the clinic (ie ,the 
participant will not complete the L ikert assesssment at home on these day s). 
Safety Follow -Up Period (Visit 13 [Day 18 ]and Visit 14 [Day 21 ])
Participants completing the double -blind treatment period should en ter the 1 -week safet y 
follow -up period. Participants who prematurely  discontinue from the study before 
completing 2 weeks of double -blind treatment should complete the early  termination (ET) 
visit and then enter the 1 -week safet yfollow -up period.
oA Patient Diary of Likert scales will be provided at Visit 12 /ET (Day 14/ET) and at 
Visit 13(Day 18). The Patient Diary will include Likert scales ,and participants will be 
instructed by site staff to complete the Likert assessments at home on Day s 15, 16 ,and 17 
(between Visits 12 and 13) and on Days 19 and 20 (between Visits 13 and 14). The date 
and time each Likert assessment was completed areto be recorded. The Likert 
assessment on the day of Visit 13 will be completed by  the participant in the clinic 
(ie,the participant will not complete the L ikert assesssment at home on this day ).
oAdditional follow -up visits may  be scheduled within 30 days of last dose of study  
medication or last study  visit, if necessary ,for safety  reasons.
Study Design Diagram –Part B

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
17
Number of Participant s:
Part A :
In Part A , approximately  100 participants who meet eligibility  criteria at Visit 2 ( Day 1 of the 
randomized inpatient treatmen t) will be randomly  assigned to stud y treatment such that 
approximately  25participants per arm will be allocated in a 1:1:1:1 ratio.
Part B:
In Part B , approximately  120 participants who meet eligibility  criteria will be randoml y assigned 
at Visit 3 (Day  1) to receive study  treatment starting on Day 1 such that approximately  
40participants per arm will be allocated in a 1:1:1 ratio. Participants who enrolled (were 
randomized) in Part A will not be permitted to screen into Part B (and vice versa).
Treatment Groups and Study Duration:
Part A Treatment Groups : AGN -241751 3 mg, 10 mg, and 25 mg and placebo , dosed weekl y 
and then once daily  for 14 days.
Part B Treatment Groups : AGN -241751 3 mg and 25 mg and placebo , dosed BID for 14 days.
Study Duration : approximately  5 weeks
Dosage Regimen : 
Part A:
During the 2 -week double -blind treatment period, a single tablet of double -blind study  treatment 
(placebo, AGN -241751 3 mg, 10 mg, or 25 mg) will be administered orall y on Day  1 in the 
clinic. A bottle of single -blind placebo tablets (blinded to the participant) will be dispensed for 
the participant to take 1 tablet once daily b y oral ingestion through the remainder of that 
correspo nding week, Day s 2 through 7. On Day  8, a single tablet of double -blind study  treatment 
(placebo, AGN -241751 3 mg, 10 mg, or 25 mg) will be administered orally in the clinic. A bottle 
of double -blind study  treatment will be dispense d for the participant to take 1 tablet once dail y 
by oral ingestion through the remainder o f that corresponding week, Day s 9through 15.
Part B:
During the 1stweek of the doub le-blind BID treatment period (inpatient ),randomized 
participants will be dosed BID from Bottle 1 starting at Visit 3(Day  1) through Visit 9 (Day 7) 
in the clinic. Each day , participants will be administered a single tablet of double -blind study  
treatmen t (AGN -241751 3 mg, AGN -241751 25 mg, or placebo) orall y in the morning after the 
daily  predose assessments are completed, and another single tablet will be administered 8 hours 
(± 1 hour) after the morning dose. On Visit 10 ( Day 8), Bottle 2 will be dispe nsed. The 1 sttablet 
from Bottle 2 will be taken in the clinic after predose assessments are completed. Upon discharge 
atVisit 10 (Day  8),the participant will take B ottle 2 home. The 2nd tablet from Bottle 2 will be 
taken at home b y the participant in the afternoon on Day 8. Participant swill continue to take 
1tablet in the morning and take the 2nd tablet in the afternoon dail y at home by  oral ingestion 
starting in the afternoon of Visit 10 (Day  8) through Visit 12 /ET(Day 14/ET).During the 
outpatient period of the study , participants should try  to adhere to the relative dosing times used 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
18
within the inpatient phase (ie, morning and afternoon doses, approximately 8 hours apart).
Should a dose not be administered accordingl y, the participant should be instructed as follows:
If within 4 hours of the scheduled dosing time, the participant should take the dose as 
soon as possible and continue to proceed with the relative dosing times used within the 
inpatient phase.
If greater than 4 hour sfrom the scheduled dosing time, the participant should abstain 
from taking this dose and proceed with the next dose at the subsequent scheduled dosing 
time used within the inpatient phase. 
Number of Sites :
Approximately  5 sites in the United States (Part A) and approximately 3 to 6 sites in the United 
States (Part B)
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
19
2. Schedule of Activities (SoA)
2.1. Part A
Double -blind Treatment PeriodSafety Follow -up 
Period
Visit Screening (1) 2 3 4 5 6/ETa7
Study Day up to –14 days 1 2 8 9 15 22
Informed consent x
Medical (surgical, neurologic) and psychiatric 
historiesx
Prior medication history x
Inclusion/exclusion x x
Randomization assessment x
Clinical laboratory determinationsbx x x
Urine drug screen x x
Serum pregnancy test x x
Pharm acogenomics consent and samplecx
Vital signsdx x x x x x x
ECG x x
Physical examination x x
SCID x
MADRS x x x x x x x
CGI-S x x x x x x
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
20
Double -blind Treatment PeriodSafety Follow -up 
Period
Visit Screening (1) 2 3 4 5 6/ETa7
Study Day up to –14 days 1 2 8 9 15 22
BPRS+ x x x x x
CADSS x x x x x
C-SSRS x x x x x x x
HAM -Aex x x x
AEs x x x x x x
Concomitant medications x x x x x x x
Study treatment administration in the clinic x x
Study treatment compliance x x x x
Screening procedures may be conducted on up to 2 separate dates where necessary to accommodate participant and site schedule;  however , every effort should be made to 
conduct all procedures as early as possible in the screening period. 
If necessary , study visits may be conducted up to 2 days before or after the scheduled visits except for visits that are 1 da y apart (ie, V isits 2 and 3 must be conducted 1 
day apart, and V isits 4 and 5 must be conducted 1 day apart). 
aPerformed for all participants, including those prematurely discontinued after randomization. Clinically significant findings upon termination should be follow ed until 
the condition returns to prestudy status or can be explained as unrelated to study treatment. If necessary , additional follow -up visits can be scheduled. 
bParticipants will be requested to fast overnight or for at least 8 hours before arriving at the study center for appointments  involving the collection of clinical laboratory 
blood tests. Clinical laborator y tests can be done at any visit for safety reasons at the discretion of the investigator .
cA separate ICF must be signed before the pharmacogen omicblood sample is taken. Participation is optional. This ICF may be signed at any visit during the study; 
however, the sample should be collected at any visit after the participant has been randomized .
dHeight  will only be measured at V isit 1 (Screening); pulse rate, blood pressure, temperature, and body weight will be assessed at every visit. Blood pressure and pulse 
will be assessed while the participant is supine and standing.
eHAM -A will be assessed predose at Visit s2, 3, 4, and 6 /ET.  The HAM -A will be collected only from  participants entering the study after the amendment has been 
IRB approved.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
21
2.2. Part B
OutPt Inpatient Outpatient
Double -Blind Treatment Safety 
Follow -
Upa
VisitbV1
Screeni
ngV2
Base
-
lineV3 V4 V5 V6 V7 V8 V9 V10
Dis-
chargeV1
1V12/
ETc,dV13 V1
4
Study Day Up to 
14
daysD
–1
Adm
itD1 (First Day of 
Dosing)D2 D3 D4 D5 D6 D7 D8 D1
1D14/
ETD18 D2
1
Assessment Time 
Relative to Morning 
Dose (h ours)eN/A P
r
e1
&
24 8 12 P
r
e1 
&
24 8 12 P
r
e1
&
24 8 12 P
r
e1
&
24 8 12 P
r
e4 8 12 P
r
e4 8 12 P
r
e4 8 12 P
r
e4 N/A
ICF X
MedHx/PsyHx X
Prior & ConMed X X X X X X X X X X X X X X
Physical Exam X X
Incl/Excl X X
Vital Signs fX X X X X X
Rando mize X
SCID X
Likert Patient 
Depressive Symptom  
Scales X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MADRS X X X
gX X X X X X
CGI-S X X X X X X X X X X X X X X X X X X X X X X
C-SSRS X X X X X X X X X X X X X X
CADSS X X X X X
BPRS + X X X X X X
ECG X X X
Clinical Laboratory 
Determinationsh,iX X X X
Hepatitis Serology X
Urine Drug ScreenjX X X X
Serum Pregnancy 
TestkX X X X
Pharmacogenetic 
Consent and X
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
22
OutPt Inpatient Outpatient
Double -Blind Treatment Safety 
Follow -
Upa
VisitbV1
Screeni
ngV2
Base
-
lineV3 V4 V5 V6 V7 V8 V9 V10
Dis-
chargeV1
1V12/
ETc,dV13 V1
4
Study Day Up to 
14
daysD
–1
Adm
itD1 (First Day of 
Dosing)D2 D3 D4 D5 D6 D7 D8 D1
1D14/
ETD18 D2
1
Assessment Time 
Relative to Morning 
Dose (h ours)eN/A P
r
e1
&
24 8 12 P
r
e1 
&
24 8 12 P
r
e1
&
24 8 12 P
r
e1
&
24 8 12 P
r
e4 8 12 P
r
e4 8 12 P
r
e4 8 12 P
r
e4 N/A
Sampling (Opt.)l
HVLT -RmX X X X X X X
KSS/qEEG/ERP 
(mid -day)X
KSS/q EEG /ERP 
(afternoon)X
KSS/qEEG/ERP n,oX X X X X X X X X X X X
CSF Pre -Dose 
Consent and 
Sampling
(Opt. 1x per pt.)pX
CSF Post -Dose 
Consent and 
Sampling
(Opt. 1x per pt.) pX
Adverse Event X
Rescue Med (Sleep/
Benzo) qNone PRN (withhold 12 hours prior to scale assessm ents and qEEG/ERPs)
Provide Patient Diary X X X X
Return & Review 
DiaryX X X X
Assign/Dispense
study treatmentX X
Study Treatment
Compliance (Return)X X X
Discharge PtrX
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002Amendment 2
23
Benzo= benzodiazepines ; B/L=baseline; D=day ; ET=e arly termination ; Excl=exclusion; h=hour(s); ICF=informed consent form; Incl=inclusion; LFT=liver function te st; MedHx= medical 
history ; PD1=post first dose ; PRN=as needed; PsyHx=psychiatric history ; Pt=participant ; OutPt=outpatient; V=visit.
aIf necessary, these study visits may be conducted up to 1 day before or after the scheduled visit day.
bDuring the inpatient treatment period, participants will have 7 visits (Visits 3 to 9); each visit will occur daily with no visit windows. A Patient Diary containing a Study Medication Dosing 
Log and Likert scales will be provided at Visits 10 and 11 for completion b y the participant at home. In addition, the Patient Diary will be provided during the safety follow -up period at 
Visit 12 and at Visit 13. Participants will return the diary for review by site staff at Visits 11 through 14.
cClinically significant finding s upon termination should be followed until the condition returns to prestudy status or can be explained as unrelated to study treatment . If necessary, additional 
follow -up visits maybe scheduled.
dThis visit is performed for all participants who receive d at least 1 dose of study treatment.
eAssessments at a given timepoint should be conducted ± 20 minutes of each other, and all psychiatric assessments (Likert Pati ent Depressive Symptom Scales, CSSR -S, MADRS, and 
CGI-S) are to be completed first prior to any other assessments.
fHeight will be measured only at Visit 1 (Screening); pulse rate, blood pressure, temperature, and body weight will be assessed at the visits indicated in the table . Blood pressure and pulse 
rate will be assessed while the particip ant is supine and standing.
gIf significant change (worsening or improvement in depressive symptoms) at Visit 3 (Day 1) prior to morning dosing based on the judgment of the PI, a MADRS assessment should be 
performed prior to the 1stdose of study medicati on.
hAbnormal LFT values will be repeated (refer to Section 9.4.4 and Appendix 2 for details) .
iParticipants will be requested to fast for at least 8 hours.
jParticipants with a positive UDS at Visit 1 may be allowed in the study provided certain circumstances are met (see Section 6.2). Participants testing positive for cocaine, barbiturates, 
methadone, or phencyclidine in the UDS at Visit 1 should be excluded from the study, with no exceptions.
kA urine pregnancy test should be done on Day –1(at baseline), if more than a week has passed since the serum pregnancy test was done atScreening. Additional urine pregnancy tests may 
be done at the PI’s discretion throughout the study. If urine test is positive at Day –1(baseline) or at any time dur ing the study , a serum β -hCG pregnancy test should be done for 
confirmation .Serum pregnancy tests may be conducted at other visits not indicated per Investigator judgment .
lA separate consent will be collected at Screening (or prior to sample collection) for optional pharmacogenetic sampling. If participants are randomized and consent to this sampling, the 
sample will be collected predose at Visit 9 (Day 7). 
mWithhold nicotine 1 hour before assessment .
nKSS is to be completed prior to qEEG/ERP assessme nts.Error windows permitted for the qEEG measurements will be ± 30 minutes at any collection timepoint up to 12 hours postdose 
and ± 1 hour at any collection timepoint up to 24 hours postdose. The qEEG/ERP t est times should not be confounded by food intake; eg, if baseline is done 30 minutes after lunch, the test 
should be 30 minutes after lunch. The ERPs will be measured approximately 10 minutes following each corresponding qEEG measur ement.
oTo be conducted at selected sites .
pCSF optional at all sites; preferred at V5 ( if not done at V5, sample can be taken at V4 or V6). Within each site, 1 sample (either pre -dose or post -dose sample) per participant will be 
collected, and study staff will alternate between predose and postdose for participants (e g, 1st patient sample is collected predose, 2nd participant sample is collected postdose, 3rd 
participant sample is collected predose, etc.). 
qWithhold 12 hours prior to psych iatric and qEEG /ERP assessments .
rDischarge post qEEG/ERP.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
24
3. Introduction
Disease Burden of Major Depressive Disorder
MDDis a highl y disabling, serious condition which is associated with significant morbidity and 
mortality . MDD manifests as a major depressive episode (which may  be singular or recurrent) in 
which the affected individual exper iences 1) depressed mood, or 2) loss of interest or pleasure 
(as well as other s ymptoms) for most of the day , nearl y ever y day, for at least 2 weeks. MDD 
affects approximately  14.8 million American adults, or about 6.7% of the US population 
18years of age and older , in a given year (Kessler 2005 ). Worldwide, about 15% of the adult 
population is at lifetime risk of developing MDD ( Kessler 1994 ).
Depression may  cause serious, long -lasting s ymptoms and often disrupts a person’s ability  to 
perform routine tasks. In 2000, unipolar depressive disorders were b y far the leading cause 
(11.9%) of worldwide years of life lived with disability  (World Health Organization 2001 ), and 
the total economic burden o f treating depression in the United States was $83.1 billion, with 
workplace costs, including missed days and lack of productivity due to illness, accounting 
formost of the total economic burden (62%). Other economic burdens in 2000 included 
$26.1 billion (31%) for treatment costs and $5.4 billion (7%) for suicide -related costs 
(Greenberg 2003 ).
MDD is a leading cause of disability in the United States ( Murray  2013 ). Moreover, MDD is 
known to be a significant risk factor for suicide and ischemic heart disease, as it accounted for 
16million of the disability adjusted life y ears (DALYs) associated with suicide and 4 million of 
the DALYs associated with ischemic heart disease. Research has shown th at untreated 
depression has both a functional (social and work role) as well as a neuroanatomical 
(hippocampal shrinkage) effect on the patient ( Videbech and Ravnkilde 2004 ). Given the disease 
burden and link to suicidality  as well as increased mortality  with other comorbid conditions, 
MDD is a serious and life -threatening condition which is a leading cause of disability  in the 
world.
Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Norepinephrine Reuptake 
Inhibitors in Major Depressive Disorder
SSRI s and SNRI s currently  represent the first line of treatment of depression in the United 
States . Unfortunatel y, a large number of patients do not experience therapeutic benefit from 
these first -line agents ( Rosenzweig-
Lipson 2007 ). Lack of sufficient response to adequate 
treatment remains a critical problem in the management of patients with MDD. Up to two -thirds 
of patients treated with first -line antidepressant monotherap y do not rea ch full remission, and as 
many  as a third become treatment resistant ( Fava and Davidson 1996; Trivedi et al 2006 ). Not 
achieving remission has been shown to be predictive of poorer psychosocial functioning, higher 
rates of relapse, and higher rates of rehospitalization ( McInt yre and O’Donovan 2004 ).
The results of the STAR*D study  suggest that with successive failures of treatment, patients are 
less and less likely  to respond to subsequent trea tment, and those who do respond are more likel y 
to relapse ( Rush 2006 ). Present strategies available to treat patients who do not respond to 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
25
first-line antidepressant monotherap y include switching of antidepressant (either wi thin or 
between classes); combination therap y in which multiple antidepressants are used 
simultaneously ; augmentation of ongoing antidepressant monotherapy  with adjunctive use of 
drugs such as mood stabilizers or aty pical antipsychotics ( Boland and Keller 2006 ); and 
nonpharmacologic treatments including ps ychotherap y and phototherap y, vagus nerve 
stimulation, transcranial magnetic stimulation, and ECT. Clearly, there remains a criticall y 
important unmet medical need for this p atient population.
Existing antidepressants have a number of limitations, leading to considerable unmet medical 
need in the effective treatment of MDD, with up to 50% of patients with MDD having an 
inadequate response to or failing current ADT. Currentl y available first -line antidepressants 
(SSRI s, SNRI s) typically take 3 to 4 weeks or more of continuous dail y dosing to relieve 
symptoms of MDD and are associated with side effects related to their pharmacological 
mechanisms of action (sexual dy sfunction, wei ght gain, jitteriness, sleep disturbances), which are 
further associated with poor patient compliance ( Masand 2003, Ashton 2005 ). Patients often 
experience undesirable side effects before they experience an improvement in dep ressive 
symptoms, which could lead to premature discontinuation of therap y. Taken together, these 
factors define significant areas for improvement of ADT.
Patients vary  greatl y in their response to antidepressants and it is not possible to reliably predict
whether an individual patient will respond to a given antidepressant. This leads to clinicians 
often using a trial -and-error approach to identify  an effective antidepressant. Due to the slow 
onset of the development of the full therapeutic effect of curre ntly available treatments, each 
antidepressant needs to be administered for 4 weeks or longer to determine the individual 
therapeutic benefit, making the process of finding an effective antidepressant a length y process 
for patients who are often severel y depressed and at a high risk for suicide. Clearly a drug that 
could induce a rapid antidepressant effect would represent a major advancement for these 
patients.
While inhibition of serotonin reuptake improves the management of patients with depression, 
these agents suffer two severe limitations: 1) they require several weeks of continued dosing 
until a patient can experience the full therapeutic benefit, and during this time patients continue 
to be affected b y the s ymptoms of depression and the risk of self -harm, and 2) a large number of 
patients do not experience therapeutic benefit ( Rosenzweig-Lipson 2007 ). Intravenous ketamine, 
an NMDAR antagonist, provides rapid relief of depressive s ymptoms, unlike the SSRI s and 
SNRI s; howe ver, this beneficial effect is accompanied by  classic NMDAR antagonist effects, 
including ps ychotomimetic activity, confusion, and dissociation. I n addition, ketamine is 
approved as an anesthetic agent, and not approved for use as an antidepressant. Psychi atric use of 
ketamine may  be limited by  the need for repeated infusions to maintain a treatment response, its 
safet y profile, and its abuse potential, being a Schedule III controlled substance. Based upon the 
available evidence of ketamine, modulation of t he NMDAR is being pursued as a therapeutic 
target for MDD treatment.
Recently , rapastinel has emerged as a representative of a potentiall y new class of antidepressants 
that positively  modulate the NMDAR function and have the potential to provide rapid and 
significant antidepressant activity  without many  of the adverse side effects of NMDAR 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
26
antagonists like ketamine. Rapastinel has demonstrated rapid and long -lasting antidepressant 
effects in rodent models of depression as well as in MDD patients, with a fav orable side -effect 
profile ( Burgdorf 2013; Preskorn 2015 ). Rapastinel’s unique mechanism of action may  explain 
its lack of ketamine -like side effects. Rapastinel is believed to activate a cascade of biochemical 
and phy siologi cal processes like L TP-based s ynaptic plasticity. Rapastinel potentiates L TP 
following acute treatment (unlike ketamine) and does not impair cognition in a variet y of animal 
models of cognition (unlike ketamine and other NMDAR antagonists like PCP and MK -801) 
(Blanke 2009; Nicholson 2009; Skolnick 2009 ). Early Phase 2 clinical trial experience suggests 
that the rapastinel pharmacology  lacks the negative sy mptomatic effects of NMDAR antagonists. 
Compared with ketamine and other NMDAR antagonists, rapastinel exhibits a significantl y 
improved CNS tolerability  profile. 
Like rapastinel, AGN -241751 is a novel NMDAR modulator with partial agonist properties. 
AGN -241751 has appropriate oral bioavailability  and blood brain barrier pene tration. 
In support of AGN -241751 investigation in human subjects, a series of nonclinical 
pharmacology  studies have been performed. These studies were designed to characterize 
AGN -241751 in terms of its potential to a) potentiate NMDAR activity ; b) stren gthen 
NMDAR- dependent LTP; and c) produce antidepressant -like effects in rat models. Additional 
safet y and tolerability studies were carried out to evaluate AGN -241751’s side effect profile, 
including potential ataxic/sedative and pro -convulsive effects. B esides display ing potent partial 
agonist activity  at NMDAR, AGN -241751 increased NMDAR -dependent sy naptic plasticit y in 
rat hippocampus and medial prefrontal cortex in vitro and ex vivo. AGN -241751 was active in 
several models of depression, and has demons trated rapid onset of action in rat models of 
depression without causing CNS side effects. AGN -241751 had no appreciable affinity  for over 
60 neurotransmitter -receptors and ion channels in a CEREP screen indicating a lack of potential 
off-target effects. Central nervous s ystem safet y and tolerability  profile of AGN -241751 was 
favorable at substantially higher doses relative to its antidepressant doses. Although transient 
lowering of blood pressure in conscious telemetered dogs was observed in cardiovascular safet y 
studies, there were no findings that preclude its use for further development. I n other safety  
pharmacology  studies, AGN -241751 was not associated with an y adverse effects. In summary , 
the safet y profile of AGN -241751 supports the proposed clinical doses (0.25 mg up to 25mg).
Following oral administration, mean oral bioavailability of AGN -241751 in rats and dogs was 
approximately  100% and 99%, respectively . There was no accumulation after repeat 
administration and AGN -241751 was rapidl y distributed to the target tissue (brain) with T maxat 
1hour post dose in rats. Brain to plasma and CSF to plasma AUC ratios were 0.16 and 0.3, 
respectivel y. 
Acute dosing in rats showed no effects on the central or peripheral nervous sy stem. Drug -related 
findings after oral dosing in rats for 28 days were limited to mild increases in absolute and 
relative (to brain and body) liver weights that correlated with m inimal hepatocellular 
hypertrophy , minimal to mild pigmented material in bile ducts, and minimal periductal 
mononuclear cell infiltrates at ≥ 300 mg/kg/day . The NOAEL in this study  was 600 mg/kg/day . 
Oral dosing in dogs was not tolerated at ≥ 40 mg/kg/day .Drug -related findings in dogs included 
decreases in bod y weight and alterations in serum chemistry (only males) at 20 mg/kg/day, 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
27
reversible increases in hepatic enzy mes and brown pigmented mat erial in hepatic sinusoids at 
≥10 mg/kg/day  and minimal to mod erate Kupffer cell hypertroph y/hyperplasia and minimal to 
mild increased incidence of mononuclear cell infiltrates at all doses. Increases in liver enzymes 
correlated with microscopic findings of hepatotoxicity  at20 mg/kg/day . The NOAEL was 
10mg/kg/day ;however, the more conservative dose of 3 mg/kg/day  is used for the calculation of 
safet y margins due to moderate liver enzymes increases observ ed at 10 mg/kg/day . A dose of 
3mg/kg/day  in dogs (the most sensitive species) results in a sy stemic exposure (AU C; Day  1) 
that is 3.5 times the exposure at the highest dose (50 mg) evaluated in the single ascending dose
study .
Data from complete dand ongoing clinical studies, a single ascending dose study (3125 -101-009) 
and multiple ascending dose study  (3125 -102-009) in healthy  male and female volunteers, have 
demonstrated an acceptable safet y and tolerability profile up to doses of 50 mg administered 
once, or dail y for consecutive 10 days. Based upon preliminary  PK data in healthy  volunteers, 
systemic exposures of AGN- 241751 demonstrate rapid absorption, rapid clearance, and dose -
related increases in exposures in plasma and CSF. Female subjects demonstrated similar PK 
exposures to male counterparts receiving a 1.0 mg dose of AGN -241751 under fasted conditions, 
hence sex does not appear to significantl y influence the overall exposures of AGN -241751. After 
multiple doses of AGN -241751, no apparent sy stemic accumulation was observed up to 25 mg.  
Although the s ystemic exposures of AGN -241751 were slightly  delay ed when d osed in the fed 
state (approximate 40% reduction in C max, and 1- hour delay  in T max), the overall exposures were 
similar for the plasma (AUC), and CSF profiles. Hence, administration of AGN -241751 can be 
in fed or fasted state.
3.1. Study Rationale
AGN -241751 is a functional modulator of the NMDAR with partial agonist properties. In rodent 
models of depression, AGN -241751 elicited potent , rapid , and long -lasting antidepressant 
activity  without adverse CNS effects. AGN- 241751 is an orally bioavailable small mole cule with 
NMDAR partial co -agonist pharmacology . Thus, it represents a novel pharmacology that may  
address a significant unmet need with minimal side effects and the feasibility of an oral dosage 
form. This is a 2-part (Part A and Part B) proof -of-concept study  of AGN -241751 monotherapy
for the treatment of patients with MDD. Part A includes weekl y and once daily administration s 
of AGN -241751 , and Part B includes BID administration. PartB participants should not have 
participated in Part A at any time, and Part A participants should not have participated at an y 
timein Part B (ie, Part A is not a contingent step to participate in PartB).
3.2. Background
AGN -241751 is a novel NMDA Rmodulator with partial agonist properties and high oral 
bioavailability . Unli ke the NMDAR antagonist, ketamine, AGN -241751 potentiates NMDAR 
function (Study  BIO -16-1126, Study  DMP -2015 -003). AGN- 241751 has the potential to provide 
rapid and significant antidepressant activity ,unlike SSRI s and SNRIs that require several weeks 
of co ntinued dosing to experience full therapeutic benefit. The compound is being developed for 
the treatment of MDD .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
28
3.3. Benefit/Risk Assessment
The expected benefits of AGN -241751 are potentially  a rapid -onset ,and long -acting, oral 
treatment for depression. The compound has the potential to have lower side effects than what is 
currentl y on the market. 
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of AGN -241751 canbe found in the investigator’s brochure.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
29
4. Objectives and Endpoints
Clinical Hypothes is
Administration of AGN -241751 will result in greater improvement of s ymptoms in participants 
with MDD compared with placebo, as measured by the MADRS total sc ore.
4.1. Part A
The primary  objective of Part A is to evaluate the efficacy , as measured b y improvement in 
MADRS total score, at 1 day  after the initial single oral dose of AGN -241751 compared with 
placebo in participants with MDD (Day  1 [predose, defined as baseline] vs Day  2). The key  
secondary  objectives are to evaluate the efficacy  at Day  8,at Day 9after single oral dose, at
Day 15 after repeated dose, and atDay 22, 7 day s after the completion of AGN -241751 dosing, 
when administered orally once dail y compared with placebo in participants with MDD.
Objectives Endpoints
Primary
To evaluate the efficacy  at 1 day  post 
the initial single oral dose of 
AGN -241751 compared with placebo 
inparticipants with MDDChange from baseline (Day  1, predose ) in 
MADRS total score at 1 day after the first 
dose of treatment (Day  2)
Key Secondary
To evaluate the efficacy  at Day  8, at 
Day 9 (single dose), at Day 15 (repeated 
dose) of AGN -241751 administered 
orally  once dail y,and at Day  22 (7 day s 
after completi on of AGN- 241751 
dosing) compared with placebo in 
participants with MDDChange from baseline (Day 1, predose ) in 
MADRS total score at Day  8, Day 9, Day 15, 
and Day  22
Additional
Additional endpoint to be explored to 
determine differences between 
AGN -241751 and placebo in 
participants with MDDChange from baseline in CGI -S total score at 
Day 2, Day  8, Day  9, and Day  15 
Rate of responders on MADRS or CGI  S at 
Day 2, Day  8, Day  9, Day  15, and Day  22
Rate of remitters on MADRS at Day  2, Day  
8, Day  9, Day 15, and Day  22
Time to first response on MADRS
Time to first remission on MADRS
Change from baseline ( Day 1, predose) in 
HAM -A at Day  2, Day  8, and Day  15
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
30
Objectives Endpoints
Safety  Measures AE recording, clinical laboratory  measures, 
vital sign parameters, ECGs, and physical 
examinations
Measure of ps ychotomimetic effects: BPRS+ 
Measure of dissociative effects: CADSS
Measure of suicidality : C-SSRS
4.2. Part B
The primary  objective of Part B is to evaluate the efficacy of the change from baseline in 
MADRS total score at 7 day s after the 1stdose of AGN -241751 (3 mg and 25 mg) compared 
with placebo in participants with MDD. The key  secondary  objectives are to evaluate the 
efficacy  at Day 2, Day  11, Day  14, Day  18, and Day 21after the 1stdoseof AGN -241751 (3 mg 
and 25 mg) compared with placebo in participants with MDD. In addition, optional CSF samples 
will be collected in a subset of participants for PKanalysis, and qEEG and ERP assessments will 
be collected in a subset of participants forpharmacody namic analy sis.
Objectives Endpoints
Primary
To evaluate the efficacy  at Day 7of 
AGN -241751 compared with placebo in 
participants with MDD dosed BIDChange from baseline in MADRS at 
7days after the first dose of treatment
Key Secondary
To evaluate the efficacy  on Day 2,
Day 11,Day 14, Day 18, and Day  21
(7days after completion of dosing) after 
BID administration of AGN -241751 
compared with placebo in participants 
with MDD dosed BIDChange from baseline in MADRS total 
score at Day  2,Day 11,Day 14, Day 18, 
and Day  21 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
31
Objectives Endpoints
Additional
Additional endpoints to be explored to 
determine differences between 
AGN -241751 and placebo in participants 
with MDD dosed BIDChange from baseline in CGI -S total score 
by visit
Rate of responders on MADRS at Day 2, 
Day 7, Day 11, Day 14, Day  18,and 
Day 21
Rate of remitters on MADRS at Day 2, 
Day 7, Day 11, Day 14, Day  18,and 
Day 21
Rate of responders on CGI -S by visit 
Time to first response on MADRS
Time to first remission on MADRS
Symptoms over time based on Likert 
Patient Depressive S ymptom S cales
Total recall scores at specified timepoints 
in HVL T-R
Evaluation of pharmacodynamic 
endpoints (qEEG/ERP) and CSF between 
AGN -241751 and placebo in participants 
with MDD dosed BIDChange from baseline in qEEG 
parameters collected during Day  1, Day 7, 
Day 14, and Day 21
Change from baseline in ERP parameters 
collected during Day  1, Day 7, Day 14, 
and Day 21
Descriptive anal ysis of CSF 
concentrations of AGN -241751
Safety  Measures AE recording, clinical laboratory  
measures, vital sign parameters, ECGs, 
and phy sical examinations
Measure of ps ychotomimetic effects: 
BPRS+ 
Measure of dissociative effects: CADSS
Measure of suicidality : C-SSRS
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
32
5. Study Design
5.1. Overall Design
Part A of th isstudy  is a multicenter, randomized, double -blind, placebo -controlled, 
parallel -group (4 arms), weekl y and once daily dose, 2 -week double -blind treatment in 
participants with MDD. Part B of this study  is a multicenter, randomized, double -blind, 
placebo -controlled, parallel -group (3 arms), BID dose, 2 -week double -blind treatment in 
participants with MDD.  
5.1.1. Part A
Part A of the stud y will include a total of 7 visits and will be approximately  5 weeks in duration:
Up to 2 -week screening period 
2-week double -blind treatment period 
1-week safet y follow -up period 
After providing written consent, participants will enter a screening period of up to 14 day s. 
Screening procedures may be conducted on up to 2 separate dates where necessary  to 
accommodate participant and site schedule; however, every  effort should be made to conduct all 
procedures as earl y as possible in the screening period. Participants meeting the eligibility 
criteria at the end of Visit 2 (Day 1 of the randomized inpatient treatment ) will be assig ned a 
treatment and enter the double -blind treatment period.
Approximately  100 participants are planned for enrollment in the double -blind treatment period 
(25 participants each in 3 different AGN -241751 dose groups and a placebo group). Participants 
will be randomized in a ratio of 1:1:1:1 to 1 of 4 treatment groups: 3 mg, 10 mg, and 25 mg dose 
AGN -241751 and placebo.  All participants will be randomized to receive active treatment or 
placebo (Day 1 and Day s 8to 15) and placebo alone (Days 2 through 7). 
AGN -241751 is being developed for once -weekl ydosing; however, the impact of repeated
administration of AGN -241751 requires testing. In order to minimize participant’s expectations 
and control for placebo response while changing dosing regimens, all treatment swill be 
presented to participants as oral dail y dosing throughout the study. On Day  1, all part icipants will 
be randomized to receive the first treatment (ie, 4 treatment groups: 3 mg, 10 mg, and 25 mg 
dose AGN -241751 or placebo), followed by  blinded placebo on Day s 2 through 7.  Starting on 
Day 8, participants will then start 7 consecutive day s of randomized treatment, administered 
once dail y through Day 15.  
On Day  1, site staff will give the participant the single dose of double -blind study  treatment from 
Bottle 1 (for applicable visit) to take by oral ingestion in the clinic (ie, the first dose of study  
treatment for that week). Site staff will then give Bottle 2 (for applicable visits), which contains 
the single- blind placebo tablets, to the participant with the instruction to take 1 tablet dail y by 
oral ingestion for the remainder of that week (Days 2 through 7). On Day  8, site staff will give 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
33
the participant the single dose of double -blind study  treatment from Bottle 1 (for applicable visit) 
to take by  oral ingestion in the clinic (ie, the first dose of study  treatment for that week). Site 
staff will then give Bottle 2 (for applicable visits), which contains double -blind study  treatment, 
to the participant with the instruction to take 1 tablet daily b y oral ingestion for the remainder of 
that week (Day s 9 through 15).
Participants will have 7 st udy visits during the study . The first 6 visits will occur in the following 
pattern: the Screening Visit (Visit 1; up to Day  –14); at Visit 2 (Day  1 of the randomized 
inpatient treatment); at Visit 3 (1 day  following the inpatient treatment day); at Visit 4 (7days 
following the first inpatient treatment day , which is the 2nd inpatient treatment day ); at Visit 5 
(1day following the 2nd inpatient treatment day ); and at Visit 6 (7days following the 
2ndinpatient treatment day ). If necessary , study  visits ma y be conducted up to 2 day s before or 
after the scheduled visits with the exception of visits that are 1 day apart (ie, Visits 2 and 3 must 
be conducted 1 day  apart; and Visits 4 and 5 must be conducted 1 day  apart). Participants will 
enter a 1 -week safety follow -up period and return for Visit 7. Participants who prematurely 
discontinue from the study before completing the double -blind treatment should enter the 1 -week 
safet y follow -up period. Additional follow -up visits may  be scheduled within 30 day s, if 
necessary  for safet y reasons.
Figure 5–1 Study Design Diagram –Part A
IP Administered
 IP Administered
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
34
All treatment swill be presented to participants as oral once daily  dosing throughout the study . 
Daily  dosing of AGN -241751 should occur at a similar time throughout the entire stud y. 
At Visit 2 (Day 1 of the randomized inpatient treatment ), all participants will be randomized to 
receive the first treatment, follow ed by  blinded placebo on Day s 2 through 7.
Starting at Visit 4(Day  8), participants will then start 7 consecutive day s of randomized 
treatment, administered once dail y through Day 15 .
5.1.2. Part B
Part B of this study  will include a total of 14 visits and wil l be approximately 5 weeks in duration 
as described below.
Up to a 2 -week screening period 
2-week double -blind treatment period (Week 1 inpatient, Week 2 outpatient)
1-week outpatient safet y follow -up period 
Approximately  120 participants are planned fo r randomization in the double -blind treatment 
period (40 placebo participants, 40 AGN -241751 3 mg participants, 40 AGN -241751 25 mg 
participants). Eligible participants will be randomized in a ratio of 1:1:1 to one of 3 double -blind 
oral administration tre atment groups: 3 mg dose of AGN -241751, 25 mg dose of AGN -241751, 
or placebo , administered BID. Participants who enrolled ( were randomized) in Part A will not be 
permitted to screen into Part B (and vice versa).
Screening Period
After providing written con sent, participants will enter a screening period of up to 14 days. 
Screening procedures may be conducted on up to 2 separate dates where necessary to 
accommodate participant and site schedule; however, every  effort should be made to conduct all 
procedures as earl y as possible in the screening period. Participants will wash out of any ADT 
and prohibited medications under the supervision of the study investigator staff during the 
screening period. At Visit 2 (Day –1), stud y procedures required to determine el igibility  will be 
completed prior to admission to the clinic. Participants meeting the eligibility  criteria at Visit 2 
(Day –1, Baseline) will be admitted to the inpatient facility , and the remainder of the Visit 2 
study  procedures will be completed. A urine pregnancy  test should be done on Day –1 (at 
baseline), if more than a week has passed since the serum pregnancy test was done at Screening.
Participants are required to not use any nicotine substances 1 hour prior to administration of the 
HVLT -R.
Doub le-Blind Treatment Period
Participants will be randomized in a ratio of 1:1:1 to 1 of 3 treatment groups (AGN -241751 3 mg 
BID, AGN- 241751 25 mg BID, or placebo BID) for the 2-week double -blind treatment . 
Participants will be administered 1 tablet in the mo rning and 1 tablet in the afternoon. At Visit 3 
(Day  1), the participant will be randomized and assigned a treatment by the interactive web 
response s ystem (IWRS) ,and t he 1stdose of stud y medication will be administered in the 
morning after all predose a sessments have been completed.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
35
Week 1 Inpatient Double -Blind Treatment Period 
It is expected that participants in the double -blind treatment period will remain inpatient 
during the 1 st week (Visit 2 to Visit 10/Discharge).
During the inpatient treatment period, participants will have 7 visits (Visits 3 to 9); each 
visit will occur daily  with no visit windows.
At Visit 3 (Day  1) during the predose evaluation period ,if there is a significant change 
(worsening or improvement in depressive s ymptom s) from the baseline Visit 2 ( Day –1) 
MADRS based on the judgment of the PI, a MADRS assessment should be performed prior 
to the 1stdose of study  medication.
Participants will be discharged at Visit 10 (Day  8) after all predose assessments, morning 
dosing , and 4- hour postdose assessments are completed.
During the inpatient treatment period, predose assessments will be performed prior to 
morning dosing at all inpatient visits (Visit 3 through Visit 10). Postdose assessments will be 
performed, as follows:
oVisit 3 to Visit 6: 1, 2, 4, 8, and 12 hours after the morning dose (± 20 minutes) 
oVisit 7 to Visit 9: 4, 8, and 12 hours after the morning dose (± 20 minutes)
oVisit 10: 4 hours after the morning dose (± 20 minutes) 
Within each timepoint, multiple assessme nts will be performed, as follows:
oAssessments should be performed within  ± 20minutes of each other
oAll psy chiatric assessments ( Likert Patient Depressive Sy mptom Scales , CSSR -S, 
MADRS, and CGI -S) are to be completed first prior to any  other assessments (ie,qEEG, 
ERP) within the timepoint.
oParticipants are required to not use any nicotine substances 1 hour prior to administration 
of the HVLT -R.
The afternoon dose of study  medication is to be administered 8 hours (± 1hour) after the 
morning dose.
Week 2 Outpatient Double -Blind Treatment Period
During the outpatient treatment period, there will be 2 visits conducted every 3 days 
(Visit 11 [Day 11] and Visit 12 [Day  14/ET]). If necessary ,these stud y visits may be 
conducted up to 1 day before or after the scheduled visit day.
All participants who receive study  medication should complete Visit 12 (Day  14/ET)
At Visit 10 (Day  8) prior to discharge, the participant will be dispensed Bottle 2 of study  
medication (refer to Section 7.1.2 for dosing instruction). Participants will be instructed to 
bring the stud y medication bottle to Visit 11 for the site staff to confirm dosing compliance
The study  medication bottle will be ret urned at Visit 12; site staff will confirm dosing 
compliance.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
36
A Patient Diary  will be provided at Visit 10 and Visit 11 for completion by  the participant at 
home. At Visits 11 and 12, the participant will return the diary ,which was provided at the 
prior v isit. Site staff will review the diary  to confirm compliance and proper completion of 
the diary . At Visit 11 and Visit 12, prior to leaving the clinic, the participant will be given a 
new diary . 
The Patient Diary  will include a Study  Medication Dosing Log and Likert scales.
oStudy  Medication Dosing Log: Participants will be instructed by  site staff to record the 
date and time of the Visit 10 (Day  8) afternoon dose and each subsequent dose the 
participant has taken (morning and afternoon) at home, inclusive of doses on days whe n 
the participant has a clinic visit (Visit 11 [Day 11] and Visit 12/ET [Day 14/ET]). 
oLikert Patient Depressive Sy mptom Scales : Participants will be instructed by site staff to 
complete the Likert assessments at home on Day  9 and Day 10 (between Visit 10 and 
Visit 11) and on Day  12 and Day 13 (between Visit 11 and Visit 12/ET). The date and 
time each Likert assessment was completed arealso to be recorded. The Likert 
assessments on day s when the participant has a clinic visit (Visit 11 [Day  11] and 
Visit 12 [Day  14/ET]) will be completed by  the participant in the clinic (ie, the 
participant will not complete the L ikert assesssment at home on these day s). 
Safety Follow -Up Period (Visit 13 [Day 18] and Visit 14 [Day 21])
Participants completing the double -blind treatment period should enter the 1 -week safet y 
follow -up period. Participants who prematurely  discontinue from the study  before 
completing 2 weeks of double -blind treatment should complete the early  termination (ET) 
visit and then enter the 1 -week saf ety follow -up period.
oA Patient Diary  of Likert scales will be provided at Visit 12/ET (Day 14/ET) and at 
Visit 13 (Day 18). The Patient Diary  will include Likert scales, and participants will be 
instructed by  site staff to complete the Likert assessments at home on Day s 15, 16, and 17 
(between Visits 12 and 13) and on Days 19 and 20 (between Visits 13 and 14). The date 
and time each Likert assessment was completed are to be recorded. The Likert 
assessment on the day of Visit 13 will be completed by  the par ticipant in the clinic 
(ie,the participant will not complete the L ikert assesssment at home on this day ).
oAdditional follow -up visits may  be scheduled within 30 days of last dose of study  
medication or last study  visit, if necessary ,for safety  reasons.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
37
Figure 5–2 Study Design Diagram –Part B
5.2. Participant and Study Completion
5.2.1. Part A
Approximately  100 participants who meet eligibility  criteria at Visit 2 (Day  1 of the randomized 
inpatient treatment) will be randoml y assigned to study treat ment such that approximately  
25participants per arm will be allocated in a 1:1:1:1 ratio.
5.2.2. Part B
Approximately  120participants who meet eligibility  criteria will be randomly  assigned at 
Visit 3(Day 1) to double -blind study  treat ment starting on Day  1 such that approximately  
40participants per arm will be allocated in a 1:1:1 ratio. Participants who enrolled (were 
randomized) in Part A will not be permitted to screen into Part B (and vice versa).
5.3. End of Study Definition
The end of the stud y is defined as the completion of enrollment (Part A)/randomization (Part B)
and completion of all periods of the study. Part A and Part B will each end when the last enrolled
(Part A)/randomized (Part B) patient terminates the study .
A participant is considered to have completed the study  if he/she has completed the double -blind 
treatment period of the study .

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
38
5.4. Scientific Rationale for Study Design
The double -blind study  design was adopted to minimize sy stematic bias resulting from the 
investigator or the participant knowing the treatment being administered. Randomization is 
expected to minimize participant selection bias and increase baseline compar ability  among the 
treatment groups. Additionally , randomized double -blind comparisons versus placebo are needed 
to permit adequate evaluation of efficacy . Comparison to a placebo treatment is also of value for 
distinguishing disease manifestations from adv erse reactions to the study  treatment ( EMA 
guidance 2013 ). The use of placebo in place of the standard therap y should not cause irreversible 
health problems or extreme suffering (depression is recognized by the FDA as a condition in 
which there is substantial improvement and variability  in placebo groups) (FDA Guidance for 
Industry : E10, May  2001 ).
5.5. Justification for Dose
The doses and regimen of AGN -241751 (3 mg, 10mg, and 25mgweekl y and daily in Part A 
and 3 mg and 25 mg BID in Part B) were selected based on summation of in vitro, nonclinical 
pharmacology ,and safety  studies and clinical studies in healthy  volunteers.  
Based upon scaling of preclinical and in vitro data, the doses for each part are expected to
provide similar clinical exposures that demonstrated potentiat ion of NMDAR activity ; 
strengthening NMDAR -dependent LTP; and producing lasting anti -depressant -like effects in 
rat models. 
Given the similar mechanism of activity  with rapastinel and ketamine (ie, NMDA 
modulation), single -dose administration of AGN -24175 1 may result in lasting improvements 
inMADRS scores and ,therefore, justify ing the weekl y interval between dosing within 
PartA. Conversel y, more frequent dosing of AGN -241751 may  be required for 
improvement inMADRS scores. As such, once daily  and BID administration of 
AGN -241751 may  be required to result in lasting improvements inMADRS scores and ,
therefore, justify ing the once daily and BID administration in Part A and Part B, 
respectivel y.
Within healthy  volunteers, there was evidence from multiple pharmacodynamic tests 
(qEEG) that AGN -241751 had beneficial effects on electroencephalographic parameters, 
such as activation and increasing dominant frequency at doses up to 25 mg. As such, similar 
doses are being utilized within this study .
Compared to t he available preclinical toxicology  studies, the proposed top dose sof 25mg 
(Part A) or 25 mg BID (Part B) are expected to result in substantial margins below the 
28-day study  NOAELs designated in the rat ( 225-fold) and dog ( 4-fold).
AGN -241751 has demonstrated acceptable safety and tolerability when administered in 
doses of 50 mg administered once or 50 mg administered dail y for 10 consecutive day s in 
healthy  male and female volunteers. Hence, it is expected that the proposed top dose in 
PartB of 2 5 mg BID, for 14 consecutive day s, will likely  be well tolerated.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
39
6. Study Population
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria apply . 
Inclusion criteria appl y to Parts A and B unless otherwise noted.
1.Written informed consent from the participant has been obtained prior to any stud y-related 
procedures (as described in Appendix 3 ). 
2.Male or female participants must be 18 to 65 y ears of age, inclusive,  at the time of signing 
the informed consent. 
3.Meet DSM -5 criteria (American Ps ychiatric Association 2013 ) for MDD (based on 
confirmation from the modified SCI D), with a current major depressive episode of at least 
8 weeks an d not exceeding 18 months in duration at Visit 1. 
4.Have a minimum score of 26 on the rater -administered MADRS at both Screening 
(Visit1) and V isit 2  (Day 1 in Part A and Day –1 [Baseline ] in Part B).
5.Have a CGI -S score ≥ 4 at both Screening (Visit1) and V isit 2 (Day 1 in Part A and 
Day –1 [Baseline ] in Part B).
6.Part A: Have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy  test at 
Screening (V isit1) if a WOCBP . Part B: If a W OCBP , have a negative serum β-hCG 
pregnancy  test at Screeni ng (V isit1) AND a negative urine pregnancy  test on Day –1 
(baseline) , if more than a week has passed since the serum pregnancy  test at Screening . If 
urine pregnancy test is positive on Day –1, then a serum  β-hCG pregnancy test  should be 
done for confirmat ion.
7.Female participants willing to minimize the risk of becoming pregnancy for the duration 
of the clinical stud y and follow -up period. A female participant is eligible to participate if 
she is not pregnant, not breastfeeding, and at least one of the foll owing conditions applies:
a.Not a WOCBP
OR
b.A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the 
treatment period and for at least 4 to 5 weeks after the last dose of study treatment.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
40
8.Male participants willing to minimize the risk of inducing pregnancy for the duration of 
the clinical study  and follow -up period. A male participant must agree to use contraception 
as detailed in Appendix 5  of this protocol during the treatment period and for at least 
10weeks  after the last dose of study  treatment and refrain from donating sperm during 
this period. 
9.Able, as assessed b y the investigator , and willing to follow study instructions and likely  to 
complete all required study  visits.
10.Normal ph ysical-examination findings, clinical -laboratory  test results, and 12-lead ECG 
results from Screening or abnormal results that are determined to be not clinically  
significant b y the investigator .
11.BMI within the ra nge 18 and 40 kg/m2 (inclusive).
6.2. Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply . Exclusion criteria 
apply  to Parts A and B unless otherwise noted.
Psychiatric and Treatment -Related Criteria
1.DSM -5–based diagnosis of an y disorder other than MDD that was the primary focus of 
treatment within 6 months before Visit 1. Comorbid generalized anxiety  disorder , social 
anxiety  disorder , or specific phobias are acceptable provided they  play  a secondary  role in 
the balance of s ymptoms and are not the primary  driver of treatment decisions.
2.Lifetime history of meeting DSM -5 criteria for:
a.Schizophrenia spectrum or other ps ychotic disorder
b.Bipolar or related disorder
c.Major neurocognitive disorder 
d.Neurodevelop mental disorder of greater than mild severit y or of a severity that 
impacts the participant ’s ability  to consent, follow study  directions, or otherwise 
safel y participate in the study
e.Dissociative disorder
f.Posttraumatic stress disorder
g.MDD with psy chotic features
3.History  of meeting DSM -5 criteria for alcohol or substance use disorder (other than 
nicotine or caf feine) within the 6 months before Screening  (Visit1).
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
41
4.DSM -5–based diagnosis of an y personality disorder of sufficient severity to interfere with 
participation in this study  in the opinion of the investigator . 
5.History  (based on participant  report  and/or  medical records, and investigator judgment) of  
the following :
a.Adjunctive treatment with an antipsy chotic or inadequate response to ECT, a 
monoamine oxidase inhibitor, or ketamine
b.Treatment with clozapine or an y depot antips ychotic
c.ECT, vagus nerve stimulation, transcranial magnetic stimulation, or any experimental 
central nervous s ystem treatment during the current episode or in the 6 months before 
Screening (Visit 1) (whichever is longer)
d.Tardive d yskinesia, serotonin sy ndrome, or neuroleptic malignant sy ndrome
6.Having received:
a.Anticonvulsant/mood stabilizer, within 1 year prior to Screening (Visit 1)
b.Antipsy chotic in the current episode, with the ex ception of quetiapine given for 
insomnia ≤ 50 mg/day  provided it can be safel y discontinued prior to Visit 2  
c.Having received in the current episode more than 2 ADT s, either in combination or 
sequentially , for an adequate dose and duration
7.Lifetime history  of nonresponse to ≥ 2 antidepressants after adequate trials (adequate 
treatment is defined as at least 6 weeks at an adequate dose(s) based on approved package 
insert recommendations).
8. Positive result at Screening ( Visit 1) from the UDS test for an y prohibited medication.
Exception: Participant s with a positive UDS at Screening  for opiates, cannabinoids, or 
episodic use of benzodiazepines (ie, up to approximately  2 mg/day  lorazepam equivalent 
dose and for up to 3 consecutive days at a time ) given fo r anxiety -related conditions and 
agitation  may be allowed in the study  provided:
a.The drug was used for a legitimate medical purpose .
b.The drug can be safel y discontinued prior to participation in the study  (except for 
episodic use of benzodiazepines which m ay be continued) . 
Part B participants who have regularly been using benzodiazepines (even for 
legitimate medical purposes) for more than 2 months should not be included in the 
study  if there is doubt that the medication can be safel y discontinued during 
screening .
AND
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
42
c.A repeat UDS is negative for these substances prior to enrollment (except for episodic 
use of benzodiazepines which may  be continued) . 
Part B participants who have regularly been using benzodiazepines (even for 
legitimate medical purposes) for more than 2 months should not be included in the 
study  if there is doubt that the medication can be safel y discontinued during 
screening.
9.Suicide risk, as determined by  meeting any  of the following criteria:
a.A suicide attempt within the past y ear
b.Signi ficant risk, as judged by  the investigator, based on the ps ychiatric interview or 
information collected in the C -SSRS at Screening (Visit 1) or Visit 2
c.MADRS I tem 10 score ≥ 5 at Screening (Visit 1) or Visit 2on the MADRS
10.At imminent risk of injuring self or others or causing significant damage to property , as 
judged b y the investigator .
11.Requiring concomitant treatment with an y of the prohibited medications, supplements, or 
herbal products listed in Appendix 6, including any  psychotropic drug or any drug with 
psychotropic activity , except as described in Section 7.7.2 .
12.Initiation or termination of psy chotherapy  for depression within the 3 months preceding 
Screening  (Visit1), or plans to initiate, terminate, or change such therap y during the 
course of the stud y. (Support meetings or counseling [eg, marital counseling] are allowed 
provided they  are no mor e frequent than weekl y and do not have treatment of depression 
as their objective .)
13.Ongoing treatment with phototherapy , or termination of phototherapy  within 1 month of 
Visit 1.
14.Known allergy or sensitivity to the study medication or its components .
Other Medical Criteria
15.BMI < 18 kg/m2 or > 40 kg/m2 at Screening . 
16.Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed 
during the study.
17.WOCBP  and male partners of WOCBP , not using a reliable means of contraception 
(Appendix 5 ).
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
43
18.Participant has a condition or is in a situation which, in the investigator's opinion, may put 
the participant at significant risk, may confound the study results, or may interfere 
significantl y with the participant’ s participation in the study .
19.Any cardiovascular disease that is clinically  significant, unstable, or decompensated .
20.Heart rate (supine) of ≤ 45 bpm or ≥ 120 bpm, or any  heart rate that is clinically  
symptomatic at Screening  (Visit1) or Visit 2 based upon vital signs .
21.Any systolic and/or diastolic BP  that is sy mptomatic or clinically  significant in the 
opinion of the investigator .
22.History  of congenital QT c prolongation or QT c prolongation (screening ECG with QT cF 
≥450 msec for men and QT cF ≥ 47 0 msec for women) .
23.Hypothy roidism or h yperthy roidism, unless stabilized on appropriate pharmacotherap y 
with no change in dosage for at least 1 month before Screening  (Visit1).
24.History  of seizure disorder , stroke, significant head injury , tumor of the cent ral nervous 
system, or any  other condition that predisposes to seizure.
25.Known HIV  infection .
26.Positive hepatitis C antibody  on screening, with the exception of participant s for whom 
the reflex HCV  RNA  test is negative .
27.Positive test for hepatitis B surface antigen and/or hepatitis B core antibod y 
immunoglobulin M.
28.Part A: Screening liver enzy me test (AST and/or ALT) results > 2 times the ULN . 
PartB:History  of, or s ymptoms/signs suggestive of, liver cirrhosis , OR Screening liver 
enzy me test (AST  and/or ALT) results > 1.5 times the ULN .
29.Part B:  Previously  diagnosed hearing loss; current hearing aid users (within the last 
6months), or h istory  of gross hearing loss , such as c onductive hearing loss, congenital 
hearing loss, sudden hearing loss, hearing loss due  to recent noise or occupational 
exposure .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
44
Other Criteria
30.Current enrollment in an investigational drug or device stud y or participation in such a 
study  within 6 months of entry  into this study  (Part A) or within 3 months of entry  into 
this study  (Part B).  
31.Part A: Prior participation in any  investigational study  of AGN -241751. Part B: Prior 
participation in an y investigational study of AGN -241751, r apastinel, ketamine , or 
esketamine . Part B participants should not have participated in Part A at an y time, and 
PartA participants should not have participated in Part B at an y time (ie, Part A is not a 
contingent step to participate in  PartB).
32.Employ ee, or immediate relative of an emplo yee, of the sponsor , any of its af filiates or 
partners, or the study  cente r. 
33.Inability  to speak, read, and understand the English  language sufficiently to understand 
the nature of the study , to provide written informed consent, or to allow the completion of 
all study  assessments .
6.3. Lifestyle Restrictions
6.3.1. Meals and Dietary R estrictions
None
6.3.2. Caffeine, Alcohol, and Tobacco
Participants should refrain from consuming alcohol during the entire study .
6.3.3. Activity
None
6.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently  randomly  assigned to treatment in the study . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participant s to meet the 
CONSORT publishing requirements and to respond to quer ies from regulatory  authorities. 
Minimal information includes demograph y, screen failure details, eligibility criteria, and an y 
SAE .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
45
7. Treatment s
Study  treatment is defined as an y investigational treatment(s), marketed product(s), placebo ,or 
medical device (s)intended to be administered to a study  participant according to the study  
protocol.
7.1. Treatment sAdministered
7.1.1. Part A
On Day 1, site staff will give the participant the single dose of double -blind study  treatment from 
Bottle 1 (for a pplicable visit) to take by  oral ingestion in the clinic (ie, the first dose of study  
treatment for that week). Site staff will then give Bottle 2 (for applicable visits) , which contains 
the single- blind placebo tablets, to the participant with the instruc tion to take 1 tablet dail y by 
oral ingestion for the remainder of that week (Days 2 through 7). On Day 8, site staff will give 
the participant the single dose of double -blind study  treatment from Bottle 1(for applicable visit) 
to take by  oral ingestion i n the clinic (ie, the first dose of study treatment for that week). Site 
staff will then give Bottle 2(for applicable visits) , which contains double -blind study  treatment, 
to the participant with the instruction to take 1 tablet daily b y oral ingestion fo r the remainder of 
that week (Day s 9 through 15).
Study Treatment Name AGN -241751 Placebo
Dosage Formulation Tablet Tablet
Unit Dose Strengths3mg
10mg
25mg-
Route of Administration Oral Oral
Dosing Instructions
(Part A)At Day 1, the f irst dose from 
Bottle 1 (for applicable visit) given 
by site staff to the participant for
oral ingestion in the clinic; Bottle 2 
(for applicable visits) will be given 
to participant to take home with 
instructions to take 1 tablet orally 
every day for the rest of the week .
At Day 8, the first dose from 
Bottle 1 (for applicable visit) given 
by site staff to the participant for 
oral ingestion in the clinic; Bottle 2 
(for applicable visits) will be given 
to participant to take home with 
instructions to take 1 tablet oral ly
every day for the rest of the week .Same as for active treatment
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
46
Study Treatment Name AGN -241751 Placebo
Packaging and LabelingAllergan will provide study 
treatment in the form of identically 
appearing tablets containing 
AGN -241751 doses of 3 mg, 
10mg, 25 mg,or placebo. 
All participants will receive 
single -blind placebo tablets for 
Days 2 to 7.Allergan will provide study 
treatment in the form of identically 
appearing tablets containing 
AGN -241751 doses of 3 mg, 
10mg, 25 mg,or placebo. 
Manufacturer Allergan, Inc. Allergan, Inc.
7.1.2. PartB
During the 1stweek of the double -blind BID treatment period, the randomized participant will be 
dosed BID from Bottle 1 starting at Visit 3(Day  1) through Visit 9 (Day 7) in the clinic. Each 
day, participants will be administered a single tablet of double -blind study  treatment 
(AGN -241751 3 mg, AGN -241751 25 mg, or placebo) orall y in the morning after the daily 
predose assessments are completed, and another single tablet will be administered 8 hours 
(±1hour) after the morning dose. AtVisit 10 (Day 8), Bottle 2 will be dispensed. The 1st tablet 
from Bottle 2 will be taken in the clinic after predose assessments are completed. Upon discharge 
atVisit 10 (Day  8),the participant will take Bottle 2 home. The 2nd tablet from Bottle 2 will be 
taken at ho me b y the participant in the afternoon on Day  8. Participants will continue to take 
1tablet in the morning and take the 2nd tablet in the afternoon dail y at home by oral ingestion 
starting in the afternoon of Visit 10 (Day  8) through Visit 12 /ET(Day  14/ET). During the 
outpatient period of the study , participants should try  to adhere to the relative dosing times used 
within the inpatient phase (ie, morning and afternoon doses, approximately 8 hours apart). 
Should a dose not be administered accordingl y, the participant should be instructed as follows:
If within 4 hours of the scheduled dosing time, the participant should take the dose as soon 
as possible and continue to proceed with the relative dosing times used within the inpatient
phase.
If greater than 4 hours from the scheduled dosing time, the participant should abstain from 
taking this dose and proceed with the next dose at the subsequent scheduled dosing time 
used within the inpatient phase. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
47
Study Treatment Name AGN -241751 Placebo
Dosage Formulation Tablet Tablet
Unit Dose Strengths3mg
25mgNA
Route of Administration Oral Oral
Dosing Instructions
(Part B)Starting with inpatient Visit 3 
(Day 1; after the participant has 
been in the inpatient unit since the 
previous day ), participants will be 
administered 1 tablet in the morning 
and 1 tablet in the afternoon from 
Bottle 1 after all predose asessments 
have been completed. From Day s2 
to 7 inpatient , each day the site staff 
will give the participant 1 tablet in 
the morning and 1 tablet in the 
afternoon at 8 hours (± 1hour) after 
the morning dose , administered 
from Bottle 1 .
At Visit 10 (Day 8) prior to 
discharge, the participant will be 
dispensed Bottle 2 of study 
treatment and will be instructed to 
each day take 1 tablet in t he 
morning and 1tablet in the 
afternoon at 8 hours (± 1 hour) after 
the morning dose . Participants will 
also be instructed to bring the 
unused study treatment to 
Visit s11and 12 for the site staff to 
confirm dosing compliance . 
A Patient Diary containing a Study 
Medication Dosing Log will be 
provided at Visit s10 and 11 for 
completion by the participant at 
home. Participants will be 
instructed by site staff to record the 
date and time of the Visit 10 
(Day 8) afternoon dose and each 
subsequent dose taken ( morning 
and afternoon) at home, inclusive of 
doses on days when the participant 
has a clinic visit (Visit 11 and 
Visit 12/ET).Same as for active treatment
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
48
Study Treatment Name AGN -241751 Placebo
At Visits 11 and 12, the participant 
will return the diary provided at the 
prior visit. Site staff will review the 
diary to confirm compliance and 
proper completion of the diary. At 
Visit s11 and 12, prior to leaving 
the clinic, the participant will be 
given a new diary.
Packaging and LabelingAllergan will provide doub le-blind
study treatment in the form of 
identically appearing tablets 
containing AGN -241751 doses of
3mg, 25 mg,or placebo. Allergan will provide double -blind 
study treatment in the form of 
identically appearing tablets 
containing AGN -241751 doses of
3mg, 25 mg,or placebo. 
Manufacturer Allergan, Inc. Allergan, Inc.
7.2. Dose Modification
Dose modification is not allowed in either Part A or Part B .  For Part B, should a dose not be 
administered accordingl y, the participant should be instructed as follows:
If within 4 hours of the scheduled dosing time, the participant should take the dose as soon 
as possible and continue to proceed with the relative dosing times used within the inpatient
phase. 
If greater than 4 hours from the scheduled dosing tim e, the participant should abstain from 
taking this dose and proceed with the next dose at the subsequent scheduled dosing time 
used within the inpatient phase. The participant should record this as a missed dose within 
the diary .
7.3. Method of Treatment Assignment
All participants will be centrally  assigned to randomized study  treatment using an IWRS. Before 
the study  is initiated, the log -in information and directions for the I WRS will be provided to each 
site.
Study  treatment will be dispensed at the study  visits summarized in the schedule of activities 
(Section 2.1[Part A] and Section 2.2[Part B]). 
Returned study  treatment should not be re -dispensed to the participants.
7.4. Blinding/Masking
For both Part A and Part B, t he IWRS will be programmed with blind -breaking instructions. The 
study  blind may  be broken if, in the opinion of the investigator, it is in the participant’s best 
interest to know the study treatment assignment. The sponsor must be notified before the blin d is 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
49
broken unless identification of the study  treatment is required for a medical emergency  in which 
the knowledge of the specific blinded study treatment will affect the immediate management of 
the participant’s condition (eg, antidote is available). In this case, the sponsor must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must be 
recorded in the source documentation and eCRF, as applicable.
7.5. Preparation/Handling/Storage/Accountability
1.All study  treatment will be provided and shipped to the study  centers b y Allergan Inc., and 
must be stored in an appropriate secure area (eg, a locked cabinet in a locked room) at 
refrigerate conditions (5°C with a permitted range of 2°C to 8°C) and must be protecte d from 
heat and moisture. Once the bottles are dispensed to participants, they  can be stored at room 
temperature .
2.The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and an y discrepancies are reported 
and resolved before use of the study  treatment .
3.Only  participants randomized in the study may receive study  treatment ,and only  authorized 
site staff may  supply  or administer study  treatment. All study  treatments must be stored in a 
secure ,environmentall y controlled ,and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.
4.The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y treatment accountability, reconciliation, and record maintenance 
(ie,receipt, reconciliation ,and final disposition records) .
5.Further guidance and information for the final disposition of unused study  treatment are 
provided in the study  reference manual .
7.6. Treatment Compliance
7.6.1. Part A
Compliance with administration of double -blind study  treatment in the clinic at Visits 4 and 6
will be monitored by  capturing the date that the participant ingested the double -blind study  
treatment at each of these visits. I f a scheduled ingestion does not occur, the sponsor must be 
notified and the reason captured in the eCRF.
Compliance with stud y treatment dosing b y the participant outside of the clinic will be monitored 
by counting the number of tablets dispensed and returned. Before dispensing new study  
treatment , study  center personnel will make every effort to collect all unused study  treatme nt and 
empty  bottles. If a participant demonstrates poor compliance at an y time during the stud y (< 80% 
or > 120% measured b y pill counts), the investigator should evaluate whether the participant 
should be discontinued from the study . 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
50
The study  centers w ill keep an accurate drug disposition record that specifies the amount of 
study  treatment administered to each participant and the date of administration. 
7.6.2. Part B
Site staff personnel will administer morning and afternoon doses of double -blind study  treatm ent 
to the participant during the inpatient double -blind treatment period ( Visit 3 [Day 1]through 
Visit 10 [Day 8])each day  and will captur ethe date and time the participant ingested each dose . 
If a scheduled ingestion does not occur, the reason must be captured in the eCRF.
During the outpatient double -blind treatment period, p articipants will be instructed b y site staff 
to try to adhere to the relative dosing times used within the inpatient phase (ie, morning and 
afternoon doses, approximately  8hours apart). Should a dose not be administered accordingl y, 
the participant should be instructed as per Section 7.2.
During the 2ndweek of the outpatient double -blind treatment period from Visit 10 (Day 8) 
afternoon dose through Visit 12/ET(Day 14/ET), participants will be instructed to record the 
date and time of the morning and afternoon dose and any missed doses on the Study  Medication 
Dosing Log in the Patient Diary on each day . The participant will be instructed to bring the study  
medication bottle to the clinic at Visit 11 and at Visit 12/ET. The outpatient dosing compliance 
will be monitored by  site staff personnel at Visit 11 (Day  11) and Visit 12/ET (Day  14/ET) b y 
reconciling the number of tablets in the bottle at each visit and by  reviewing the dosing log in the 
Patient Diary  (see Section 5.1.2 ).
Study  center pe rsonnel will make every  effort to collect all unused study  treatment and empt y 
bottles on Visit 12/ET ( Day 14/ET ). If a participant demonstrates poor compliance at an y time 
during the stud y (< 80% or > 120% measured b y pill counts), the investigator should evaluate 
whether the participant should be discontinued from the study . 
The study  centers will keep an accurate drug disposition record that specifies the amount of 
study  treatment administered to each participant and the date of administration.
7.7. Concomitant Therapy
The use of an y concomitant medication, prescription or over -the-counter, is to be recorded on the 
participant’s eCRF at each visit along with the reason the medication is taken.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
51
7.7.1. Prohibited Treatments 
Participants must discontinue an y of the medications listed below for the specified period prior to 
baseline. These medications are prohibited for the duration of the study. Other medications being 
used at Screening may  be continued.
The following medicati ons are prohibited: 
Antipsy chotics
Antidepressants 
Stimulants
Anticonvulsants/mood stabilizers
Dopamine -releasing drugs or dopamine agonists
Psychotropic drugs not otherwise specified (including herbal products , such as St. John ’s 
Wort, and certain nutri tional supplements)
See Appendix 6Concomitant Medications for a comprehensive list of prohibited medications 
and allowed medication usage.  Appropriate washout of prohibited medications is to be 
conducted at the discretion of the investigator and should begin as soon as practical following 
consent and S creening.
The decision to administer a prohibited medication/treatment during the study  period is done 
with the safet y of the study participant as the primary cons ideration. When possible, the sponsor
is to be notified before the prohibited medication/treatment is administered.
7.7.2. Permitted Treatments
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) t hat the participant is receiving at the time of enrollment or receives 
during the stud y must be recorded along with:
Indication
Dates of administration including start and end dates
Dosage information including dose and frequency
Therap y considered necessary  for the participant’s welfare may  be given at the discretion of the 
investigator. If the permissibility  of a specific medication/treatment is in question, please contact 
the sponsor.
The sponsor or designee should be contacted if there are an y questions regarding concomitant or 
prior therap y.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
52
For Insomnia
Eszopiclone, zolpidem, zolpidem extended -release, zopiclone ,or zaleplon for insomnia may  be 
continued provided the medication has been used in a consistent manner for 4 weeks prior to 
enrollment . Following enrollment, these medications may also be introduced in participant s not 
previously  treated as necessitated by  insomnia that emerges or worsens during the stud y. In these 
participant s, the medications will be permitted up to 3 times a week ,as follows:
Part A —not permitted within 8 hours of psychiatric or neurological measures
Part B —not permitted within 12 hours of psy chiatric or neurological measures or a scheduled 
qEEG/ERP measurement
The medications are permitted at the following doses:
Zolpidem (maximum of 10 mg/day )
Zolpidem extended release (maximum of 12.5 mg/day)
Zaleplon (maximum of 20 mg/day )
Eszopiclone (maximum of 3 mg/day )
Zopiclone (maximum of 7.5 mg/day )
Suvorexant (maximum of 10 mg/day )
These medications must be administered before bedtime as recommended in their prescribing 
information. The medication must be documented on the concomitant medications page of the 
eCRF. No such medication is permitted within 8 hours (Part A) or within 12hours (Part B) of 
psychiatric or neurological assessments or a scheduled qEEG/ERP measurement .
For Anxiety or Agitation
Episodic use of benzodiazepines up to approximately  2 mg/day  lorazepam equivalent dose and 
for up to 3 consecutive days at a time may be given for anxiety -related condit ions and agitation 
(not permitted within 8 hours of psychiatric or neurological assessments [Part A] or not 
permitted within 12 hours of psychiatric or neurological assessments or a scheduled qEEG/ERP 
measurement [Part B] ).
7.8. Treatment after the End of the Study
Participant s whose MDD sy mptoms worsen or are determined b y the investigator not to be 
adequatel y controlled prior to completing the double -blind treatment period will be allowed to 
discontinue the study  and start appropriate treatment at the invest igator’s discretion. This new 
treatment will not be provided by  the sponsor. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
53
8. Discontinuation/Withdrawal Criteria
Notification of early  participant discontinuation from the study  and the reason for 
discontinuation will be made to the sponsor and will be clearl y documented on the appropriate 
case report form.
Reasons for discontinuation from the study  treatment and/or the study  may  include the 
following:
Adverse event
Lack of ef ficacy
Lost to follow -up
Non- compliance with study  drug
Other
Pregnancy
Protocol deviation
Screen failure
Site terminated by  sponsor
Study  terminated by  sponsor
Withdrawal by subject (withdrawal of consent to participate in the stud y)
8.1. Discontinuation ofStudy Treatment
All randomized participants who prematurel y discontinue from the study, regardless of cause, 
should be seen for a final assessment at an ET Visit. A final assessment will be defined as 
completion of the evaluations scheduled for all participant s at the Follow -Up Visit. Participant s 
who prematurely  discontinue from the study  before completing 2weeks of double -blind 
treatment should enter the 1-week safety  follow -up period . 
Any participant may be withdrawn due to AE at the discretion of the investigator .
Any participant who meets any of the following criteria at an y point during the study must be 
withdrawn from participation, due to AE (s)related to suicide:
a.A suicide attempt
b.Significant risk, as judged by the investigator , based on the ps ychiatric interview or 
information collected in the C -SSRS
c.MADRS I tem 10 score ≥ 5
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
54
In the event that a participant is withdrawn for a suicide -related AE, the participant should be 
referred for additional treatment or hospitalization, as clinically indicated, in addition to 
withdrawing the participant from the study .
Discontinuation of study  treatment for abnormal liver function (criteria for potential Hy’s law 
described in Section 9.2.6 ) should be considered by  the investigator if the investigator believes 
that it is in best interest of the participant .
If a clinically  significant finding is identified after enrollment, the investigator or qualified 
designee will determine if the participant can continue in the study andif any  change in 
participant management is needed .Any new clinically  relevant finding should be reported as an 
AE.Clinically  significant findings upon termination should be followed until the condition 
returns to prestud y status or can be explained as unrelated to study  treatment . If necessary , 
additional follow -up visits may be scheduled.
See the schedule of activities (Section 2.1[Part A] and Section 2.2[Part B]) for data to be 
collected at the ETvisit and the Safety Follow -Up Visit.
8.2. Withdrawal from the Study
A participant  may withdraw from the stud y at an y time at his/her own request, or  may be 
withdrawn at an y time at the discretion of the investigator  for safety , behavioral , 
compliance, or administrative reasons .
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may  
retain and continue to use an y data collected before such a withdrawal of consent .
If a participant  withdraws from the study , he/she may  request destruction of an y samples 
taken and not tested , and the investigator must document this in the site study  records .
See the schedule of activi ties for data to be collected at the time of study  discontinuation 
and follow -up and for any further evaluations that need to  be completed .
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken ifa participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant  and reschedule the m issed vi sit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant  wishes to and/or should continue in 
the study .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
55
Before a  participant  is deemed lost to follow up, t he investigator or designee must make 
every  effort to regain contact with the participant (where possible, 2 telephone calls , and if 
necessary , a certified letter to the participant ’s last known mailing address or local 
equivalent methods). These contact a ttempts should be documented in the participant ’s 
medical record .
Should the participant continue to be unreachable, he  or she will be considered to have 
withdrawn from the study with a primary  reason of lost to f ollow -up. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
56
9. Study Assessments and Procedures
Study  procedures and their timing are summarized in the schedule of a ctivities 
(Section 2.1 [Part A] and Section 2.2 [Part B]).
Protocol waiver s or exemptions are not allowed.
Immediate  safety  concerns  should be discussed with the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  treatment .
Adherence to the stud y design requirements, including those specified in the schedule of 
activities , is essential and required f or study  conduct.
All screening evaluations must be completed and reviewed by the investigator  or qualified 
designee  to confirm that  potential participant s meet all eligibility  criteria. The investigator 
will maintain a screening log to record details of a ll participant s screened and to confirm 
eligibility  or record reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’ s routine clinical management (eg, blood 
count) and obtained before signing of the ICF  may be utili zed for screening or baseline 
purposes provided the procedure met the protocol -specified  criteria and were performed 
within the time  frame defined in the schedule of activities .
Repeat or unscheduled blood samples may  be taken for safety  reasons or for tec hnical 
issues with the samples.
Diagnostic Assessments
The SCI D will be administered during the screening interviews b y a ps ychiatrist, doctoral -level 
clinical psy chologist, or other clinician who has extensive professional training and experience in 
the diagnosis of mental illness and who meets the training r equirements and qualification 
standards set b y the sponsor and rater training vendor. 
9.1. Efficacy Assessments
The efficacy  assessments (MADRS and CGI -S) will be administered by  a psy chiatrist, 
doctoral -level clinical psy chologist, or other clinician who has extensive professional training 
and experience in the diagnosis of mental illness and who meets the training requirements and 
qualifications standards set by  the sponsor and rater training vendor .Efficacy  assessments will 
be performed as specified in the schedule of activities in Section 2.1(Part A) and Section 2.2
(Part B).
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
57
9.1.1. Diagnostic Assessments
For Part A and Part B, t he SCI D will be administered during the screening interviews b y a 
psychiatrist, doctoral level clinical psy chologist, or other clinician who has extensive 
professional training and experience in the diagnosis of mental illness and who meets the training 
requirements and qualifications standards set by  the sponsor and rater training vendor.
9.1.2. The Montgomery -Åsberg Depression Rating Scale
The MADRS ( Montgomery  and Åsberg 1979 ) is a cl inician -rated scale (Appendix 8 ). The 
MADRS will be used to assess depressive sy mptomatology . Participants are rated on 10 items to
assess feelings of sadness, lassitude, pessimism, inner tension, suicidali ty, reduced sleep or 
appetite, difficult y concentrating, and lack of interest. Each item will be scored on a 7 -point 
scale. A score of 0 indicates the absence of s ymptoms, and a score of 6 indicates s ymptoms of 
maximum severity . 
A qualified rater (ie, who meets the training requirements and qualifications set by the rater 
training vendor ) at each investigational center will conduct the MADRS assessment.  
For Part A, a t Screening (Visit 1) and Visit 2 (predose) ,the MADRS will be administered with a 
look-back timeframe of 1 week. At all other evaluations, the MADRS w ill be administered with 
a look -back timeframe of “since last evaluation .”
For Part B, at Visit 1 (Screening )and Visit 2 ( Day –1, baseline), the MADRS will b e 
administered with a look -back timeframe of 1 week. At all other evaluations, the MADRS will 
be administered with a look -back timeframe of “since last evaluation.” 
MADRS assessments will be performed as specified in the schedule of activities in Section 2.1
(Part A) and Section 2.2(Part B).
9.1.3. The Clinical Global Impressions -Severity
The CGI -S (Guy 1976 ) is a clinician -rated scale used to rate the severit y of the patient’s current 
state of men tal illness compared with a patient population with MDD (Appendix 9 ). The
participant will be rated on a scale from 1 to 7 with 1 indicating a “normal , not at all ill” and 
7indicating “among the most extremely  ill patients .” The CGI -S will be administered by  the 
investigator or a sub -investigator with extensive professional training and experience in 
assessing mental illness and qualification standards set by the sponsor and rater training vendor.
For Part Aand Par t B, at Screening (Visit 1) and Visit 2,the CGI -S will be administered with a 
look-back timeframe of 1 week. At all other evaluations, the CGI -S will be administered with a 
look-back timeframe of “since last evaluation .”
CGI-S assessments will be performed as specified in the schedule of activities in Section 2.1
(Part A) and Section 2.2(Part B).
9.1.4. The Hamilton Anxiety Rating Scale (Part A Only)
The HAM -A (Hamilton 1959 ) is a clinician -rated scale to rate the severity of an xiety  symptoms 
(Appendix 1 4). The participant will be tested using 14 questions , and responses will be rated on a 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
58
scale from 0 to 4, with 0 indicating “none” (ie, no anxiety ) and 4 indicating a response of “severe , 
gross disabling ” anxiety . The HAM -A will be administered at Visit 2, Visit 3, Visit 4, and Visit 6 
by the investigator or a sub -investigator with extensive professional training and experience in 
assessing mental illness and qualification standards set by the sp onsor and rater training vendor.
The HAM -A will be collected onl y from participants entering the study after the amendment has 
been IRB approved.
9.1.5. Likert Patient Depressive Symptom Scales (Part B Only)
TheLikert Patient Depressive Symptom Scales are a set of questions framed in a L ikert format, 
which is the most widely used approach to scaling responses in survey research aimed to capture 
the full domain /indication under study . In theBID cohort part of the study , a set of Likert Patient 
Depressive S ymptom Scales will be used to collect the participant self-reported outcomes on 
domains related to MDD, including depression, anxiety , and sleep qualit y (Appendix 15).The 
Likert Patient Depressive Sy mptom Scales will be completed by the research participant as 
specified in the schedule of activities in Section 2.2.
During the outpatient double -blind treatment week and the safety  follow -up, the L ikert Patient 
Depressive S ymptom Scale questions will be provided to the participants in a diary  to be 
completed at home.
9.1.6. Hopkins Verbal Learning Test -Revised (Part B Only)
The HVLT -R is the most recent ( Shapiro et al 1999 ) version of the verbal learning and episodic 
memory  test. It includes 6 different forms aimed to reduce practice effects, which this trial will 
employ  in respective study  visits. The HVLT -R is comprised ofimmediate recall trials o f 
12 nouns with 3 different categories and a delay ed recall followed b y a recognition task
(Appendix 16). For the immediate recall, on each trial ,the participant is asked to say  as m any
words enunciated b y the rater administering the test as possible. For the delayed recall, after 
approximately  20to 25minutesof the immediate recall trials, the participant is requested to 
evoke all words he/she can remember without any cues. The recognition trial is composed o f 
24words, including 12 target words and 12 false -positives, and the participant is asked which of 
the 24 words were the ones read during the immediate recall trial. The HVLT -R will be 
administ ered by the trained site professional as specified in the sche dule of activities in 
Section 2.2.
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4.
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant’ s legall y authorized representative) .
The investigator and an y designees are responsible for detecting, documenting, and recording 
events that meet t he definition of an AE or SAE. Any AEs that are ongoing at the time of the 
final protocol -defined study  visit will be followed until the condition returns to prestudy  status, 
has resolved or stabilized, or can be explained as being unrelated to study  treatment . If a 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
59
follow -up visit is deemed necessary  for appropriate safet y surveillance, it will take place within 
30 day s of the final protocol -defined stud y visit.
9.2.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs from the signing of the ICFwill be collected at the timepoints specified in the schedule 
of activities (Section 2.1[Part A] and Section 2.2[Part B]), and as observed or reported 
spontaneously  by stud y participants ,until 30 day s from the last dose of study  treatment .
All AE sfrom the signing of the I CFwill be collected at the time points specified in the schedule 
of activities (Section 2.1[Part A] and Section 2.2[Part B]), and as observed or reported 
spontaneously  by stud y participants ,until 30 day s from the last dose of study  treatment .
Medical occurrences that begin before the start of study treatme nt but after obtaining informed 
consent willbe recorded on the AEsection of the eCRF .
All SAE swill be recorded and reported to the sponsor or designee within 24 hours, as indicated 
inAppendix 4.The investigator will submit any updated SAE data to the sponsor within 
24hours of it being available.
Investigators are no t obligated to activel y seek AE or SAE information in former stud y 
participant s. However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the stud y, and he/she considers the event to be reasonabl y 
related to the stud y treatment or study participation, the investigato r must promptly  notify  the 
sponsor .
The method of recording, evaluating ,and assessing causality  of AE sand SAE s and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4.
9.2.2. Method of Detecting AE sand SAE s
Care will be taken not to introduce bias when detecting AE s and/or SAEs . Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence s.
9.2.3. Follow -up of AE sand SAE s
After the initial AE/SAE report, the investigator is required to proactivel y follow each participant 
at subsequent visits/contacts. All AEs/ SAE swill be followed until resolution, stabiliz ation , until 
the event is otherwise explained, or the participant is lost to follow -up (as d efined in Sectio n8.3).
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y the sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may include 
additional laboratory  tests or investigations, histopathological examinations, or consultation with 
other health care professionals.
If a participant dies dur ing participation in the study  or during a recognized follow -up period, the 
investigator will make every  effort to provide the sponsor with a cop y of any postmortem 
findings including histopathology . 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
60
New or updated information will be recorded in the orig inally  completed eCRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of receipt of 
the information.
9.2.4. Regulatory Reporting Requirements for SAE s
Prompt notification by  the investigator to the sponsor  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participant s and the safet y of a 
study  treatment under clinical investigation are met. 
The sponsor  has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a study  treatment under clinical investigation.  The 
sponsor  will comply  with country -specific regulatory requirements relating to safet y 
reporting to the regulatory authorit y, institutional revie w bo ards (IRB s)/independent ethics 
committee s (IEC s), and investigators.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safet y information ( eg, summary  or listing of SAE s) from the sponsor  will review and the n 
file it along with the investigator ’s brochure  and will notify  the IRB/IEC, if appropriate 
according to local requirements .
9.2.5. Pregnancy
Site per sonnel must report every  pregnancy  in female participants, and female partners of 
male participants, from the time the participant signs the ICF until 30 day s after the last dose 
of study  treatment .
Within 24 hours of learning of the pregnancy , the investigator must report the event to the 
sponsor  on the Clinical Trial Pregnancy  Form and fax or e-mail it to the SAE reporting fax 
number or e-mail provided on the title page of this protocol, even if no AE has occurred . The 
investigator should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
61
9.2.6. Potential Hy’s Law
Criteria for potential Hy ’s law cases are as follows: 
ALT or AST ≥ 3 × ULN AND 
Total bilirubin ≥ 2 × ULN AND 
Alkaline phosphatase < 2 × ULN
Study  site personnel must report every  participant who meets these potential criteria. Ty pically , 
all 3 analytes will be obtained from the same sample, but they  may  come from multiple samples 
taken within a 24 -hour period. This requirement applies from the time the participant signs the 
ICF for the study until 30 day s after the final protocol -defined stud y visit or the last known dose 
of study  treatment (if the final visit does not occur). 
A lab oratory alert for potential Hy ’slaws cases will be in place, and must notify  investigators 
and the s ponsor immediately  when the above criteria have been met. A potential Hy’s law case 
must be faxed or e-mailed to the sponsor on an adverse event of interest form , as soon as 
possible (within 24 hours of learning of the potential Hy’s law case) to the SAE fax number or 
e-mail shown on the title page of this protocol , even if no AE has occurred. The eCRF for 
potential Hy ’s law cases must be completed within 7 calendar days. Every  effort to determine the 
cause of the liver enz yme abnormalities must be made, and close monitoring should be initiated 
in conjunction with the medical monitor and in accordance with the FDA Guidance for Industry,
Drug -Induced Liver Injury: Pre marketing Clinical Evaluation, July 2009 .
9.2.7. Medication Errors
Medication error refers to any unintended error in the dosing and/or administration of the study 
treatment as per instructions in the protocol. Medication errors generall y fall into 4 categories as 
follows:
Wrong study drug
Wrong dose (including dosing regimen, strength, form, concentration, amount)
Wrong route of administration
Wrong p articipan t (ie, not admi nistered to the intended p articipa nt)
Medication errors include occurrences of overdose and underdose of the stud
y treatment .For 
Part B, participants should be instructed as described in Section 7.2(Dose Modification) for
missed doses.
9.3. Treatment of Overdose
AGN -241751 has a short half-life;hence, even in the event of an overdosage, the lik elihood of 
lasting high expos ureswould be minimal .Although not observed within healthy volunteers 
receiving 50 mg of AGN -241751 for 10 consecutive day s, minimal liver findings have been 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
62
observed in toxicology  studies within the dog .Part B s afetylaboratory  tests, including AST and 
ALT,will be performed at Visit 9 (Day 7), Visit 12/ET (Day 14/ET), and Visit 14 (Day  21) 
(Safet y Follow -Up) to monitor participants should dosing errors occur. Unscheduled safet y 
assessments may  be performed as clinicall y indicated at an y time during the study at the 
discretion of the investigator.
9.4. Safety Assessments
Planned timepoints for all safet y assessments are provided in the schedule of activities
(Section 2.1and Section 2.2).In addition, unscheduled asses sments of vital signs, clinical 
laboratory  tests, and ECG s may  be performed as clinically  indicated at any  time during the stud y
at the discretion of the investigator .
9.4.1. Physical Exam ination s
A complete ph ysical examination will be performed at Screening and at Visit 6/ET (Part A) or at 
Screening and Visit 12/ET ( Part B) by a professionally  trained phy sician or health professional 
listed on Form FDA 1572 and licensed to perform physical examinations.
9.4.2. Vital Signs
Vital signs (pulse rate, s ystolic and diastolic blood pressure , oral or t ympanic temperature, and 
body  weight) will be assessed at every  visit (Part A) and at Screening, Baseline ( Day –1), 
4hours postdone atVisit 3 and Visit 10/Discharge (Day 8), Visit 12/ET (Day  14/ET), and 
Visit 14 (Day 21)(Part B). Height will be assessed at Screening onlyin both par tsof the stud y.
Blood pressure and radial pulse rate will be measured in the supine position followed b y the 
standing position. The standing measurements should be assessed after a sufficient amount of 
time (approximately  1to 3 minutes) has been elapsed to allow the BP to equilibrate in the 
standing state. 
Radial pulse rate should be measured after blood pressure measurements. B lood pressure may be 
measured manually  or by machine, but radial pulse rate should onl y be measured manually and 
for a sufficien t time to acquire an accurate measurement.
Participant s should be instructed not to wear clothing with tight sleeves when they come for 
clinic visits. Additionally , participant s should be kept as calm and undisturbed as possible while 
blood pressure and pu lse rate measurements are taken (eg, there should be no talking while the 
blood pressure is being measured). The same arm and blood pressure cuff (appropriate to the arm 
circumference) should be used for all blood pressure measurements. 
Whenever possible, the participant ’s weight will be measured at the same time of day ; 
participant s should wear their usual indoor clothing, but take off their jacket and shoes. For each 
participant , bod y weight should be determined using the same equipment during the stud y after 
ensuring its proper calibration. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
63
9.4.3. Electrocardiogram s
A 12 -lead ECG will be performed at Screening and Visit 6/ET (Part A) and at Visit 1 
(Screening ), Visit 12/ET (Day  14/ET),and Visit 14(Day  21)(Part B). ECGs will be performed 
and electronicall y transmitted to a central ECG laboratory  for anal ysis according to the 
instructions provided by  the central ECG laboratory . Measurements (in msec) will be recorded 
for the following parameters: PR interval, QRS duration, and uncorrected QT interval. QTcB 
(Bazett corrected QT interval) and QTcF (Fridericia corrected QT interval) will be calculated. 
The overall interpretation and determination of the clinical relevance of ECG findings using the 
central ECG interpretation laboratory  report will be the responsi bility  of the investigator and will 
be recorded in the participant ’s eCRF. 
Throughout the stud y, the investigator will review the central ECG reports and indicate the 
clinical significance of all abnormal values, and then sign and file the report in the participant ’s 
study  file. In case of any abnormal ECG finding, unscheduled ECG smay be conducted at the 
discretion of the PI .
9.4.4. Clinical Safety Laboratory Assessments
See Appendix  2 for the list of clinical laboratory  tests to be performed and the schedule of 
activities  (Section 2.1 [Part A] and Section 2.2 [Part B]) for the timing and frequency . 
The investigator must review the laboratory  report, document this review , and record an y 
clinically  relevant changes occurring during the study that are considered Adverse Events per 
the judgment of the investigator in the AE section of the eCRF. The laboratory reports must 
be filed with the source documents.  Clinically  significant abnormal laboratory  findings are 
those which are not associated with the underl ying disease, unless judged by the investigator 
to be more severe than expected for the participant ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in t he study  or after the last dose of study  treatment should be repeated until the 
values return to normal or baseline  or are no longer considered clinicall y significant by the 
investigator.
oFor liver function tests, if a participant has the following, an uns cheduled retest should be 
performed: ALT or AST ≥ 3 × ULN, total bilirubin ≥ 2 × ULN, and/or alkaline 
phosphatase < 2 × ULN (see also Section 9.2.6 ).
oIf such value s do not return to normal /baseline within a period of time judged reasonable 
by the investigator, the etiology  should be identified and the s ponsor notified.
oAll protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the schedule of activities .
oIf laboratory  values from non-protocol specified laboratory  assessments performed at the 
institution’s local labor atory  require a change in participant management or are 
considered clinically  significant by  the investigator ( eg,SAE or AE or dose 
modification) , then the results must be recorded in the eCRF.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
64
9.4.5. Columbia -Suicide Severity Rating Scale
The C -SSRS is an inst rument that reports the severity of both suicidal ideation and behavior
(Appendix 12and Appendix 13). Suicidal ideation is classified on a 5 -item scale: 1 (wish to be 
dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods [not 
plan] without intent to act), 4 (active suicidal ideation with some intent to act, without specific 
plan), and 5 (active suicidal ideation with s pecific plan and intent). The C -SSRS also captures 
information about the intensity  of ideation, specifically  the frequency , duration, controllability , 
deterrents, and reasons for the most severe t ypes of ideation. Suicidal behavior is classified on a 
5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 
3(interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected 
provided they  represent separate episodes. For actual attempts only , the a ctual or potential 
lethality  is classified for the initial, most lethal, and most recent attempts. 
For Part Aand Part B, the C-SSRS will be completed at all study  visits (once per visit ; predose 
atapplicable visits ) (see Section 2.1[Part A] and Section 2.2[Part B]). At Screening, the 
C-SSRS will be completed for the participant ’s lifetime history  of suicidal ideation and behavior. 
At all other visits, the C -SSRS will be completed for ideation and behavior since the previous 
visit. The C -SSRS will be evaluated and signed at each visit by a qualified staff member (ie, the 
investig ator or designee who has extensive professional training and experience in assessing 
mental illness), before the participant leaves the study  center.
9.4.6. Brief Psychiatric Rating Scale —Positive Symptoms Subscale
The BPRS is an 18 -item evaluation that assesses psychiatric s ymptoms and unusual behavior 
(Overall and Gorham 1962 ). The BPRS+ is a subset of the BPRS that assesses 4 components of 
the BPRS related to the degree of ps ychosis: Conceptual Disorganization, Suspiciousness, 
Hallucinatory  Behavior, and Unusual Thought Content (Appendix 10). Only the 4 items of 
BPRS+ subscale will be collected and anal yzed. The BPRS+ will be administered b y the 
investigator or designee with extensive professional training and experience in assessing mental 
illness. For Part Aand Part B , at Screening (Visit 1) ,the BPRS+ will be administered with a 
look-back timeframe of 1 week. At all other evaluations, the BPRS+ will be administered with a 
look-back timef rame of “since last evaluation .”
The BPRS+ will be completed as specified in the 
schedule of activities in Section 2.1(Part A) and Section 2.2(Part B) (including the designated 
look-back periods for each BPRS+ administration) .
9.4.7. Clinician Administered Dissociative States Scale
The CADSS is a 28-item clinician -administered measure of perceptual, behavioral, and 
attentional alterations occurring during active dissociative experiences composed of 
23subjective self -reported and 5 objective observer -reported ratings, each scored from 0 (not at 
all) to 4 (extremely )
(Appendix 11). Only  the 23 subjective items will be collected and analy zed. 
The CADSS provides a validated assessment of dissociative states sensitive to change over time 
and amenable to repeated measures ( Bremner 1998 ). The CADSS will be administered by  the 
investigator or designee with extensive professional training and experience in assessing mental 
illness. For Part A and Part B , at Screening (Visit 1) ,the CADSS will be administered with a 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
65
look-back timeframe of 1 week. At all other evaluations, the CADSS will be administered with a 
look-back timeframe of “since last evaluation .”
The CADSS will be completed as specified in the schedule of activities in Section 2.1(Part A) 
and Section 2.2(Part B) (including the designated look -back periods for each CADSS 
administration) .
9.5. Pharmacok inetics (Part B Only)
In Part B of this stud y, collection of a single CSF sample is an optional procedure, as participants 
may/may  not choose to allow this sample coll ection without impacting their par ticipation in the 
study . For those participants who agree and have given consent to provide a CSF sample for PK 
analysis, lumbar puncture will be used to collect CSF, and a maximum of 4 mL  of CSF will be 
collected . Collection of CSF is preferred at Visit 5 (Day 3), but can be done at Visit 4 or Visit 6,
either immediatel y prior to the morning dose or at 8 hours after the morning dose . Within each 
site, 1 sample per participant will be collected, and study staff will alterna te between predose and 
postdose for participants (eg, 1 stparticipant sample is collected predose, 2 ndparticipant sample 
is collected postdose, 3 rdparticipant sample is collected predose, etc. ).Additional details of the 
CSF sample collection, handling, and storage arepresented in Appendix 18. 
Additional exploratory  analy sis may  be performed on collected CSF samples.   
9.6. Pharmacodynamics (Part B Only)
9.6.1. Quantitative Electroencephalography and Event Related Potential Assessments 
and Outputs
In Part B of the study , evaluation of pharmacody namic endpoints (qEEG/ERP) between 
AGN -241751 and placebo (double -blinded) will be performed at selected sites using the 
measures described below.
9.6.1.1. Karolinska Sleepiness Scale
The KSS i s a 9-point self -reported scale of subjective assessment of a participant’s level of 
drowsiness at the time ( Appendix 17 ). The KSS will be conducted prior to each qEEG 
measurement to assess for sleep -deficit related differences between qEEG measurements. The 
scale will control for an y sleepiness variations in the qEEG and ERP outputs .The scale will be 
measured as follows:
Baseline : Mid-day (approximately  1200 hours), and afternoon (approximately  1700 hours)
(window of ± 2hours between mid -day and afternoon assessments)
Day 1: Predose and 4, 8, and 12 hours postdose
Day 2: 24 hours post Day  1 morning dose (prior to the Day  2morning dose)
Day 7: Predose and and 4, 8, and 12 hours postdose
Day 8: 24 hours post Day  7 morning dose (prior to the Day  8 morning dose)
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
66
Day 14
Day 21
Error windows permitted for the KSS measurements will be ± 30 minutes at an y collection 
timepoint up t o 12 hours postdose and ± 1 hour at any collection timepoint up to 24 hours 
postdose. 
9.6.1.2. Event -Related Potential and Electroencephalography Measurements
The qEEG and ERP are noninvasive tests that analyze the electrical activity of the brain using 
data from surface electrodes in contact with 19 or more areas of the scalp. Engagement of the 
NMDA receptor b y AGN- 241751 is expected to result in measurable changes in qEEG and ERP 
data.
Prior to the qEEG assessments on Day –1, each participant will undergo a heari ng test to ensure 
detection of the stimuli used for the ERP assessments. Should a participant not be able to detect 
the planned stimuli, the intensity  of the stimuli may  be adjusted accordingly .  
The qEEG will be measured as follows:
Baseline : Mid-day (approximately  1200 hours), and afternoon (approximately  1700 hours)
(window of ± 2hours between mid -day and afternoon assessments)
Day 1: Predose and 4, 8, and 12 hours postdose
Day 2: 24 hours post Day  1 morning dose (prior to the Day  2 morning dose)
Day 7: Predose and and 4, 8, and 12 hours postdose
Day 8: 24 hours post Day  7 morning dose (prior to the Day  8 morning dose)
Day 14
Day 21
Error windows permitted for the qEEG measurements will be ± 30minutes at an y collection 
timepoint up to 12hours postdose and ± 1 hour at any  collection timepoint up to 24 hours 
postdose. Test times should not be confounded b y food intake ;eg,if baseline is done 30 minutes 
after lunch, the test should be 30 minutes after lunch. 
The ERPs will be measured approximately  10 mi nutes following each corresponding qEEG 
measurement. 
qEEG and ERP Assessments and Outputs
At the times specified above, a 5 -minute resting qEEG with ey es closed, a 5 -minute resting 
qEEG with ey es open, a 10.5-minute MMN task (Appendix 20 )and a 10.5-minute ASSR task 
(Appendix 20) will be performed with participants seated comfortabl y in a sound -attenuated 
room . In addition to 19 qEEG leads according to the international 10/20 s ystem, vertical and 
horizontal EOGs will be recorded. The reference electrode will be left mastoid (A1) with ear 
lobe (A2) recorded as an active lead. Digital referencing to linked ears will be done off -line. An 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
67
additional electrode on the nose (Nz) is required for accurate i dentification of the MMN. The 
resting qEEGs will be evaluated b y means of spectral anal ysis, coherence analy sis, and 
frequency  analy sis. After artifact rejection or correction , the mean absolute amplitude spectra 
(square root of power spectral densit y func tion) will be computed . The primary  qEEG endpoints
will be changes from predose baseline intheabsolute spectral amplitude sin 1Hz bands from 1.0 
to 50.0 Hz. Secondary  measures will include changes from predose baseline in the absolute
spectral amplitude sand magnitude squared coherence sin various clinical bands (Delta [1.0-4.0 
Hz], Theta [4.0 -8.0 Hz ], Alpha [8.0-12.0 Hz], Beta [12.0 -25.0 Hz ], Hi- Beta [25.0 -30.0 Hz ], 
Gamma [30.0 -50.0 Hz], Alpha 1 [8.0 -10.0 Hz ], Alpha 2 [10.0 -12.0 Hz ], Beta 1 
[12.0 -15.0 Hz], Beta 2 [15.0 -18.0 Hz], Beta 3 [18.0 -25.0 Hz ], Gamma 1 [30.0 -35.0 Hz ], 
Gamma 2 [35.0 -40.0 Hz ], Gamma 3 [40.0 -50.0 Hz];coherence in these bands) and derived 
frequency  measures. Additional secondary  endpoints will include coherences and derived 
frequency  measures, for each of which the endpoints will be changes from predose baseline 
values. M agnitude squared coherence will be measured for specific pairwise combinations of the 
19qEEG electrodes in the same clinical bands. These pairs will capture the relevant inter -and 
intra- hemispheric coherences and will include F3 -F4, C3 -C4, P3 -P4, O1 -O2, F3 -P3,and F4 -P4. 
Derived frequency  analysis will consist of computing the dominant frequency  in the range of 
6.0to 12.5 Hz, the ASI,and the TBR.
Each ERP task will be assessed in sequential multiple blocks . For the MMN task ,the assessment 
will be done using deviant stimuli differing in pitch from standard stimuli. For the ASSR task ,
the assessment will be done using stimulus rates of 30/s and 40/s. 
Each ERP task will y ield several measurements, which will serve to compute primary  ERP 
endpoints. For the MMN task, the components include P50, N100, and P200 for the standard and 
deviant stimuli, and the MMN, which derives from a differen ce of deviant -standard ERPs. For 
all ERP components, measures of peak latency , peak amplitude, and average amplitude (AUC) 
will be computed and analy zed for change with respect to predose baseline. Baseline -adjusted 
ERP component measures will serve as end points for statistical anal ysis. The primary  ASSR 
measure is the peak -to-peak amplitude of the sustained portion (latency  > 150 ms) of the ASSR 
in the time domain. Secondary  measures include the averaged wavelet magnitude and inter -trial 
phase coherence (Appendix 20 ). Baseline -adjusted ASSR measures will serve as endpoints for 
statistical analy sis.
For all qEEG and ERP endpoints ,the baselines for computing changes at each postdose 
timepoint will be the mean of the 3 baseline v alues on Day –1(mid -day), Day –1 (afternoon ),
and Day 1 (predose). Change scores will be computed as normalized differences ((V(t) –V(b) / 
V(t) + V(b)), where V(b) is the value at mean baseline and V(t) is the value at a specific 
timepoint. Other change metrics may  also be examined, such as simple differences from baseline 
and simple ratios of postdose to baseline values, as these provide different levels of control for 
baseline variation. The change metric that shows the greatest sensitivity to changes w ithout 
introducing excessive bias will be selected for formal anal yses of variance.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
68
9.7. Genetics
For Part A, randomized participants may  consent to participate in the genetic anal ysis component 
of the study . For those randomized participants who agree, the consent may  be collected at any  
time prior to collection of the sample. For Part B, if participants consent to this sampling and are 
randomized, the sample will be collected predose at Visit 9 (Day  7).
For both Part A and Part B, f or those who consent andare randomized , a4 mL  sample for DNA 
isolation will be collected at an y time during the study after the consent has been signed (Part A) 
or at Visit 9 (Day 7)(Part B) . With the samples, poly morphisms within the NMDA receptors 
may be assessed to understa nd treatment response to AGN -241751. Additional exploratory  
assessments may  also be conducted from DNA collected within these samples. Participation is 
optional. Participants who do not wish to participate in the genetic research may still participate 
in the study . Participant confidentiality  will be maintained at all times.
9.8. Biomark ers
Biomarker sample s are not being collected within this study .
9.9. Medical Resource Utilization and Health Economic s
Medical resource utilization and health economics parameters are not evaluated in this study .
10. Statistical Considerations 
10.1. Sample Size Determination
10.1.1. Part A
The sample size of approximately  25randomized participant s in each of the 4treatment groups 
is not based on statistical power consideration due to the lack of information of AGN -241751 for 
the variability  of change from baseline to 1 day after first dose in MADRS total score. 
10.1.2. Part B
In Part B of the study , the sample size of approximately  40randomized participants in each of 
the 3treatment groups is not based on statistical power consideration since this is an exploratory  
study . 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
69
10.2. Populations for Analyses
10.2.1. Part A
The anal ysis populations will consist of participants as defined below:
The mITT population  includes all randomized parti cipants who received at least 
1administration of study treatment, and have a baseline M ADRS total score and at least 
1postbaseline assessment for the MADRS total score during the double -blind treatment 
period. Participants will be summarized according to  the randomized study  treatment.
The safet y population includes all participants who received ≥ 1 administration of study 
treatment . Participants will be summarized according to the study  treatment  they actuall y 
received.
10.2.2. Part B
The anal ysis populations inPart B will consist of participants as defined below:
The mITT population  includes all randomized parti cipants who received at least 
1administration of study treatment and have a baseline M ADRS total score and at least 
1postbaseline assessment for the MADRS total score during the double -blind treatment 
period. Participants will be summarized according to the randomized study treatment.
The safet y population includes all participants who received ≥ 1 administration of stud y 
treatment . Participants will be summarized according to the study  treatment  they actuall y 
received.
The PD population includes all randomized participants who received ≥ 1administration 
of study  treatment and have Day –1 qEEG and ERP  assessments and at least 
1postbaseline assessment for the qEEG and ERP  assessments  during the double -blind 
treatment period. Participants will be summarized according to the randomized study  
treatment.
The PK population includes all randomized participants who received ≥ 1 administration 
of study  treatment and have at least 1 CSF collection in Part B. Participants will be 
summarized according to the randomized study  treatment.
10.3. Statistical Analyses
There will be 2 separate SAPs, 1 each for Part A and Part B. Each SAP will be developed and 
finalized before database lock for that part of the protocol and will describe in detail the 
participant populations to be included in the analyses, the safet y and efficacy  analy sis, and the 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
70
procedures for accounting for missing or unschedule d data. This section is a summary  of the
planned statistical anal yses of the primary  and secondary  endpoints. 
10.3.1. Efficacy Analyses (Part A and Part B)
The efficacy  anal yses will be based on the mITT population of each Part, A or B, respectivel y. 
Baseline for efficacy  for Part A and Part B, respectively , is defined as the last nonmissing 
efficacy  assessment before the 1st dose of stud y treatment in each corresponding part of the 
study . All statistical tests will be 2 -sided hy pothesis tests perfor med at the 5% level of 
significance for main effects. All confidence intervals will be 2 -sided 95% confidence intervals, 
unless stated otherwise.
For efficacy  analy ses in which study  center is a factor, a small center will be defined as a center 
with fewe r than 2participant s for at least 1 treatment group in the mITT Population. All the 
small centers will be pooled to form a pseudo -center. If the pseudo -center is still a small center, 
it will be pooled with the smallest non -small center. If there is more than one smallest non -small 
center, the small pseudo -center will be pooled with the smallest non -small center that has the 
largest center number.
10.3.1.1. Primary and Secondary Endpoint s(Part A and Part B)
10.3.1.1.1. Part A
The primary  and secondary  efficacy  endpoints are listed below and anal yses will be defined in 
the following sections. All analyses for other efficacy endpoints listed below will be defined in 
more detail in the SAP for Part A.
Primary  efficacy  endpoint for Part A of the stud y:
Change from b aseline  
(Day 1, predose)  in MADRS total score  at 1 day after the first dose 
of treatment (Day 2)
Secondary  efficacy  endpoint for Part A of the study:
Change from baseline (Day 1, predose) in MADRS total score  at Day  8 and Day 9 after 
single oral dose, on Day 15 after repeated dose, and on Day 22, 7 days after the 
completion of AGN -241751 dosing
10.3.1.1.2. Part B
The primary  and secondary  efficacy  endpoints are listed below and anal yses will be defined in 
the following sections. All analyse s for other efficacy  endpoints listed below will be defined in 
more detail in the SAP for Part B.
Primary  efficacy  endpoint for Part B of the study :
Change from baseline in MADRS at 7 day s after first dose of treatment
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
71
Secondary  efficacy  endpoint for Part B of the study :
Change from baseline in MADRS total score  at Day  2, Day  11, Day  14, Day  18, and 
Day 21, 7days after the completion of AGN -241751 BID dosing
10.3.1.2. Primary Analyses (Part A and Part B)
The primary  anal ysis for the primary  and secondary  endpoints in Part A and Part B will be 
performed using a nMMRM with treatment group, visit, pooled study  center, and treatment 
group -by-visit interaction as fixed effects and the baseline value and baseline value -by-visit 
ascovariates. An unstructured covariance ma trix will be used to model the covariance of 
within -participant scores. If the model fails to converge based on the unstructured covariance 
matrix, then structures of Heterogenous Toeplitz, Toeplitz, and Compound Sy mmetry  will be 
applied, in the specified order, until the model converges. The Kenward -Roger approximation 
will be used to estimate denominator degrees of freedom ( Kenward and Roger 1997 ). These 
analyses will be performed based on all postbaseline scores using onl y the OCs without 
imputation of missing values.
In addition, a sensitivity  anal ysis using the MI approach under MNAR assumptions will be 
performed on the primary and secondary efficacy  parameter s. 
Detailed methods and procedures for the above outlined missi ng data -derived sensitivity  
analyses will be documented in the final SAP sprior to the study  database lock s.
10.3.1.3. Additional Efficacy Parameters (Part A and Part B)
10.3.1.3.1. Part A
Additional efficacy  parameters are as follows , with the Day 1 (predose) value serv ingas the 
baseline :
Change from baseline in CGI -S total score at Day 2, Day 8, Day 9, and Day 15 
Rate of responders on MADRS or CGI-S at Day 2, Day 8, Day 9, Day 15, and Day 22
Rate of remitters on MADRS at Day 2, Day 8, Day 9, Day 15, and Day 22
Time to first response on MADRS
Time to first remission  on MADRS
Analy sis of change from baseline in MADRS total score and CGI -S score will be performed 
using a similar MMRM to that used for the key secondary  parameter.
CGI-S responder is defined as participants achieving a score of ≤ 2 on the CGI S of Illness ̀
scale.
CGI-S sustained responder: Meet responder criteria at ≥ 2 consecutive visits and continued 
through to final assessment.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
72
During the randomized treatment period, 4types of events for MADRS total score will be 
defined based on the following criteria:
Responder: ≥ 50% reduction from baseline MADRS total score
Sustained responder: Meet responder criteria at ≥ 2 consecutive visits and continued 
through to final assessment
Remitter:  MADRS total score ≤ 10
Sustained remitter: Meet remitter criteria at ≥ 2 consecutive visits and continued through 
to final assessment
Rates of responders and remitters will be reported by treatment group for each timepoint of 
assessment (Day 1 [predose] defined as baseline and Da ys 2, 8, 9, 15 ,and 22 after first dose of 
randomized treatment). A logistic regression model will be used to model the probability of a 
response or the probability of a remission as a function of a treatment group, and baseline 
MADRS or CGI -S total score.
The time to onset of first event is defined as the number of day s from the first randomized dosing 
to the first event. The time to onset in days will be calculated for each t ype of event (response or 
remission) in person level. Pa rticipants who do not me et the criteria for respective type of event 
will be censored at the time of their last MADRS assessment during the treatment period. 
For each t ype of event, the proportion of participant s with onset of first events, Kaplan -Meier 
estimate in terms of the median time to onset of first event, and its 95% CI will be presented for 
each treatment group. Plots of the Kaplan -Meier estimate of the distribution of the time toonset 
of events will also be provided for each treatment arm. Log -rank tests comparing the time to
onset of event distribution between each AGN -241751 dose andplacebo will be conducted.
10.3.1.3.2. Part B
Additional efficacy  parameters are as follows, with the Day –1(predose) value serving as the 
baseline:
Change from baseline in CGI -S total score  by visit
Rate of responders on MADRS at Day 2, Day 7, Day 11, Day 14, Day 18, and Day 21
Rate of responders on CGI -S by visit 
Rate of remitters on MADRS at Day 2, Day 7, Day 11, Day 14, Day 18, and Day 21
Time to first response on MADRS
Time to first rem ission on MADRS
Analy sis of change from baseline in MADRS total score and CGI -S score will be performed 
using a similar MMRM to that used for the key secondary  parameter.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
73
During the randomized treatment period, 2 t ypes of events will be defined based on th e following 
criteria:
Responder: ≥ 50% reduction from baseline MADRS total score
Remitter:  MADRS total score ≤ 10
Rates of responders and remitters will be reported by treatment group for each timepoint of 
assessment ( Day –1[predose] defined as baseline and Day s 2, 7, 11, 14, 18, and 21 after the 
1stdose of randomized treatment). A logistic regression model will be used to model the 
probability  of a response or the probability  of a remission as a function of a treatment gro up, and 
baseline MADRS or CGI -S total score. 
The time to onset of first event is defined as the number of day s from the first randomized dosing 
to the first event. The time to onset in days will be calculated for each t ype of event (response or 
remission) in person level. Participants who do not meet the criteria for respective t ype of event 
will be censored at the time of their last MADRS assessment during the treatment period. 
For each t ype of event, the proportion of participants with onset of first ev ents, Kaplan -Meier 
estimate in terms of the median time to onset of first event, and its 95% CI will be presented for 
each treatment group. Plots of the Kaplan -Meier estimate of the distribution of the time to onset 
of events will also be provided for each treatment arm. Log -rank tests comparing the time to 
onset of event distribution between each AGN -241751 dose and placebo will be conducted.
10.3.2. Exploratory Analyses
10.3.2.1. Part A
The exploratory analysesof HAM -A scores will be performed using the safety  population for the 
double -blind treatment period and for the safety  follow -up period, if applicable, and will be full y 
defined in the SAP. The exploratory parameters will include change from baseline in HAM -A 
scores Day 2, Day 8, and Day 15.At Visit 2, the HAM -A will be administered with a look -back 
timeframe of 1 week. At all other evaluations, the HAM -A will be administered with a look -back 
timeframe of “since last evaluation.” The HAM -A will be collected onl y from par ticipants 
entering the stud y after the amendment has been IRB approved.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
74
10.3.2.2. Part B
The exploratory analysesinclude the following :
Analy sis of Likert Patient Depressive S ymptom Scales of each assessed doma ins 
(including depression, anxiety ,and sleep qualit y,etc.) will be performed based on the 
safet y population for the double -blind treatment period and for the safety  follow -up 
period , if applicable, and will be described descriptively  and in more detail in the SAP 
for Part B.
Analy sis of HVLT -R assessment will be performed using the safet y population for the 
double -blind treatment period and for the safety  follow -up period , if applicable, and will 
be described in more detail in the SAP for Part B. 
10.3.3. Pharmacokinetic Analysis (Part B Only)
Analy sis of the CSF concentrations of AGN -241751 will be performed using the PK population 
for the double -blind treatment period . Descriptive anal ysis of the CSF concentrations will be 
performed.
10.3.4. Pharmacodynamic Analysis (Part B Only)
Analy sis of the qEEG and ERP assessments will be performed using the PD population for the 
double -blind treatment period. Initial details of the anal ysis of the qEEG and ERP data are 
described in Appendix 20 , but will be fully  defined in a PD SAP. 
10.3.5. Safety Analyses (Part A and Part B)
The safet y analysis will be performed using the safety  population for the double -blind treatment 
period and for the safety  follow -up period, if applicable, and will be fully  defined in the SAP for 
each Part A and Part B of the study . The safet y parameters will include AEs, clinical laboratory 
including potential Hy’s law cases, vital sign s, ECG , C-SSRS, BPRS+, and CADSS parameters. 
For each safet y parameter, the last nonmissing safety  assessment before the first dose of study  
intervention will be used as the baseline for all analy ses of that safet y parameter .
10.3.5.1. Adverse Event (Part A and Part B)
For each part of the study , A and B, an AE will be considered a TEAE if the AE began or
worsened (increased in severity or became serious) on or after the date of the first dose of stud y 
medication. However, an AE that occurs more than 30 day s after the last dose of study  
medication of each part A and B, respectively, will not be counted as a TEAE. An AE will be 
considered a TESAE if it is a TEAE that additionally  meets an y SAE criteria .
The number and percentage of participants reporting TEAEs in each stud y treatment will be 
tabulated as follows:
By system organ class and preferred term
By system organ class, preferred term, and severity .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
75
An AE will be considered a TEAE if:
The AE began on or after the date of the first dose of study  treatment ; or
The AE was present before the date of the first dose of study  treatment , but increased in 
severit y or became serious on or after the date of the first dose of stud y treatment
If more than 1 AE is reported before the first dose of study treatment and is coded to the same 
preferred term, the AE with the greatest severity will b e used as the benchmark for comparison 
with the AEs that were also coded to that preferred term and that occurred during the period. An 
AE that occurs more than 30 day s after the last dose of study  treatment will not be counted as a 
TEAE.
An AE will be con sidered a TESAE if it is a TEAE that additionally  meets any  SAE criteria
The number and percentage of participants reporting TEAEs in each stud y treatment will be 
tabulated as follows:
By system organ class and preferred term
By system organ class, preferr ed term, and severity .
The number and percentage of participants reporting treatment related TEAEs in each stud y 
treatment will be tabulated by  system organ class and preferred term.
If more than 1 AE is coded to the same preferred term for the same partic ipant, the participant 
will be counted only  once for that preferred term using the most severe and most related 
occurrence for the summarization by  severity  and by  relationship to study  treatment .
Summary  tables will be provided for participants with TESAE s and participants with TEAEs 
leading to discontinuation if 2or more participants reported such events. Listings of all AEs, 
SAEs, and AEsleading to discontinuation by  participant will be presented.
The definitions of an AE and SAE can be found in Appendix 4 .
10.3.5.2. Clinical Laboratory Assessments (Part A and Part B)
For Part A and Part B of the study , descriptive statistics of actual values and change from 
baseline for clinical laboratory values (in SI units) will be presented at each asses sment time point 
by treatment. In addition, descriptive statistics for values and changes from the baseline values in 
conventional units at each assessment timepoint will be presented for selected clinical laboratory 
parameters listed in the SAP.
The criteria for PCS laboratory  values will be detailed in the SAP for Part A and the SAP for 
PartB, respectively . The number and percentage of participants who have PCS postbaseline 
clinical laboratory  values will be tabulated by  study  treatment at each assessment. The 
percentages will be calculated relative to the number of participants who have available non -PCS 
baseline values and at least 1 postbaseline assessment. The numerator will be the total number of 
participants with available non -PCS baseline values and at least 1 PCS postbaseline value. A 
supportive listing of participants with PCS postbaseline values will be provided.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
76
10.3.5.3. Vital Signs (Part A and Part B)
For Part A and Part B of the study , descriptive statistics of actual values and c hange from 
baseline for vital signs (systolic and diastolic BP, pulse rate, weight, and temperature) will be 
presented at each assessment time point by  treatment.
Vital sign values will be considered to be PCS if they meet both the observed value criteri onand 
the change from baseline value criteri onthat will be detailed in the SAP for Part A and the SAP 
for Part B, respectivel y. The number and percentage of participants who have PCS postbaseline 
vital sign values will be tabulated b y study treatment for ea ch assessment. The percentages will 
be calculated relative to the number of participants who have an available baseline value and at 
least 1 postbaseline assessment. The numerator will be the total number of participants with at 
least 1 PCS postbaseline value. A supportive listing of participants with PCS postbaseline values 
will be provided.
10.3.5.4. Electrocardiograms (Part A and Part B)
For Part A and Part B of the study , descriptive statistics of actual values and change from 
baseline for ECG parameters (ie, h eart rate, PR interval, QRS interval, QT interval, and QTc 
interval) will be pr esented at each assessment time point by  treatment.
The number and percentage of participants with PCS postbaseline values will be tabulated by 
study  treatment . The criteria for PCS ECG values will be detailed in the SAP for Part A and the 
SAP for Part B, respectively . The percentages will be calculated relative to the number of 
participants with an available non -PCS baseline value and at least one postbaseline assessment. 
The num erator will be the total number of participants with an available non -PCS baseline value 
and at least one PCS postbaseline ECG value. A supportive listing of participants with PCS 
postbaseline values will be provided and will include the participant number and the baseline and 
postbaseline values. A listing of all AEs for participants with PCS ECG values will also be 
provided.
A shift table from baseline to the end of stud y in the investigator’s overall interpretation of the 
ECG will be presented by treatme nt group for the following categories: normal; abnormal, not 
clinically  significant; abnormal, clinically  significant. A tabular display  of participant s with 
postbaseline clinically  significant ECG abnormalities according to the investigator’s overall 
interpretation will be provided.
The number and percentage of participant s with a change from baseline QTc > 30 msec but not 
exceeding 60 msec and of participant s with an increase > 60 msec will be tabulated b y treatment 
group. A supportive listing that includ es the participant identification number, all QTc values 
(including change from baseline values), and all AEs will be provided for all participant s who 
have postbaseline QTc changes > 30 msec.
10.3.5.5. Other Safety Parameters (Part A and Part B)
Other safety  parameters for Part A and Part B include the BPRS+, CADSS, and C-SSRS.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
77
Descriptive statistics of actual values and change from baseline for BPRS+ total score will be 
presented at each assessment time point by  treatment.
Descriptive statistics of actual values and change from baseline for CADSS total score will be 
presented at each assessme nt timepoint by  treatment. The CADSS total score is defined as the 
sum of scores for 23 subjective items.
The number and percentage of participants with suici dal ideation or suicidal behavior as 
recorded on the C -SSRS will be summarized by  treatment. The distribution of responses for most 
severe suicidal ideation and most severe suicidal behavior during the participant’s lifetime, 
during the double -blind treatm ent period, and during the safet y follow -up period will also be 
presented b y treatment. Supportive listings will be provided and will include the participant 
number, lifetime history , and postbaseline values. Intensit y of suicidal ideation, suicidal behavi or 
type, and lethality  of suicidal behavior will also be included in these listings. A listing of all AEs 
occurring in participants who have suicidal ideation or suicidal behavior will also be provided.
10.3.6. Interim Analyses
Aninterim anal ysis is not planned a t this time but may  be conducted if deemed appropriate .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
78
11. References
American Ps ychiatric Association (2013). Diagnostic and Statistical Manual of Mental 
Disorders , 5thedition : DSM -5. Washington, DC: American Ps ychiatric Association .
Ashton AK, Jamerson B D, Weinstein W, Wagoner C . Antidepressant -related adverse effects 
impacting treatment compliance: Results of a patient survey . Curr Ther Res, Clin and Exper 
2005;66:96 -106.
Blanke ML, VanDongen AMJ. Activation Mechanisms of the NMDA Receptor. I n: Van Donge n 
AM, editor. Biology  of the NMDA Receptor. Boca Raton, Florida: CRC Press/Tay lor & Francis; 
2009. Chapter 13. Available from: http://www.ncbi.nlm.gov/books/NBK5274.
Boland RJ, Keller MB. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. 
Essentials of clinical ps ychopharmacology. 2nd ed. Arlington, VA: American Psychiatric 
Publishing, I nc.; 2006. p 465 -78.
Bremner JD, Kry stal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM.
Measurement of dissociative states with the Clinician A dministered Dissociative States Scale 
(CADSS). J Trauma Stress .1998;11:125 –136.
Burgdorf J, Zhang X, Nicholson K, Balster R, Leander J, Stanton P, et al. GLYX -13, a NMDA 
receptor gly cine-site functional partial agonist, induces antidepressant -like effects without 
ketamine -like side effects. Neurops ychopharm. 2013;38:729 –742.
EMA/CHMP/185423/2010 Rev. 2 previously (CPMP/EWP/518/97, Rev. 1) Committee for 
Medicinal Products for Human Use (CHMP) 30 May  2013 Guideline on clinical investigation of 
medicinal prod ucts in the treatment of depression.
Fava M, Davidson KG. Definition and epidemiology of treatment -resistant depression. Psy chiatr 
Clin North Am. 1996;19:179 -200.
FDA Guidance for Industry : Drug Induced L iver Injury -Pre-Marketing Clinical Evaluation, July
2009.
FDA Guidance for Industry : E10, Choice of Control Group and Related Issues in Clinical Trials, 
May 2001.
Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, L owe SW, Berglund PA, Corey -Lisle PK . 
The economic burden of depression in the United States: how did it change between 1990 and 
2000? J Clin Psy chiatry .2003;64:1465 -1475.
Guy W: ECDEU Assessment Manual for Ps ychopharmacology –Revised 1976 , in (ed DHEW 
Publ No ADM 76 -338). Rockville, MD, U.S., U.S. Department of Health, Education, and 
Welfare, Pu blic Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NI MH 
Psychopharmacology  Research Branch, Division of Extramural Research Programs .pp 218 -222.
Hamilton, M. The assessmen t of anxiety  states b y rating. Br J Med Psy chol 1959;32: 50-55.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
79
Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum 
likelihood. Biometrics 1997; 53:983 -997.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S , et al. L ifetime and 
12-month prevalence of DSM -III-R psy chiatric disorders in the United States: results from the 
National Comorbidity  Survey . Arch Gen Ps ychiatry 1994;51:8 -19.
Kessler RC, Chiu W T, Demler O, Walter O . Prevalence, severit y, and comorbidity of 12 -month 
DSM -IV disorders in the National Comorbidity Survey Replication (NCS -R). Arch Gen 
Psychiatry  2005;62:617 -627.
Masand PS. Tolerability  and adherence issues in antidepressant therap y. Clin Ther 
2003;25:2289 -2304.
McInty re RS and O’Donovan C. The human cost of not achieving full remission in depression.
Can J Psy chiatry  2004;49( 3 suppl 1):10S -16S.
Montgomery  SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J 
Psychiatry .1979;134:382 -389
.
Murray  CJ, Atkinson C, Bhalla K, Birbeck C, Burstein R, Chou D, et al. The state of US health, 
1990 -2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591 -608.
Nicholson KL , Balster RL. The discriminative stimulus effects of N -methy l-D-aspartate 
glycine -site ligands in NMDA antagonist -trained rats. Psy chopharm. 2009;203(2):4 41–451.
Overall JE and Gorham DR. The brief ps ychiatric rating scale. Ps ychological Reports 
1962;10:799 -812.
Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM. GLYX -13 Clinical 
Study  Group. Randomized proof of concept trial of GLYX -13, an N -methyl-D-aspartate receptor 
glycine site partial agonist, in major depressive disorder nonresponsive to a previous 
antidepressant agent. J Psy chiatr Pract. 2015;21:140 –149.
Rosenzweig- Lipson S, Bey er CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE . 
Differe ntiating antidepressants of the future: efficacy  and safet y. Pharmacol Ther 2007;
113:134 –153.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D . Acute and 
longer -term outcomes in depressed outpatients requiring one or several treatme nt steps: a 
STAR*D report. Am J Psy chiatry  2006;163:1905 -1917.
Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity  of the 
Hopkins Verbal Learning Test -revised. Clin Neuropsy chol. 1999;13:348 –358.
Skolnick P, Popik P, Trullas R. Glutamate -based antidepressants: 20 y ears on. Trends Pharmacol 
Sci. 2009;30:563 –569.
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication 
augmentations after the failure of SSRI s for depression. N Engl J Med 2006;354:1243 -1252.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
80
Videbech P and Ravnkilde B. Hippocampal volume and depression: a meta -analysis of MRI 
studies. Am J Psy chiatry  2004;161:1957 -1966.
World Health Organization. Mental health: new understanding, new hope. World Health Report 
2001 .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
81
12. Appendices
12.1. Appendi x 1:Abbreviations and Trademarks
ADT antidepressant therapy
AE adverse event
ALT alanine aminotransferase 
AESI adverse event of special interest 
ASI alpha slow wave index
ASSR Auditory Steady -State Response
AST aspartate aminotransferase
AUC area unde r the concentration -time curve
BID twice daily
BMI body mass index
BPRS+ Brief Psychiatric Rating Scale -Positive Symptoms Subscale
CADSS Clinician Administered Dissociative States Scale
CFR Code of Federal Regulations
CGI-S Clinical Global Impressions- Severity
CIOMS Council for International Org anizations of Medical Sciences
Cmax maximum concentration
CNS central nervous system
CONSORT Consolidated Standards of Reporting Trials
CSF cerebrospinal fluid
C–SSRS Columbia –Suicide Severity Rating Scale
CWT continuous wavelet transform
DALY disability adjusted life years
DSM-5 Diagnostic and Statistical Manual of Mental Disorders , 5thEdition
ECT electroconvulsive therapy
ECG electrocardiogram, electrocardiographic
eCRF electronic case report form
EEG electroencephalography
EOG electro -oculograms
ERP event related potential
ERSP event-related spectral perturbation
ET early termination
FDA Food and Drug Administration
FSH follicle stimulating hormone
GCP good clinical practice
HAM -A Ham ilton Anxiety Rating Scale
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
82
HbA1c Hem oglobin A1c
β-hCG β-human chorionic gonadotropin
HCV hepatitis -C virus
HIPAA Health Insurance Por tability and Accountability Act of 1996
HIV human immunodeficiency virus 
HRT hormonal replacement therapy
HVLT -R Hopkins Verbal Learning Test –Revised
IB Investigator’s Brochure
ICF informed consent form
ICH International Council forHarmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
IEC independent ethics committee
IP investigational product
IRB Institutional Review Board
ITPC inter-trial phase coherence
ITT Intent -to-Treat
IWRS Interactive Web Response S ystem
KSS Karolinska Sleepiness Scale
LOCF last observation carried forward
LTP long-term potentiation
MADRS Montgomery -Åsberg Depression Ra ting Scale
MDD major depressive disorder
MI multiple imputation
mITT modified intent -to-treat
MMN mismatch negativity
MMRM mixed -effect model for repeated measures
MNAR missing not at random
NMDA N-methyl -D-aspartate
NMDAR N-methyl -D-aspartate receptor
NOAEL no-observed -adverse -effect level
OC observed case
PCS potentially clinically significant
PD pharmacodynamic(s)
PI principal investigator
PK pharmacokinetic(s)
qEEG quantitative electroencephalography
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using the Bazett formula (QTcB =QT/[RR]½)
QTcF QT interval corrected for heart rate using the Fridericia formula (QTcF =QT/[RR]⅓)
RMS root means square
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
83
SAE serious adverse event
3-SAOT 3–stimulus auditory oddball task
SAP Statistical Analysis Plan
SCID Structured Clinical Interview for DSM Disorders
SDMT Symbol Digit Modalities Test
SNRI selective serotonin and norepinephrine reuptake inhibitor
SOA stimulus onset asynchrony
SPL sound pressure level
SSRI selective serotonin reuptake inhibitor
T3 triiodothyronine
T4 thyroxine
TBR theta -beta ratio
TEAE treatment -emergent adverse event
TESAE treatment -emergent serious adverse event
Tmax time to reach maximum concentration 
TSH thyroid -stimulating hormone (
UDS urine dr ug screen
ULN upper limit of normal
WOCBP woman of childbearing potential
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
84
12.2. Appendix 2:Clinical Laboratory Tests 
Blood and urine samples for clinical laboratory  tests will be collected as listed in the schedule of 
activities (Section 2.1[Part A] and Section 2.2[Part B]). 
A central laboratory  will be used to evaluate all urine and blood samples, which will be 
collected, processed, and stored according to the instructions provided by the laboratory .
During screening, the investigator will assess the clinical significance of any values that are 
outside the refer ence ranges provided by  the central laboratory ; participant s with abnormalities 
judged to be clinically  significant will be excluded from the study .
Participant s will be asked to fast overnight or for at least 8 hours before arriving at the stud y 
center for appointments involving the collection of clinical laboratory  blood tests. 
For Part A and Part B, t he following clinical laboratory  levels will be measured at Screening
only:
Clinical laboratory 
screening tests :HbA1c, fasting insulin, TSH, T3, and free T4
Hepatitis screening: HCV antibody , hepatitis –B surface antigen, and hepatitis -B 
core antibod y total will be tested. Reflex hepatitis -B core 
antibody  IgM will be performed for all hepatitis –B core 
antibody  total positive or reactive results. Positive test 
results will be sent for confirmation testing. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
85
The following clinical laboratory  levels will be measured at Screening , Visit 2,and Visit 6/ET
(Part A) and at Screening , predose at Visit 9 (Day 7), Visit 12/ET (Day  14/ET), and Visit 
14(Day 21) (Safet y Follow -Up) (Part B)unless otherwise noted :
Hematology: Absolute and differential white blood cell count, erythrocy te 
count, hemoglobin, hematocrit, platelet count, and red blood 
cell indices (mean corpuscular volume, mean corpuscular 
hemoglobin, and mean corpuscular hemoglobin 
concentration)
Chemistry: Sodium, potassium, calcium, chloride, bicarbonate, 
magnesium, gamma glutamy l transferase, phosphate, 
glucose, blood urea nitrogen, creatinine, creatine 
phosphokinase, total protein, alkaline phosphatase, albumin, 
bilirubin (total ; direct; indirect), ALT, AST, total 
cholesterol, low -densit y lipoprotein, high -density  
lipoprotein , trigl yceridesa
Urinalysis: Specific gravit y, pH, protein, glucose, ketones, and blood
UDS: Benzoy lecgonine (cocaine), barbiturates, amphetamines, 
benzodiazepines, cannabinoids, opiates, methadone, 
phency clidine
Pregnancy (Part A) : Serum β -hCG at Screening and Visit 6/ET
Pregnancy (Serum) 
(Part B)(for WOCBP: Serum β-hCG at Screening , predose at Vist 9 (Day 7), 
Visit 12/ET (Day  14/ET), and Visit 14(Day 21)
Pregnancy (Urine) 
(Part B)(for WOCBP):Serum β- hCG pregnancy test at Screening (Visit 1) AND a 
negative urine pregnancy test on Day –1(baseline), if more 
than a week has passed since the serum pregnancy  test at 
Screening. If urine pregnancy  test is positive on Day –1, 
then a serum β- hCG pregnancy  test should be done for 
confirmation . Additional urine pregnancy  tests may  be done 
at the investigator’s discretion throughout the study. If any 
urine pregnancy  test during the stud yis positive, a serum 
β-hCG pregnancy  test should be done for confirmation .
aAbnormal liver function test values will be repeated.
Clinical laboratory  tests may  be performed under special circumstances (and at investigator’s 
discretion).
A negative UDS for cocaine, phency clidine, barbiturates, and methadone is required at Screening 
for the participant to continue in the study . Participant s with a positive screening UDS for opiates 
(other than methadone), cannabinoids, or episodic use of be nzodiazepines may  continue in the 
study  provided the drug was prescribed for a legitimate medical purpose and can be discontinued 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
86
prior to study  participation and a repeat UDS is negative for these substances prior to enrollment. 
An exception is made for e pisodic use of benzodiazepines, which may  be continued as described 
in Section 7.7.2 .
A UDS may  be performed at any  time during the study  at the dis cretion of the investigator. A 
participant with a positive UDS for benzodiazepines or opiates at an y postrandomization visit 
may be allowed to continue in the study  provided the participant has been prescribed the 
medication and it is being used for legiti mate medical purpose in the investigator’s judgment.
For Part A of the study , serum pregnancy  tests will be conducted at Screening and Visit 6/ET as 
specified in the schedule of activities ( Section 2.1)and at investigator’s discretion at an y time 
during this part of the study . Positive results on the pregnancy  test at Screening will exclude 
participant s from participating in the stud y. Inves tigators should inquire at every  study  visit 
about the continued use of acceptable methods of contraception in women of childbearing 
potential. If there is an y question of noncompliance with contraception or if there is an y reason 
to suspect pregnancy , the following should be performed:
Urine pregnancy  test
oIf the urine pregnancy test is positive, the participant must be discontinued from the 
study  immediatel y.
oIf the urine pregnancy  test is negative, a serum β -hCG pregnancy  test must be performed 
for confi rmation.
For Part B of the stud y, serum pregnancy tests will be conducted at Screening , predose at Visit 9 
(Day 7),at Visit 12/ET (Day  14/ET), and at Visit 14 (Day 21) (Safet y Follow -Up) as specified in 
the schedule of activities (Section 2.2).At entry , the female participant, if a WOCBP, must have 
a negative s erum β-hCG pregnancy  test at Screening (Visit 1) AND a negative urine pregnan cy 
test on Day –1(baseline), if more than a week has passed since the serum pregnancy test at 
Screening. If the urine pregnancy  test is positive on Day –1, then a serum β -hCG pregnancy  test 
should be done for confirmation . Additional urine pregnancy tests may be done at the 
investigator’s discretion throughout this part of the study .If any urine pregnancy test during the 
study  is positive, a serum β -hCG pregnancy  test should be done for confirmation .
For both Part A and Part B, p ositive pregnancy  test res ults during the stud y will result in 
participant termination from the study .  
Other laboratory  assessments may  be repeated at any  visit if there was an abnormal finding at the 
most recent previous evaluation or if additional information is clinically nece ssary  to 
appropriatel y evaluate the participant ’s current condition, follow -up, and/or manage an adverse 
experience. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
87
12.3. Appendix 3:Study Governance Considerations
Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following :
Consensus ethic alprinciples derived from international guidelines including the Declaration 
of Helsinki and CIOMS international ethical gu idelines
Applicable ICH GCP guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, investigator ’sbrochure ,and other relevant documents 
(eg,advertisements) must be submitted to an I RB/IEC b y the investigator and reviewed and 
approved b y the IRB/IEC before the stud y is initiated.
Any amendments to the protocol will require IRB /IECapproval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study  participant s.
The investigator will be responsible for the following :
oProviding written summaries of the status of the study  to the IRB/ IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/ IEC
oNotify ing the IRB/IEC of SAE sor other significant safet y findings as required by 
IRB/IEC procedures
oProviding oversight of the overall conduct of the study  at the site and adherence to 
requirements of applicable local regulations , for example 21 CFR, I CH guidelines, 
the IRB/IEC, and European regulation 536/2014 for clinical studies (ifapplicable) 
Financial Disclosure
Investigators and sub investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the stud y and for 
1 yearafter completion of the study .
Informed Consen t Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study . 
Participant s must be informed that their participation is voluntary . Participant s will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements , where applicable , and the IRB/IEC 
or study  center. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
88
The medical record mus t include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.
Participant s must be re -consented to the most current version of the ICF(s)during their 
participation in the study . 
A cop y of the ICF(s)must be provided to the participant or the participant’s legall y 
authorized representative. 
Data Protection
Participants will be assigned a unique identifier by the sponsor . Any  participant records or 
datasets that are transferred to the sponsor will contain the identifier only; participant names 
or an y information which would make the participant identifiable w ill not be transferred. 
The participant must be informed that his/her personal study -related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor ,by 
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
Publication Policy
Allergan as the sponsor has proprietary  interest in this study . An integrated clinical and 
statistical report will be prepared at the completion of the study.
The sponsor will comply  with the requirements for publication of study  results. In 
accordance wit h standard editorial and ethical practice, the sponsor will generall y support 
publication of multicenter studies only in their entirety  and not as individual sitedata.
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements and will follow the sponsor’s standard 
operating procedure on publications.
Data Quality Assurance
All participant data relating to the stud y will be reco rded on printed or electronic CRF s
unless transmitted to the sponsor or designee electronically  (eg,laboratory  data). The 
investigator is responsible for verify ing that data entries are accurate and correct b y 
physicall y or electronically  signing the CRF. 
The investigator must maintain a ccurate documentation (source data) that supports the 
information entered inthe CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections andprovid edirect access to source data documents. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
89
Thesponsor or designee is responsible for the data management of this study including 
quality  checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accur ate, complete, and verifiable from source 
documents; that the safety  and rights of participant s are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other stud y 
agreements, ICHGCP, and all a pplicable regulatory  requirements. 
Records and documents, including signed ICF s, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period or otherwise notified in writing b y the 
sponsor . No records may be destroyed during the retention period without the written 
approval of the sponsor . No records may  be transferred to another location or part y without 
written notification to the sponsor . 
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF orentered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also,current medical records must be available.
Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been collected and a study -site closure visit has been performed .
The investigator may  initiate study -site closure at any  time, provided there is reasonable c ause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requir ements of the I RB/IEC 
or local health authorities, the sponsor ’s procedures, or GCP  guidelines
Inadequate recruitment of participant s by the investigator
Discontinuation of further study treatment development
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
90
12.4. Appendix 4:Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of AE
AEDefinition
An AE is an y untoward medical occurrence in a patient or clinical study  participant , 
temporally  associated with the use of study  treatment , whether or not considered 
related to the study  treatment .
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  treatment .
AE of Special Interest (AESI)
An AESI (serious or nonserious) is one of scientific and medical concern specific to the 
sponsor’s study  drug/device or program, which warrants ongoing monitoring and rapid 
communication by  the investigator to the spo nsor. Such an event might warrant further 
investigation in order to characterize and understand it.
Nonserious AESIs should be reported to the sponsor within 72 hours and serious AESIs 
should be reported to the sponsor within 24 hours.
The AESI should be reported to the SAE reporting fax number (provided on the 
title page of this protocol ).
The Adverse Event of Special Interest form, along with a targeted questionnaire, 
if applicable, should be used for reporting the AESI ,even if a serious outcome 
may not appl y.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
91
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) 
or other safet y assessments ( eg, ECGs , radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease )
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition
New condition detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected drug-drug interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication . Overdose per se will not be repo rted as an 
AE/SAE unless itis an intentional overdose taken with possible suicidal/self -
harming intent. Such intentional overdoses should be reported regardless of sequelae.
Lack of efficacy  or failure of expected pharmacological action per se will not be
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE sor SAE sif they  fulfil the definition of an AE 
or SAE.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments thatare associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant ’s condition
The disease/disorder being studied or expected progression, signs, or s ymptoms 
(clearly  defined) of the disease/disorder being studied, unless more severe than 
expected for the participant ’s condition
Medical or surgical procedure ( eg,endoscopy , appendectom y): the condition that 
leads to the procedure is theAE
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital)
Anticipated day -to-day fluctuations of pre -existing disea se(s) or condition(s) present 
or detected at the start of the study that do not worsen
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
92
Definition of SAE
SAEs must meet both the AE criteria described above and the seriousness criteria listed below.
AnSAE is defined as any untoward medical occurrence t hat, at any dose:
a.Results in death
b.Is life threatening
The term lifethreatening in the definition of serious refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AE s.If a 
complication prolongs hospitalization or ful fills any other serious criteria, the event is 
serious. When in doubt as t o whether hospitalization occurred or was necessary , the A E 
should be considered serious.
Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( eg,sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption .
e.Is a c ongenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  lifethreatening or result in death or hospitalization but may  
jeopardize the participant or may  require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These events should usually
be considered serious .
Examples of such events include invasive or malignant cancers, intensive treatment 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
93
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abus e.
Recording an AE and /orSAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all
documentation ( eg,hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the eCRF .
It is notacceptable for the investigator to send photocopies of the participant ’s 
medical records to the sponsor in lieu of completion of the AE/SAE eCRF page.
There may  be ins tances when copies of medical records for certain cases are 
requested b y the sponsor .In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copies of the medical records 
before submission to the sponsor .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible , the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE .
Assessment of Intensity
MILD A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere 
with usual activities of daily living.
MODERATE A type of adverse eve nt that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily 
living, causing discomfort but poses no significant or permanent risk of harm 
to the research participant.
SEVERE A type of adverse e vent that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic 
intervention.
An event is defined as serious when it meets at least 1of the predefined outcomes as 
described in the definition of an SAE ,NOT when it is rated as severe.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
94
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A reasonable possibility of a relationship convey sthat there are facts , evidence ,
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease (s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to stud y treatment 
administration will be considered and investigated.
The investigator will also consult the IB and/or product info rmation, for marketed 
products, in his/her assessment.
For each AE/SAE ,the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in wh ich an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor .However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor .
The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  
assessment .
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
95
Reporting of SAE s
SAE Reporting to the Sponsor via Fax or Email
Facsimile transmission is the preferred method to transmit SAE information . 
The fax number is +1 -714-796-9504 (backup number is +1 -714-246-5295). 
Email of the SAE information is also acceptable . The email address is
IR-Clinical -SAE@allergan.com.
In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE form, sent by overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE form within the designated reporting time frames.
Contacts for SAE reporting can be found on the protocol title page.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
96
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions
Woman of Child bearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanentl y sterile (see below) .
Women in the following cate gories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documente d bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of the participant ’s 
medical records, medical examination, or medical history interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. A high FSH level in the postmenopausal range may  be us ed to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. However ,in the 
absence of 12 months of amenorrhea, a single FSH measu rement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to use one of the 
acceptable non-hormonal contraception methods if they  wish to continue their HRT during 
the study . Otherwise, they  must discontinue HRT to allow confirmation of postmenopausal 
status before study  enrollment .
Contraception Guidance
Male Participants
Male participants with female p artners of childbearing potential are eligible to participate if 
they agree to ONE of the following during the study :
oAre abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and a gree to remain abstinent
oVasectom y
oFemale partners of male study  participant s reliably  use one of the following:
oHormonal contraceptives (ie, oral, patch, injection, implant)
oVaginal contraceptive ring 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
97
oIntrauterine device
oBilateral tubal ligation
oEnsure p lacement with correct placement verified by  hysterosalpingogram
oSurgical sterilization
oMale or female condom with spermicide 
oCap, diaphragm, or sponge with spermicide
Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile 
vaginal intercourse or use a male condom during each episode of vaginal intercourse during 
the study .
Refrain from donating sperm for the duration of the study  and for 10 weeks following the end 
of study .
Refrain from attempting pregnancy  with female for 10 weeks following the end of study .
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use an 
acceptable method of contraception consistentl y and correctly, as listed below.
Hormonal contraceptiv es (ie, oral, patch, injection, implant) 
Vaginal contraceptive ring 
Intrauterine device
Bilateral tubal ligation
Essure placement with correct placement verified by  hysterosalpingogram
Surgical sterilization
Male or female condom with spermicide 
Cap, di aphragm, or sponge with spermicide
Abstinence (as described above)
Male partner has vasectomy
Refrain from attempting pregnancy  for 4 –5 weeks following the end of study .
Pregnancy Testing
WOCBP  should only  be included after a confirmed menstrual period and a negative highly  
sensitive serum pregnancy test.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
98
Additional pregnancy  testing during the treatment period can be performed any time at the 
Investigator ’s discretion and after the last dose of study  treatment.
Pregnancy  testing will be performed whenev er a menstrual cy cle is missed or when pregnancy  is 
otherwise suspected.
Collection of Pregnancy Information 
Male Participant s with Partners Who Become Pregnant 
The investigator will attempt to collect pregnancy  information on any  male participant’s 
fema le partner who becomes pregnant while the male participant is in this study . This 
applies only  to male participants who receive study treatment.
After obtaining the necessary  signed informed consent from the pregnant female partner 
directly , the investigat or will record pregnancy  information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner’s pregnancy . The female 
partner will also be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the sponsor. Generall y, the follow -up 
will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination 
of the pregnancy  will be reported regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure.
Female Participants Who Become Pregnant 
The investigator will collect pregnancy  information on any  female participant who becomes 
pregnant while participating in this study . Information will be recorded on the appropriate 
form and submitted to the sponsor within 24 hours of learning of a partici pant’s pregnancy . 
The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generall y, follow -up will not be required for 
longer than 6 to 8 weeks beyond the estimated delivery date. An y termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication 
for the procedure.
While pregnancy  itself is n ot considered to be an AE or SAE, an y pregnancy complication 
or elective termination of a pregnancy  will be reported as an AE or SAE. A spontaneous 
abortion is alway s considered to be an SAE and will be reported as such. Any poststudy  
pregnancy  related SAE considered reasonabl y related to the study treatment by the 
investigator will be reported to the sponsor as described in Section 9.2. While the 
investigator is not obligated to activel y seek this information in former study participants, he 
or she may  learn of an SAE through spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study  will be 
withdrawn from the study .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
99
12.6. Appendix 6: Concomitant Medications
Therap y considered necessary  for the participant 's welfare may  be given at the discretion of the 
investigator . If the permissibility  of a specific medication/treatment is in question, please contact 
the sponsor .
Medications Allowed (Y) and Medications Not Allowed (N) as Concomitant Medications
Drug ClassFrequency of Use
Restrictions/Exceptions/Clarifications Episodic 
(PRN)Chronic
Attention deficit hyperactivity 
disorder medications/stimulantsN N
Analgesics Y YNonnarcotic analgesics are allow ed. Pregabalin and 
indomethacin are not allow ed. Medically appropriate 
episodic use of narcotic analgesics including tramadol 
for acute medical indications limited to 3 days for an 
episode is allow ed. 
Anesthetics –general N NIf procedures requiring general anesthesia are to 
occur/have occurred, please contact the Study 
Physician to report the medical condition(s).
Anesthetics –local Y NTopical anesthetics for venipuncture (eg, EMLA 
cream) are allow ed. 
Anorectics N N
Antacids Y Y
Antiacne agents Y YTopical agents only, including topical antibiotics. 
Isotretinoin (Accutane) is not allow ed.
Antianginal agents Y Y
Antiarrhythmics N YOnly class II agents (eg, esmolol ), class IV agents (eg, 
diltiazem, verapamil), and digoxin are allowed. 
Dosage must be stable for 1 month before screening. 
For participant s on digoxin, there should be a digoxin 
level obtained within 2 months prior to screening. 
Adenosine, parasympatholytics (atropine), and 
sympathomimetics (epinephrine, dopamine) are not 
allow ed. Propranolol (Inderal) is not allowed.
Anti-asthma agents Y YSystemic corticosteroids are not allow ed. Inhaled 
steroids at approved dosages are allow ed.
Antibiotics Y Y
Anticoagulants N N Please see under antiplatelet below .
Anticonvulsants N N
Antidepressants N N
Antidiarrheal preparations Y NOnly Imodium (loperamide HCl), Pepto -Bismol, and 
kaolin preparations are allowed.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
100
Medications Allowed (Y) and Medications Not Allowed (N) as Concomitant Medications
Drug ClassFrequency of Use
Restrictions/Exceptions/Clarifications Episodic 
(PRN)Chronic
Antifungal agents
Systemic
TopicalN
YN
Y
Antihistamines Y YSedating antihistamines are not allow ed. Only 
fexofenadine (Allegra), loratadine (Claritin), 
desloratadine (Clarinex), cetirizine (Zyrtec), and 
levcetirizine (Xyzal) are allowed for episodic or 
chronic use. Terfenadine is not allowed. See Cough 
and Cold Preparations for combination products.
Antihypertensives N YReserpine (Diupres), clonidine (Catapres), guanabenz 
(Wytensin), guanfacine (Tenex and Intuniv), 
guanethidine (Ismelin), methyldopa (Aldomet), direct 
vasodilators (hydralazine, minoxidil), nitroglycerin, 
sodium nitroprusside, and diazoxide are not allow ed. 
Propranolol (Inderal) is not allow ed. For all others 
(α1-blockers, β -blockers, calcium channel blockers, 
ACE inhibitors, etc.), the medication and dosage 
should be stable for 1 month before Screening (for 
diuretics, the participant should have been treated with 
the diuretic for at least 3 months, with at least 1 month 
on the current dose).
Anti-inflammatory drugs Y YChron ic use is allowed if dosage is stable for 1 month 
prior to Screening. Indomethacin (Indocin) and 
systemic corticosteroids are not allow ed.
Antinauseants/antiemetics Y NAntidopaminergic agents (such as metoclopramide, 
domperidone, and phenothiazines), scopolamine, 
5-HT3 receptor antagonists (eg, ondansetron) and 
sedating (H1) antihistamines are notallow ed. 
Phosphoric acid preparations (Emetrol, Emecheck), 
bismuth subsalicylate (Pepto -Bismol), and cola syrup 
are allow ed. 
Antineoplastics N N
Antiobesity agents/appetite 
suppressantsN NOver- the-counter Alli (Xenical) is not allowed.
Sibutramine (Meridia), phenylpropanolamine, and 
phentermine (Adipex -P, others) are not allow ed.
Antiplatelet agents N YAspirin (maximum dosage of 325 mg/day) and
clopidogrel (Plavix) are allowed. Medication dosage 
must be stable for 1 month prior to screening.
Antipsoriatic treatments Y YOnly topical treatments are allow ed (vitamin D 
analogs, anthralin, topical retinoids); 1 month 
stability is required. Oral medications, such as oral 
retinoids (eg acitretin), methotrexate, azathiaprine, 
cyclosprorin, and immunomodulator drugs are not
allow ed.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
101
Medications Allowed (Y) and Medications Not Allowed (N) as Concomitant Medications
Drug ClassFrequency of Use
Restrictions/Exceptions/Clarifications Episodic 
(PRN)Chronic
Antipsychotics N N
Antismoking medications N NVarenicline (Chantix) and bupropion (Zyban) are not 
allow ed. However, nicotine replacement therapies are 
allow ed.
Antiviral agents Y YOnly oral or topical agents are allow ed. Acyclovir, 
famciclovir, valacyclovir, penciclovir, docosanal, 
trifluridine, and vidarabine are allow ed. 
Interferons are not allow ed. 
Anti-HIV drugs are not allowed.
Contact the medical monitor if participant is taking 
anti-Hepatitis C medications .
Anxiolytics Y NEpisodic use of benzodiazepines up to approximately 
2 mg/day lorazepam equivalent dose and for up to 
3consecutive days at a time can be given for 
anxiety -related conditions and agitation (not permitted 
within 8 hours of psychiatric or neurological measures
for Part A or w ithin 12 hours of psychiatric or 
neurological measures or a scheduled qEEG/ERP 
measurement for Part B ).
Cough an d cold preparations Y NCough/cold preparations containing dextromethorphan 
or narcotics are not allow ed. Decongestant 
preparations containing pseudoephedrine or 
phenylpropanolamine are not allowed. Phenylephrine 
nasal sprays are allowed for brief medicall y 
appropriate use, for up to 5 days. Combination 
products containing the word “Nighttime” or some 
synonym routinely include a sedating antihistamine 
are not allow ed. Combination products ending in “D” 
routinely contain a stimulant such as pseudoephedrine 
or phenylpropanolamine and are not allow ed (also see 
Antihistamines).
H2blockers/proton pump 
inhibitors/prokinetic agentsY YTagamet (cimetidine) is not allow ed. 
Metoclopramide and cisapride are notallow ed.
Hormones (nonreproductive) N YThyroid hormone replacement is allow ed. Therapeutic 
use in psychiatric disorders (eg, T3 augmentation 
therapy) is notallowed. Dosage of thyroid medication 
must be stable for 1 month prior to screening. 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
102
Medications Allowed (Y) and Medications Not Allowed (N) as Concomitant Medications
Drug ClassFrequency of Use
Restrictions/Exceptions/Clarifications Episodic 
(PRN)Chronic
Hormones (reproductive) Y YHormonal contraception such as oral contraceptives 
(estrogen -progestin combination or progestin alone), 
transdermally delivered contraceptives (eg, Ortho 
Evra), depot injections (eg, Depo -Provera), vaginal 
contraceptive ring (eg, NuvaRing), and contraceptive 
implant (eg, Implano n, Norplant) are allowed. Must 
follow  package inserts for hormonal contraception, 
regarding time must be taking same before they are 
effective (eg, often 1 cycle). Refer to Section 12.5 for 
specifics of allowed contraception.
Hormone suppressants N YOnly Proscar (finasteride) and Avodart (dutasteride) 
are allow ed. Dosage must be stable for 1 month prior 
to screening.
Hypoglycemic agents N YOral hypoglycemic agents are allow ed, except 
pioglitazone and troglitazone are not allowed. Chronic 
use of insulin is allow ed. Dosage must be stable for 
1month prior to screening.
Hypolipidemics N YNiacin and niacinamide are allow ed if dosage has 
been stable for 3 months prior to screening. Statins 
(lovastatin, pravastatin, simvastatin, atorvastatin, 
fluvastatin, rosuvastatin), fibrates (gemfibrozil, 
fenofibrate), and ezetimibe are allow ed. Dosage must 
be stable for 1 month prior to screening. Bile 
sequestrants are not al lowed.
Laxatives Y YEpisodic and chronic use of bulk laxatives and 
emollient laxatives are allowed. Episodic use of 
stimulant laxatives containing senna, bisacodyl, and 
anthraquinone derivatives is allow ed. Episodic use of 
osmotic laxatives such as oral magnesium hydroxide 
(milk of magnesia), oral sodium citrate, and sodium 
biphosphate is allowed. Hyperosmotic laxatives such 
as sorbitol, lactulose, and polyethylene glycol are not 
allow ed.
Migraine medications Y NTriptans should be used with some caution. Note that 
cases of s erotonin syndrome have been reported w ith 
the concomitant use of triptans and serotonergic 
reuptake inhibitors. Ergotamine or ergot derivatives 
are not allow ed. 
Muscle relaxants N N
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
103
Medications Allowed (Y) and Medications Not Allowed (N) as Concomitant Medications
Drug ClassFrequency of Use
Restrictions/Exceptions/Clarifications Episodic 
(PRN)Chronic
Psychotropic drugs not otherwise 
specified (including herbal products)N NNo drugs with psychomotor effects or with anxiolytic, 
antidepressant, stimulant, antipsychotic, or sedative 
properties are allow ed except as stipulated by the 
protocol. Herbal/dietary products and supplements 
with potential psychoactive actions, inclu ding 
St.John’s w ort, ginkgo biloba, kava kava, SAMe, 
valerian root, DHEA, tyrosine, tryptophan and 5 -HTP 
are not allow ed. Omega -3 supplements are allow ed if 
the dose of EPA is ≤1000 mg/day, and the participant
has been taking same for at least 1 month.
Sedatives/hypnotics Y NOnly zolpidem (Ambien up to 10 mg/day and Ambien 
CR up to 12.5 mg/day), zaleplon (Sonata) up to 
20mg/day, eszopiclone (Lunesta) up to 3mg/day, 
zopiclone up to 7.5 mg/day, and suvorexant 
(Belsomra) up to 10 mg/day are permitted, up to 
3times a week, if required for sleep. 
Sedatives/hypnotics may not be used in the 8 hours 
before any psychiatric or neurological measures for 
Part A or w ithin 12 hours of psychiatric or 
neurological measures or a scheduled qEEG/ERP 
measurement for Part B ).
Steroids, inhalant Y Y
Steroids, intra -articular Y N
Steroids, systemic N N
Steroids, topical Y Y
Vaccines Y N
N =not allow ed; PRN =as needed; Y =yes, allowed.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
104
12.7. Appendix 7: Standard Discontinuation Criteria
CDISC Submission V alue CDISC Definition
Adverse event Any untoward medical occurrence in a patient or 
clinical investigation subject administered a 
pharmaceutical product and which does not 
necessarily have a causal relationship with this 
treatment. An adverse event (AE) can therefore be 
any unintended sign (including an abnormal 
laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal 
(investigational) product, whether or not related 
to the medicinal (investigational) product. For 
further information, see the ICH Guideline for 
Clinical Safety Data Management: Definitions 
and Standards for Expedited Reporting. [Modified 
from ICH E2A] Synonyms: side effect, adverse 
experience. See also serious adverse event, 
serious adverse experi ence. (CDISC glossary)
Com pleted To possess every necessary or normal part or 
component or step; having come or been brought 
to a conclusion (NCI)
Lack of efficacy The lack of expected or desired effect related to a 
therapy (NCI)
Lost to follow -up The loss or lack of continuation of a subject to 
follow -up
Non-compliance with study drug An indication that a subject has not agreed with or 
followed the instructions related to the study 
medication (NCI)
Other Different than the one(s) previously specified or 
mentioned (NCI)
Pregnancy Pregnancy is the state or condition of having a 
developing embryo or fetus in the body (uterus), 
after union of an ovum and spermatozoon, during 
the period from conception to birth (NCI)
Protocol deviation An event or decisi on that stands in contrast to the 
guidelines set out by the protocol (NCI)
Screen failure The potential subject who does not meet one or 
more criteria required for participation in a trial
Site terminated by sponsor An indication that a clinical study was stopped at 
a particular site by its sponsor (NCI)
Study terminated by sponsor An indication that a clinical study was st opped by 
its sponsor (NCI)
Withdraw al by subject An indication that a study participant has 
removed itself from the study (NCI)
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
105
12.8. Appendix 8: Montgomery -Åsberg Depression Rating Scale
1.APPARENT SADNESS —Representing despondency , gloom and despair (more than just 
ordinary  transient low spirits) reflected in speech, facial expression, and posture. Rate b y 
depth and inability to brighten up.
0No sadness.
1
2Looks dispirited but does brighten up without difficulty.
3
4Appears sad and unhappy most of the time.
5
6Looks miserable all the time. Extremely  despondent.
2.REPORTED SADNESS —Representing reports of depressed mood, regardless of whether it 
is reflected in appearance or not. I ncludes low spirits, despondency , or the feeling of being 
beyond help and without hope. Rate according to intensity , duration and the extent to which 
the mood is reported to be influenced b y even ts.
0Occasional sadness in keeping with the circumstances.
1
2Sad or low but brightens up without difficulty .
3
4Pervasive feelings of sadness or gloominess. The mood is still influenced by external 
circumstances.
5
6Continuous or unvary ing sadness, misery  or despondency .
3INNER TENSION —Representing feelings of ill -defined discomfort, edginess, inner 
turmoil, mental tension mounting to either panic, dread, or anguish. Rate according to 
intensity , frequency , duration, and the extent of reassurance ca lled for.
0Placid. Only  fleeting inner tension.
1
2Occasional feelings of edginess and ill -defined discomfort.
3
4Continuous feelings of inner tension or intermittent panic which the patient can onl y 
master with some difficulty .
5
6Unrelenting dread or anguish. Overwhelming panic.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
106
4.REDUCED SLEEP —Representing the experience of reduced duration or depth of sleep 
compared to the patient’s own normal pattern when well.
0Sleeps as usual.
1
2Slight difficulty  dropping off to sleep or slightly  reduced, light, or fitful sleep.
3
4Sleep reduced or broken by  at least 2 hours.
5
6Less than 2or 3 hours sleep.
5.REDUCED APPETITE —Representing the feeling of a loss of appetite compared with 
when well. Rate b y loss of desire for food or the need to force oneself to eat.
0Normal or increased appetite.
1
2Slightly  reduced appetite.
3
4No appetite. Food is tasteless.
5
6Needs persuasion to eat at all.
6.CONCENTRATION DIFFICULTIES —Representing difficulties in collecting one’s 
thoughts mounting to incap acitating lack of concentration. Rate according to intensity , 
frequency , and degree of incapacit y produced.
0No difficulties in concentrating.
1
2Occasional difficulties in collecting one’s thoughts.
3
4Difficulties in concentrating and sustaining tho ught which reduces ability  to read or hold 
a conversation.
5
6Unable to read or converse without great difficulty.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
107
7.LASSITUDE —Representing a difficulty getting started or slowness initiating and 
performing every day activities.
0Hardl y any difficulty getting started. No sluggishness.
1
2Difficulties in starting activities.
3
4Difficulties in starting simple routine activities which are carried out with effort.
5
6Complete lassitude. Unable to do anything without help.
8.INABILITY TO FEEL —Represe nting the subjective experience of reduced interest in the 
surroundings, or activities that normally  give pleasure. The abilit y to react with adequate 
emotion to circumstances or people is reduced.
0Normal interest in the surroundings and in other people.
1
2Reduced ability  to enjoy  usual interests.
3
4Loss of interest in the surroundings. Loss of feelings for friends and acquaintances.
5
6The experience of being emotionally  paral yzed, inability  to feel anger, grief or pleasure 
and a complete or even painful failure to feel for close relatives or friends.
9. PESSIMISTIC THOUGHTS —Representing thoughts of guilt, inferiority, self -reproach, 
sinfulness, remorse and ruin.
0No pessimistic thoughts.
1
2Fluctuating ideas of failure, self -reproach or self -deprecation.
3
4Persistent self -accusations, or definite but still rational ideas of guilt or sin. Increasingl y 
pessimistic about the future.
5
6Delusions of ruin, remorse, or unredeemable sin. Self -accusations which are absurd and 
unshakable.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
108
10.SUICI DAL THOUGHTS —Representing the feeling that life is not worth living, that a 
natural death would be welcome, suicidal thoughts, and preparations for suicide. Suicidal 
attempts should not in themselves influence the rating.
0Enjoy s life or takes it as it comes.
1
2Weary  of life. Onl y fleeting suicidal thoughts.
3
4Probably  better off dead. Suicidal thoughts are common, and suicide is considered as a 
possible solution, but without specific plans or intention.
5
6Explicit plans for suicide when there i s an opportunity . Active preparations for suicide.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
109
12.9. Appendix 9: Clinical Global Impressions –Severity
SEVERITY OF ILLNESS
Considering your total clinical experience with this population, how mentally ill is the patient at 
this time? (Check one)
1 Normal, no t at all ill
2 Borderline ill
3 Mildly  ill
4 Moderatel y ill
5 Markedl y ill
6 Severel y ill
7 Among the most extremely  ill patients
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
110
12.10. Appendix 10: Brief Psychiatric Rating Scale –Positive Symptoms 
Subscale

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
111
12.11. Appendix 11: Clinician Administered Dissociative States Scale

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
112

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
113

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
114

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
115

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
116
12.12. Appendix 12: Columbia -Suicide Severity Rating Scale –
Baseline/Screening

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
117

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
118

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
119
12.13. Appendix 13: Columbia –Suicide Severity Rating Scale -Since Last 
Visit
COLUMBIA -SUICIDE SEVERITY
RATING SCALE
(C-SSRS)
Since Last Visit
Version 1/14/09
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; Oquendo, M.; Mann, J.
Disclaimer: 
This scale is intended for use by trained clinicians. The questions contained in the Columbia -Suicide Severity 
Rating Scale are suggested probes. Ultimately, the determination of the presence of suicidality depends on 
clinical judgment. 
Definitions of be havioral suicidal events in this scale are based on those used in The Columbia Suicide 
History Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of 
Mental Disorders (CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032. 
(Oquendo M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of 
research instruments. In M.B. First [Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
For reprints of the C -SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside 
Drive, New York, New York, 10032; inquiries and training requirements contact 
posnerk@childpsych.columbia.edu
© 2008 The Research Foundation for Mental Hygiene, Inc.
SUICIDAL IDEATION
Ask questions 1 and 2. If both are negative, proceed to “Suicidal Behavior” section. If the answer to 
question 2 is “yes”, ask questions 3, 4, and 5. If the answer to question 1 and/or 2 is “yes”, complete 
“Intensity of Ideation” section below.Since Last 
Visit
1. Wish to be Dead
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up. 
Have you wished you were dead or wished you could go to sleep and not wake up? 
If yes, describe:Yes No
□ □
2. Non -Specific Active Suicidal Thoughts
General, non -specific thoughts of wanting to end one’s life/commit suicide (e.g., “I’ve thought about killing myself” ) without 
thoughts of ways to kill oneself/associated methods, intent, or plan during the assessment period. 
Have you actually had any thoughts of killing yourself?
If yes, describe:Yes No
□ □
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
120
3. Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different t han a 
specific plan with time, place, or method details worked out (e.g., thought of method to ki ll self but not a specific plan). I ncludes 
person who would say, “I thought about taking an overdose but I never made a specific plan as to when, where, or how I would 
actually do it…and I would never go through with it.”
Have you been thinking about how you might do this?
If yes, describe:Yes No
□ □
4. Active Suicidal Ideation with Some Intent to Act, without Specific Plan
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts , as opposed to “I have the 
thoughts but I definitely will not do anything about them.”
Have you had these thoughts and had some intention of acting on them ?
If yes, describe:Yes No
□ □
5. Active Suicidal Ideation with Specific Plan and Intent
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
If yes, describe:Yes No
□ □
INTENSITY OF IDEATION
The following features should be rated with respect to the most severe type of ideation (i.e., 1 -5 from above, with 1 
being the least severe and 5 being the most severe). 
Most Severe Ideation: ______________________________________________________
Type # (1 -5) Description of IdeationMost 
Severe
Frequency
How many times have you had these thoughts ?
(1) Less than once a week (2) Once a week (3) 2 -5 times in week (4) Daily or almost daily (5) Many times each day____
Duration
When you have the thoughts, how long do they last?
(1) Fleeting -few seconds or minutes (4) 4 -8 hours/most of day
(2) Less than 1 hour/some of the time (5) More than 8 hours/persistent or continuous
(3) 1 -4 hours/a lot of time ____
Controllability
Could/can you stop thinking about killing yourself or wanting to die if you want to?
(1) Easily able to control thoughts (4) Can control thoughts with a lot of difficulty
(2) Can control thoughts with little difficulty (5) Unable to control thoughts
(3) Can control thoughts with some difficulty (0) Does not attempt to control thoughts____
Deterrents
Are there things -anyone or anything (e.g., family, religion, pain of death) -that stopped you from wanting to die 
or acting on thoughts of committing suicide?
(1) Deterrents definitely stopped you from attempting suicide (4) Deterrents most likely did not stop you 
(2) Deterrents probably stopped you (5) Deterrents defin itely did not stop you 
(3) Uncertain that deterrents stopped you (0) Does not apply____
Reasons for Ideation
What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or 
stop the way you were feeling (in other words, you couldn’t go on living with this pain or how you were feeling) 
or was it to get attention, revenge ,or a reaction from others? Or both?
(1) Completely to get attention, revenge or a reaction from others (5) Completely to end or stop the pain (you 
(2) Mostly to get attention, revenge or a reaction from others living couldn’t go on living with the pain or how 
(3) Equally to get attention, revenge or a reaction from others you were feeling)
and to end/stop the pain
(4) Mostly to end or stop the pain (you couldn’t go on living (0) Does not apply
with the pain or how you were feeling).____
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
121
SUICIDAL BEHAVIOR
(Check all that apply, so long as these are separate events; must ask about all types)Since Last 
Visit
Actual Attempt:
A potentially self -injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as 
method to kill oneself. I ntent does not have to be 100%. If there is anyintent/desire to die associated with the act, then it can be 
considered an actual suicide attempt. There does not have to be any injury or harm , just the potential for injury or harm. If person 
pulls trigger while gun is in mouth but gun is broken so no i njury results, this is considered an attempt. 
Inferring I ntent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circums tances. 
For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be inferred (e.g., gunshot to head, 
jumping from window of a high floor/story). Also, if someone denies intent to die, but they thought that what they did could be 
lethal, intent may be inferred. 
Have you made a suicide attempt?
Have you done anything to harm yourself?
Have you done anything dangerous where you could have died?
What did you do?
Did you______ as a way to end your life? 
Did you want to die (even a little) when you_____? 
Were you trying to end your life when you ___ __?
Or did you think it was possible you could have died from_____?
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, feel 
better, get sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)
If yes, describe:
Has subject engaged in Non -Suicidal Self -Injurious Behavior?Yes No
□ □
Total # of
Attempts
______
Yes No
□ □
Interrupted Attempt:
When the person is interrupted (by an outside circumstance) from starting the potentially self -injurious act (if not for that, actual 
attempt would have occurred).
Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt rather than an 
interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevent ed 
from pulling trigger. Once they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is 
grabbed, and taken down from ledge. Hanging: Person has noose around neck but has not yet started to hang -is stopp ed from 
doing so.
Has there been a time when you started to do something to end your life but someone or something stopped you 
before you actually did anything?
If yes, describe:Yes No
□ □
Total # of 
interrupted
______
Aborted Attempt: 
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in a ny 
self-destructive behavior. Examples are similar to interrupted attempts, except that the individual stops him/herself, instead o f 
being stopped by something else.
Has there been a time when you started to do something to try to end your life but you stopped yourself before 
you actually did anything?
If yes, describe:Yes No
□ □
Total # of
aborted
______
____
Preparatory Acts or Behavior:
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought,
such as assembling a specific method (e.g., buying pills, purchasing a gun) or preparing for one’s death by suicide (e. g., giving 
things away, writing a suicide note). 
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, 
getting a gun, giving valuables away, or writing a suicide note )?
If yes, describe:Yes No
□ □
Suicidal Behavior :
Suicidal behavior was present during the assessment period?Yes No
□ □
Completed Suicide:Yes No
□ □
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
122
Answer for Actual Attempts OnlyMost L ethal 
Attempt
Date:
Actual Lethality/Medical Damage: 
0. No physical damage or very minor physical damage (e.g., surface scratches).
1. Minor physical damage (e.g., lethargic speech; first -degree burns; mild bleeding; sprains).
2. Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second -degree burns; 
bleeding of major vessel).
3. Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes 
intact; third -degree burns less than 20% of body; extensive blood loss but can recover; major fractures).
4. Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third -degree 
burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area).
5. DeathEnter Code
______
Potential Lethality: Only Answer if Actual Lethality = 0
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had 
potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on 
train tracks with oncoming train but pulled away before run over).
0 =Behavior not likely to result in injury
1 =Behavior likely to result in injury but not likely to cause dea th
2 =Behavior likely to result in death despite available medical care Enter Code
______
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
123
12.14. Appendix 14 : Hamilton Anxiety Rating Scale (Part A Only)

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
124
12.15. Appendix 15: Likert Patient Depressive Symptom Scales (Part B 
Only)

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
125

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
126

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
127

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
128

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
129

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
130

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
131

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
132

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
133

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
134

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
135

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
136
12.16. Appendix 16: Hopkins Verbal Learning Test -Revised (Part B Only)
Due to cop yright restriction, the HVLT -R scale is not included.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
137
12.17. Appendix 17: Karolinska Sleepiness Scale (Part B Only)

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
138
12.18. Appendix 18: CSF Sample Collection, Handling ,and Storage 
Instructions (Part B Only)
A local anesthetic may  be applied to minimize discomfort to the subject. Once the spinal needle 
is inserted to the lumber region (eg, L3 -4 or L4 -L5), collect approximately  4 mL  of CSF fluid at 
a rate of 0.5 mL/minute. This collection is carried out under ambient conditions. Upon 
completion, transfer harvested CSF immediately into 4 prechilled, labeled polyprop ylene 
cryovials (Nalgene®1.5mL polyprop ylene External Thread Cry ogenic Vials, Catalog 
#5000 -1020), placing approximately  1 mL in each of the 4 polypropy lene vials. Tubes should be 
labeled with the study  number, participant identification number, date, and timepoint. 
Immediately  place and store upright the frozen tubes in freezer maintained at nominal –20°C 
±10°C. Samples will be batched and shipped according to the sponsor or at the end of the stud y.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
139
12.19. Appendix 19: Sample Shipment Guide (Part B Only)
BIOLOGICAL SAMPLES INCOMING TO KEYSTONE BIOANALYTICAL
Samples will be batched and shipped according to the sponsor or at the end of the study.
Ship CSF samples on sufficient dry  ice to keep them frozen for a minimum of 96 hours.
Sample Packing
Place the samples b y subject number in compartmentalized boxes, label the box(es) with 
study  number and subject number(s). Place the box in a freezer bag(s)
Place the samples in a thick -wall foam shipping box (eg, 19 ″ × 19″ × 12″) that has a slab 
of dry  ice on the bottom and on 2 of the 4 sides. Pack the remaining spaces with dry  ice or 
ice pellets
Make a note in the sourc e documents, air  bill, and shipping box of the estimated weight of 
the dry  ice used per box
Put lid on box and seal lid with tape
To the lid of the box, attach a sample transfer record and an inventory of the samples 
contained inside (eg, 3125 -104-002 CSF samples, Subject 301-001-001, 
Subject 301-001-002). I nclude a note explicitly  stating an y scheduled samples that may 
have been missed or not included in the shipment
Put the box in a cardboard shipping carton, if available, and seal
Shipping Label
Mark the  outside of the cartons with the tally  number (1 of 5, 2 of 5, etc.)
Affix to each box an address label with the following information:
Kaiwen Su
Keystone Bioanal ytical, Inc.
501 Dickerson Road
North Wales, PA 19454, USA
Put 1 “PERI SHABLE GOODS” label on each carton
Mark each carton “KEEP  FROZEN”
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
140
Put on each carton 2 carbon dioxide labels, inscribed with the following:
Carbon Dioxide Solid UN -1845
Class 9 PKG GR III
Quantity (weight to nearest pound)
Put the return address and name of the contact person on  each carton
Notification
Notify  Allergan and Keystone Bioanal ytical by  e mail immediately  after the samples leave 
your premises. The notification should include the following:
1.Name of courier or transport compan y
2.Time and date the shipment left y our premi ses
3.Airway  bill number
4.Allergan stud y number and period number
5.Name, telephone number , and fax number of the appropriate contact person at your 
study  center
Your contact person at Keystone Bioanal ytical for all shipments is:
Kaiwen Su
Keystone Bioanal ytical, Inc.
Phone: +1 -212-699-8885
E-mail: ksu@key stonebioanal ytical.com
Your contact person at Allergan Department of Clinical Pharmacology  (Irvine, CA) is :
Lisa Borbri dge
Phone: +1 -714-246-5845
E-mail: Lisa.Borbridge@allergan.com
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
141
12.20. Appendix 20: qEEG and ERP Assessments and Outputs (Part B 
Only)
Single- Deviant Mismatch Negativity Task 
In the MMN task, 1 standard tone (standard tone, probability  0.9, 1000 Hz, 50 msec duration, 
5msec rise/fall time, 80 dB SPL ) will be presented binaurally  through headphones with a 
constant SOA of 0.5 sec, randomly interrupted b y higher -pitch deviant tone bursts (deviant tone, 
probability  0.1, 1500 Hz, 50 msec duration, 5 msec rise/fall time, 70 dB SPL). The total number 
of tones presented will be 600 per block, of which 60 will be deviant tones. Two blocks will be 
performed with a total task duration of approximately  10.5 minutes. Participants will be seated 
comfortabl y in a chair facing a monitor and viewing a slowl y changing slide show of nature 
scenes (landscapes , animals). Participants will be instructed to ignore the tones and silently count 
the number of different nature scenes shown. No responses are required during the MMN task; 
however, participants will be asked to report the number of slide show scenes the y counted, and 
this number will be recorded by the task software. Including an additional electrode on the nose 
(Nz) is required for accurate identification of the MMN. The primary ERP measurements are the 
peak amplitude, latency , and area under the curve or AUC of the MMN, which is a negative -
going peak in the difference wave computed b y subtracting the ERP average for standard stimuli 
from the ERP average for deviant stimuli. Secondary  outcome measures will include peak 
amplitude, latency , and AUC measure s of the P50, N100, and P200 components for the standard 
and deviant ERPs. The latency  windows for peak and AUC measures will be defined using the 
grand averages of ERPs across all participants and then applied to each participant. The window 
will extend f rom the point on the rising edge of the component where it reaches half the peak 
amplitude to the point on the falling edge of the component where it reaches half the peak 
amplitude. Each measurement will be made at a single key  electrode for each componen t. The 
key electrode will be defined as the electrode showing the maximum absolute peak amplitude of 
the component in the grand average ERP across participants.
Auditory Steady -State Response Task
The ASSR is continuous scalp -recorded potential composed of superimposed overlapping 
transient event- related potentials produced b y brief stimuli presented at high rates. Bursts of 
clicks at rates of 30/s or 40/s are presented repeatedly with short periods of silence in between 
the bursts. The task includes four b locks of 150 stimuli consisting of 500 -ms long trains of 1 -ms 
white noise bursts (clicks) at 80 dB S PL with a 1.0 -s SOA: Block 1: 30/s (500 ms train of 1 -ms 
noise bursts at 30 per second); Block 2: 40/ s (500 ms train of 1 -ms noise bursts at 40 per 
second) ; Block 3: repeat Block 1; Block 4: repeat Block 2. Participants will be seated 
comfortabl y in a chair facing a monitor and viewing a slowl y changing slide show of nature 
scenes (landscapes, animals). Participants will be instructed to ignore the tone burs ts and silently  
count the number of different nature scenes shown. No responses are required during the ASSR 
task; however, participants will be asked to report the number of slide show scenes they counted, 
and this number will be recorded b y the task soft ware. The primary  ASSR measure is the peak -
to-peak amplitude of the sustained portion (latency > 150 ms) of the ASSR in the time domain. 
Secondary  measures include the averaged wavelet magnitude and inter -trial phase coherence. All 
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
142
endpoints of the ASSR ta sk will be measured at the electrode with the maximal ASSR response. 
This electrode will be determined during the anal ysis for each subject separately.
Peak -to-peak endpoint
In MATLAB the time -domain peak -to-peak endpoint will be computed. Because of the e xpected 
zero-mean noise in the signal, the RMS of the zero -mean post -stimulus time period will be 
computed. This effectively  represents the standard deviation of the signal. Then, 99.9% of the 
signal distribution is equal to 6.6*RMS and this will be taken as the estimate of the peak -to-peak 
endpoint. For each subject, the interval within the 500 ms stimulation period that represents the 
maximum continuous response will serve for the RMS estimate. Time -frequency  endpoints, that 
is, event -related spectral per turbation and inter -trial phase coherence, will be computed for each 
data segment b y decomposition into its time -frequency  representation using the continuous 
complex Morlet wavelet.  The result of this decomposition is a set of complex wavelet 
coefficient s for each time sample in the original EEG time series and each of several frequency 
scales. Scales corresponding to the frequency  range of 5 to 60 Hz with a step of 1 Hz will be 
used. To equalize scales (frequency bands) of the CWT coefficients an energy -based 
normalization approach will be applied. Dividing every  CWT coefficient cwt(s,t) at a given scale 
s and time sample t by  the square root of the corresponding scale value carries out this 
normalization :
This square root division is applied separately for the real and imaginary  part of the CWT 
coefficient. In the permutation testing step, the normalization allows for a balanced statistical 
correction for multiple comparisons ERSP: ERSP is a measure of mean power difference from 
baseline. The ERSP measu re is defined as :

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
143
where cwt(f,t,n) represents the CWT coefficient computed for the epoch n, frequency  f and time 
sample t. N is the total number of epochs and T_B represents all time samples from the baseline, 
pre-stimulus period. The norm sy mbol | . | represents a complex norm. I nter-trial phase 
coherence (ITPC): ITPC (sometimes named the phase locking index/value) is sensitive to 
phase -locked activit y regardless of its magnitude, so represents a more pure estimate of 
phase -locking in contrast to the ER SP measure. This could be important when the change in the 
brain activity  is mostly  arising from phase or response -onset variability  as opposed to the power 
of a response. The ITPC measure is defined as :
where the cwt(f,t,n) coefficient and other equation indexes are defined in the same way as  in the 
case of ERSP. The ITPC value can range from 0 (absence of s ynchronization) to 1 (perfect 
synchronization or phase reproducibility  across trials at a given time sample and frequency ).

CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
144
12.21. Appendix 21 : Protocol Amendment History
Amendment 1 (March 2019)
Overall Rationale for the Amendment:
As part of t his proof -of-concept study  in participants with major depressive disorder (MDD), an 
additional exploratory  assessment, the Hamilton Anxiety  Rating Scale (HAM -A), has been 
added to the study  design to further characterize the potential pharmacology of AGN -241751. 
The HAM -A is designed to assess potential improvements in feelings of anxiety  within MDD 
study  participants.
In addition, minor administrative, editorial, and formatting changes have been made throughout 
the protocol; these revisions are not included in the table below.
Section No. and Nam eDescription of Change Brief Rationale
Synopsis For the primary objective, baseline 
was defined as Day 1 (predose) 
and it w as clarified that 1 day after 
the first dose is Day 2. This information was updated in the text and 
table of objectives and endpoints as a 
clarification.
For the key secondary objective, 
baseline was defined as Day 1 
(predose), it w as clarified that 
1day after the first dose is Day 2, 
and Day 9 was added as an 
endpoint.This information was updated as a 
clarification.
An additional exploratory 
objective w as included regarding
evaluation of change from Day 1 
(predose) in Hamilton Anxiety 
Rating Scale (HAM -A) scores 
compared with placebo.This objective w as added because it will be 
considered an exploratory endpoint for 
AGN -241751 treatment compared with 
placebo in participants with MDD.   
In the overall study design section, 
a statement was added to indicate 
that daily dosing of AGN -241751 
should occur at a similar time 
throughout the entire study.  This statement was added as a clarification on 
daily dosing .
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
145
Section No. and Nam eDescription of Change Brief Rationale
2 Schedule of Activities The HAM -A assessment (and 
corresponding footnote with more 
information) was added to the 
schedule of activities at Visits 2, 3, 
4, and 6/ET. It w as also noted that 
the HAM A will be collected only 
from participants entering the 
study after the ame ndment has 
been IRB approved.The HAM -A assessment was added because 
evaluation of this instrument is now an 
exploratory objective in the study.
The timing for the consent and 
sample for pharmacogenomics w as 
revised to have one “x” for all 
timepoints for this assessment 
instead of under only Screening. In 
addition, the corresponding 
footnote was updated to indicate 
that the ICF may be signed at any 
visit during the study and that the 
same should be collected at any 
visit after the participant has been 
randomized.This information was updated as a 
clarification.
4 Objectives and 
EndpointsFor the primary objective, baseline 
was defined as Day 1 (predose) 
and it w as clarified that 1 day after 
the first dose is Day 2This information was updated as a 
clarification.
For the key secondary objective, 
baseline was defined as Day 1 
(predose), it w as clarified that 
1day after the first dose is Day 2, 
and Day 9 was added as an 
endpoint.This information was updated as a 
clarification.
For the additional endpoint of 
CGI-S, it was noted that this 
assessment gives a total score, 
baseline was defined as Day 1 
(predose), and Day 2 and Day 9 
were added.This information was updated as a 
clarification.
An additional exploratory 
objective/endpoint to determine 
differences between AGN -241751 
and placebo w as added, as follow s:
Change from baseline in HAM -A 
at Day 1 (predose, defined as 
baseline) and at Day 2, Day 8, and 
Day 15This objective w as updated to describe the 
evaluation of change from baseline in HAM -A 
scores compared w ith placebo w as added 
because evaluation of this instrument is now 
an exploratory objective in the study.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
146
Section No. and Nam eDescription of Change Brief Rationale
4 Objectives and 
EndpointsFor the rate of responders, 
MADRS and CGI -S were added as 
the parameter being measured and 
predose w as ad ded after Day 1. In 
addition, for rate of remitters, time 
to first response, and time to first 
remission endpoints, MADRS w as 
added as the parameter being 
measured and predose w as added 
after Day 1.This information was updated as a 
clarification.
5.1 Study Design Astatement was added to indicate 
that daily dosing of AGN -241751 
should occur at a similar time 
throughout the entire study.  This statement was added as a clarification on 
daily dosing .
5.5 Justification for 
DoseThe follow ing changes (shown in 
bold italics and strikethroughs) 
were made:
Com pared to the available 
preclinical toxicology studies, 
the proposed top dose of 
2510mg is expected to result 
in substantial margins below 
the 28 -day study NOAELs 
designated in the rat 
(225575-fold) and dog 
(410-fold).This information was updated as a correction.
6.1 Inclusion Criteria Inclusion criterion #6 w as updated 
to indicate the assessment is done 
at Screening (Visit 1).This criterion w as updated as a clarification.
Inclusion criterion #1 2 regarding 
eligibility being confirmed through 
a formal adjudication process was 
removed.This criterion w as rem oved as a correction.
9.1.3 The Hamilton 
Anxiety Rating ScaleA section was added to describe 
the HAM -A scale and the 
timepoints at which it will be 
administered. It was also noted that 
the HAM A will be collected only 
from participants entering the 
study after the amendment has 
been IRB approved.This section was added to provide information 
regarding the HAM -A, which is now an 
assessment in the study.
9.7 Genetics This section was revised to 
indicate that that the sample for 
DNA isolation will be collected at 
any visit after the participant has 
been randomized.This information was updated as a clarifica tion
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
147
Section No. and Nam eDescription of Change Brief Rationale
10.3.1 Efficacy 
AnalysesThe statement that the LOCF 
approach will be used to impute 
missing postbaseline values was 
removed.This statement was removed to simplify the 
statistical analysis of study outputs.
The statement regarding by -visit 
analyses being carried out for all 
efficacy parameters using the 
MMRM and LOCF approaches 
was removed.This statement was removed to simplify the 
statistical analysis of study outputs.
10.3.1.1 Primary and 
Secondary EndpointsFor the primary efficacy endpoint , 
baseline was defined as Day 1 
(predose) and it w as clarified that 
1day after the first dose is Day 2 .This information was updated as a 
clarification.
For the secondary efficacy 
endpoint, baseline was defined as 
Day 1 (predose), it was clarified 
that 1 day after the first dose is 
Day 2, and Day 9 was added .This information was updated as a 
clarification.
10.3.1.2 Primary 
AnalysesThe statement that the LOCF 
approach will be used to impute 
missing postbaseline values 
provided that a t least 
1postbaseline assessment is 
available was removed.
In addition, the other information 
regarding a sensitivity analysis 
using the LOCF approach for the 
primary efficacy parameter was 
revised to using a multiple 
imputation approach under missing 
notat random assumptions for the 
primary and secondary efficacy 
parameters. In addition, a 
statement was added that the 
detailed methods and procedures 
for the sensitivity analyses will be 
documented in the statistical 
analysis plan prior to database 
lock.TheLOCF statement has been removed as part 
of the study outputs. As such, the sensitivity 
analysis using the multiple imputation (MI) 
approach under missing not at random 
(MNAR) assumptions will be performed on 
the primary efficacy and key secondary 
parame ters.
10.3.1.3 Multiple 
Com parisons ProcedureThe section on the multiple 
comparisons procedure w as 
removedThis section was removed as a correction.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
148
Section No. and Nam eDescription of Change Brief Rationale
10.3.1.3 Additional 
Efficacy ParametersIn this section (formerly 
Section 10.3.1.4 and now  
Section 10.3.1.3), baseline w as 
defined as Day 1 (predose) for the 
assessments. For the rate of 
responders, MADRS and CGI -S 
were added as the parameter being 
measured and predose w as added 
to Day 1. In addition, for rate of 
remitters, time to first respons e, 
and time to first remission 
endpoints, MADRS was added as 
the parameter being measured and 
predose w as added to Day 1. For 
CGI-S, it was also noted that this 
assessment gives a total score, 
baseline was defined as Day 1 
(predose), and Day 2 and Day 9 
were added.This information was updated as a 
clarification.
10.3.2 Exploratory 
AnalysesA section regarding statistical 
information for the exploratory 
analysis of HAM -A was added. It 
was also noted that t he HAM -A 
will be collected only from 
participants entering the study after 
the amendment has been IRB 
approved.This section was added to explain the 
statistical analysis methods for the newly 
added efficacy parameter of HAM -A.
10.3.3.2 Clinical 
Laboratory 
AssessmentsThe follow ing revisions were made 
(shown in bold italics):
The numerator w ill be the total 
number of participants with 
available non -PCS baseline 
values and at least 1 PCS 
postbaseline value.This section was revised as a correction.
CONFIDENTIAL
AGN -241751Protocol 3125 -104-002 Amendment 2
149
Section No. and Nam eDescription of Change Brief Rationale
10.3.3.3 Vital Signs The follow ing revisions were made 
(shown in bold italics and 
strikethroughs):
Vital sign values will be 
considered to be PCS if they meet 
both the observed value criterion 
and the change from baseline value 
criterion , if both criteria are 
available, or meet either the 
observed value criter ion or the 
change from baseline value 
criterion that will be detailed in the 
SAP. The number and percentage 
of participants who have PCS 
postbaseline vital sign values will 
be tabulated by study treatment for 
each assessment. The percentages 
will be calcul ated relative to the 
number of participants who have 
an available baseline or non -PCS 
baseline (for parameters with only 
the observed value criterion) 
value sand at least 1 postbaseline 
assessment. This section was revised as a correction.
11 References The follow ing reference w as
added: 
Ham ilton, M. The assessment of 
anxiety states by rating. British J 
Medical Psychol 1959;32:50 -55.This reference was added because it is cited in 
the protocol for the newly added efficacy 
parameter of HAM -A.
12.2. Appendix 2: 
Clinical Laboratory 
TestsThe timing of the final clinical 
laboratory tests was changed from 
Follow -up Visit to Visit 6/ET. The timing of the final clinical laboratory test 
was clarified.
12.14 Appendix 14 
Ham ilton Anxiety 
Rating ScaleThis s cale was added as an 
appendix.This scale was added to an appendix because 
the HAM -A is now an efficacy assessment in 
the study.